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VEGFR Vascular endothelial growth factor receptor 
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Summary 
Angiogenesis, the growth of new blood vessels, is critical during development. 
Indeed blockade of this process results in embryonic lethality. Furthermore 
angiogenesis also plays a major role during several physiological but also 
pathological conditions. Aberrant blood vessel growth contributes to several 
pathologies such as ocular disease and cancer, thus blocking angiogenesis has 
become an attractive therapeutic strategy. Current anti-angiogenic therapies 
focus on blockade of the growth factors that initiate angiogenesis. While this 
strategy is successful for treatment of ocular disease, its success for cancer 
treatment is limited due to toxicity and resistance. There is thus an urgent need 
for novel anti-angiogenic strategies.  
 
 Vessel sprouting by migrating tip and proliferating stalk endothelial cells 
(ECs) is controlled by genetic signals (such as Notch), but it is unknown whether 
metabolism also regulates this process. We hypothesized that pro-angiogenic 
growth factors converge onto metabolism to initiate a metabolic reprogramming 
that allows sufficient biomass and energy production to fuel proliferation and 
migration of ECs during angiogenesis. In this PhD thesis we therefore 
investigated the role of metabolism during vessel sprouting, thereby focusing on 
glycolysis and fatty acid oxidation.  
 
 In a first study, we showed that ECs relied on glycolysis rather than on 
oxidative phosphorylation for ATP production and that loss of the glycolytic 
activator phosphofructokinase-fructose-2,6-bisphophatase 3 (PFKFB3) in ECs 
impaired vessel formation. Mechanistically, PFKFB3 not only regulated EC 
proliferation but also controlled the formation of filopodia/lamellipodia and 
directional migration, in part by compartmentalization with F-actin in motile 
protrusions. Mosaic in vitro and in vivo sprouting assays further revealed that 
PFKFB3 overexpression overruled the prostalk activity of Notch, whereas 
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PFKFB3 deficiency impaired tip cell formation upon Notch blockade, implying 
that glycolysis regulates vessel branching. 
 
 Having identified PFKFB3 as a potential anti-angiogenic target, we next 
explored its therapeutic potential in several in vivo models of physiological and 
pathological angiogenesis. We demonstrate that blockade of PFKFB3 by the 
small molecule 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) reduced 
vessel sprouting in zebrafish embryos and in the postnatal mouse retina by 
inhibiting EC proliferation and migration. 3PO also suppressed vascular 
hyperbranching induced by inhibition of Notch or VEGF receptor 1 (VEGFR1) 
signaling and amplified the anti-angiogenic effect of VEGF blockade. Although 
3PO reduced glycolysis only partially and transiently in vivo, this sufficed to 
decrease pathological neovascularization in ocular and inflammatory models, 
with minimal systemic effects. These insights may offer therapeutic anti-
angiogenic opportunities. 
 
 Besides glycolysis, the metabolism of endothelial cells during vessel 
sprouting remains poorly studied. More specifically, the role of oxidative 
mitochondrial metabolism during angiogenesis is unknown. Even more, current 
literature does not ascribe a crucial role for oxidative metabolism during vessel 
sprouting. We therefore evaluated the role of fatty acid oxidation (FAO) during 
vessel sprouting and demonstrated that endothelial loss of carnitine palmitoyl 
transferase 1a (CPT1a), a rate-limiting enzyme of FAO, causes vascular 
sprouting defects due to impaired proliferation, not migration, of human and 
murine endothelial cells. Reduction of FAO in endothelial cells did not cause 
energy depletion or disturb redox homeostasis, but impaired de novo nucleotide 
synthesis for DNA replication. Isotope labelling studies in control endothelial cells 
showed that fatty acid carbons substantially replenished the Krebs cycle, and 
were incorporated into aspartate (a nucleotide precursor), uridine 
monophosphate (a precursor of pyrimidine nucleoside triphosphates) and DNA. 
CPT1A silencing reduced these processes and depleted endothelial cell stores of 
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aspartate and deoxyribonucleoside triphosphates. Acetate (metabolized to 
acetyl-CoA, thereby substituting for the depleted FAO-derived acetyl-CoA) or a 
nucleoside mix rescued the phenotype of CPT1A-silenced endothelial cells. 
Finally, CPT1 blockade inhibited pathological ocular angiogenesis in mice, 
suggesting a novel strategy for blocking angiogenesis. 
 
 Overall, our research has uncovered two potential metabolic targets for 
anti-angiogenic therapy. We have provided proof of principle for each of these 
targets in pre-clinical models of pathological angiogenesis. Future research will 
allow further drug development for these targets towards clinical use. 
 
 
 
 
 
 
 
 
 
 
	   8	  
 Samenvatting 
Angiogenese, de groei van nieuwe bloedvaten, is cruciaal tijdens ontwikkeling. 
Blokkade van dit proces veroorzaakt embryonale letaliteit. Verder speelt 
angiogenese speelt ook een belangrijke rol tijdens verschillende fysiologische 
maar ook pathologische situaties. Abnormale bloedvatvorming draagt bij tot 
verschillende ziekten zoals kanker en oogziekten, daarom is blokkeren van 
angiogenese een interessante therapeutische strategie. De huidige anti-
angiogene therapieën focussen op het blokkeren van de groeifactoren die 
angiogenese starten. Deze strategie is succesvol voor de behandeling van 
oogziekten maar niet voor de behandeling van kanker, waar er problemen 
optreden door toxiciteit en resistentie. Er is dus een noodzaak om nieuwe anti-
angiogene strategieën te onderzoeken. 
 
 Bloedvatvorming gebeurt door middel van een migrerende tip cel en een 
prolifererende stalk cel. Dit proces wordt geleid door genetische signalen maar 
het is niet geweten of metabolisme ook kan bijdragen. Onze hypothese is dat de 
pro-angiogene groeifactoren het metabolisme herprogrammeren zodat 
voldoende biomassa en energie geproduceerd kan worden om celdeling en 
migratie van de endotheelcellen te ondersteunen tijdens bloedvatgroei. In deze 
PhD thesis onderzochten wij de rol van metabolisme tijdens angiogenese waarbij 
wij focusten op glycolyse en vetzuuroxidatie. 
 
 In een eerste studie toonden wij aan dat endotheelcellen voornamelijk 
glycolyse gebruiken om energie te produceren en dat blokkade van PFKFB3 
(een activator van glycolyse) in het endotheel resulteert in defecte 
bloedvatvorming. PFKFB3 stimuleerde niet alleen proliferatie maar ook de 
vorming van filopodia en lamellipodia die nodig zijn voor migratie. Het 
mechanisme hiervan was de binding van PFKFB3 met F-actin in de filopodia en 
lamelliodia. In vitro en in vivo competitieve sprouting assays toonden aan dat 
PFKFB3 de sterke pro-stalk activiteit van notch kan compenseren en de cel 
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dwingen om een tip cel te worden. Blokkade van PFKFB3 bewerkstelligde het 
tegenovergestelde effect. Deze data toonden voor het eerst aan dat het 
glycolytisch metabolisme angiogenese kan regelen. 
 
 Na identificatie van PFKFB3 als regulator van angiogenese werd de 
potentiele therapeutische toepasbaarheid hiervan geëvalueerd. 3PO, een 
farmacologisch blokker van PFKFB3, verminderde pathologische angiogenese in 
verschillende muismodellen van onder andere oogziekten en ontsteking. Hoewel 
PFKFB3 blokkade glycolyse met slechts 30% verminderde, bleek dit voldoende 
om pathologische bloedvatvorming te verminderen. Door de beperkte blokkade 
van glycolyse vonden we minimale neveneffecten in de muizen. Deze inzichten 
kunnen veelbelovend zijn voor ontwikkeling van PFKFB3 blokkade als anti-
angiogene strategie. 
 
 Afgezien van onze studie naar glycolyse, bleef het metabolisme van 
endotheelcellen slecht bestudeerd. Vooral de rol van het mitochondriaal 
metabolisme tijdens angiogenese is zeer vaag beschreven. Wetenschappelijke 
literatuur schrijft enkel een signaling rol toe aan mitochondriën. Om meer inzicht 
te krijgen in een mogelijke rol van mitochondriaal metabolisme tijdens 
angiogenese, hebben wij ons gefocust op vetzuuroxidatie. Blokkade van CPT1a, 
een belangrijke vetzuur transporter, verminderde bloedvatvorming zowel in 
fysiologische als pathologische modellen van angiogenese. Dit effect was enkel 
toe te schrijven aan een defecte celdeling, terwijl migratie volledig normaal was. 
Verder onderzoek wees uit dat vetzuuroxidatie in endotheelcellen een grote rol 
speelt in de opbouw van nucleotiden voor DNA synthese. Deze rol was tot nog 
toe onbeschreven en bleek relatief uniek te zijn voor endotheelcellen: enkel 
fibroblasten gebruikten vetzuuroxidatie voor eenzelfde doel.  
 
 Ons onderzoek heeft nu twee potentiele metabole targets opgeleverd voor 
anti-angiogene therapie. Wij hebben ook een eerste bewijs geleverd dat 
blokkade van deze targets angiogenese in pathologische muismodellen 
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reduceert. Verder onderzoek zal uitwijzen of deze targets effectief bruikbaar zijn 
in de kliniek. 
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Chapter 1 
 
INTRODUCTION 
 
1. ANGIOGENESIS	  
	  
1.1. ANGIOGENESIS IN HEALTH AND DISEASE	  
 
The vasculature is one of the largest organs as it spreads through the entire 
body. Evolutionary, blood vessels developed when organisms became too large 
for diffusion to meet the body’s need for oxygen and nutrients. There are several 
mechanisms for the growth of new blood vessels: vasculogenesis and 
angiogenesis (Patan, 2004; Velazquez, 2007). 
 
Vasculogenesis is the process whereby blood vessels are formed from 
progenitor cells. During development of the fetus, vessels develop from 
mesodermal-derived hemangioblasts. It was long thought that vasculogenesis 
could only occur during embryonic development.  However, bone marrow 
derived endothelial progenitor cells were identified in adult peripheral blood, 
which contributed to vessel formation (Velazquez, 2007).  
 
Angiogenesis, is the process whereby new blood vessels are formed from 
pre-existing vessels. Two types of angiogenesis have been described: 
intussusceptive angiogenesis and sprouting angiogenesis. Intussusceptive 
angiogenesis involves the splitting of an existing blood vessel by the formation 
of a pilar of tissue and is more important during embryonic development (Burri 
and Tarek, 1990). Sprouting angiogenesis on the other hand, involves the 
formation of new blood vessels in tissues previously devoid of vessels. This 
process is not only critical during development to allow organ growth, but also in 
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a healthy adult for the cycling ovary, placental growth during pregnancy and 
wound healing (Carmeliet, 2003).  
 
A major role for angiogenesis was also described in many pathological 
conditions. Best known is its role during cancer growth, inflammation and ocular 
diseases where excessive and faulty angiogenesis contributes to the 
pathogenesis of these disorders. Besides these, angiogenesis has been 
implicated in up to 70 other disorders (Carmeliet, 2003). Thus angiogenesis has 
far reaching implications in health and disease and is therefore subject of 
intense research. Indeed blocking blood vessel growth can be of great 
therapeutic relevance.  
 
 
1.2. THE MECHANISM OF VESSEL BRANCHING 
 
The inside of blood vessels is lined by Endothelial cells (ECs). For structural 
purposes, basement membrane, pericytes and smooth muscle cells support the 
endothelial cells (Figure 1), and together they will comprise the mature blood 
vessel. The main function of ECs in quiescent blood vessels is the transport of 
oxygen and nutrients to the surrounding tissues. Whenever oxygen and/or 
nutrients become limiting, for instance during ischemia or in the tumor 
microenvironment, the tissue will secrete pro-angiogenic growth factors to initiate 
the formation of new blood vessels.  
 
 
 1.2.1. ENDOTHELIAL TIP CELL 
 
Endothelial cells express receptors on their surface and binding of 
secreted growth factors will initiate angiogenesis. A first step during angiogenesis 
is the selection of an endothelial tip cell. Secreted vascular endothelial growth 
factor (VEGF) will activate VEGF receptors (VEGFR), which are expressed on 
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the EC surface (Carmeliet and Jain, 2011a). There are 3 VEGF receptors 
described: VEGFR1, a decoy receptor for VEGF-A and thus anti-angiogenic; 
VEGFR2, considered the main receptor for VEGF-A and the most important for 
vessel sprouting; and VEGFR3, the main receptor for VEGF-C and of major 
importance for lymph-angiogenesis. Activation of VEGFR2 is considered the 
main regulator of tip cell specification and its activity is enhanced by the co-
receptor Neuropilin 1 (Nrp1). Activation of VEGFR3 also contributes to tip 
selection, but to a lesser extent (Tammela et al., 2011; Welti et al., 2013). The 
selected tip cell will then extend filopodia that probe the environment for the 
secreted growth factors to lead the newly formed sprout towards the demanding 
tissue (Potente et al., 2011). Typically, tip cells migrate and only minimally 
proliferate. Stalk cells follow directly behind the tip cell and proliferate to elongate 
the newly formed sprout. 
 
To ensure organized tip cell specification, expression of Notch ligands by 
the tip cell (such as Delta like ligand 4, Dll4) activates Notch signaling in the 
adjacent stalk cell to prevent it from becoming a tip cell (Benedito et al., 2012; 
Phng et al., 2009). Indeed activation of Notch reduces VEGFR2 expression, 
while increasing VEGFR1 expression at the surface of the cell, to prevent tip cell 
selection. Notch signaling was shown to be dynamic, so that ECs dynamically 
switch between tip and stalk position during angiogenesis (Jakobsson et al., 
2010). Typically, the cells with the highest VEGFR2 and lowest VEGFR1 levels 
will migrate to the tip. It has been suggested that this process ensures that the 
cell, best equipped to sense the VEGF gradient, becomes tip cell and takes the 
lead.  
 
Besides the critical VEGFR2/Notch interaction for tip cell specification, 
other pro-angiogenic signals also contribute to tip cell function. While 
Angiopoietin 1 (Ang1)/ Tie2 signaling typically supports EC adhesion and 
maturation, the Angiopoietin 2 (Ang2) /Tie2 pathway will support tip cell migration 
whenever pro-angiogenic signals are present (Gerald et al., 2013). Ang2 
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supports migration by antagonizing Ang1 signaling and through activation of 
integrins (Felcht et al., 2012). Adhesion of the tip cell to the extracellular matrix 
(ECM) is mediated by integrins and supports migration along the growth factor 
gradient (Welti et al., 2013). To probe the environment for the guidance 
molecules, the endothelial tip cell expresses guidance receptors. Semaphorins 
bind to Nrp1 expressed on the tip cell surface and in this way regulate VEGF 
activity but also Dll4 expression, thereby maintaining the balance of tip versus 
stalk cells (Welti et al., 2013). Ephrins are another class of guidance molecules. 
Upon binding to ephrin receptors, expressed on the EC surface, they also 
regulate EC migration (Cheng et al., 2002). Other classes of guidance molecules 
include netrins and slit proteins, which also contribute to tip cell migration (Welti 
et al., 2013).   
 
 
1.2.2. ENDOTHELIAL STALK CELL 
 
Endothelial stalk cells are located directly behind the tip cell (Figure 1) and 
proliferate to elongate the sprout. As discussed above, the tip cell expresses Dll4 
- which activates Notch signaling in the adjacent stalk cell - to prevent it from 
becoming a tip cell. However Notch activation reduces proliferation in vitro while 
endothelial stalk cells must proliferate rapidly to elongate the sprout. To 
overcome this limitation, Notch signaling induced expression of Notch-regulated 
ankyrin repeat protein (Nrarp), which coordinates Notch and Wnt signaling to 
allow proliferation of the stalk cells (Phng et al., 2009). More specifically, Nrarp 
limits Notch signaling and induces Wnt signaling. Indeed combined stimulation of 
ECs with Wnt3a and Dll4 allows proliferation only when Nrarp is present. ECs 
express Wnt receptors and previous reports showed that activation of Wnt/B 
catenin signaling induces EC proliferation (Masckauchan et al., 2005). 
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1.2.3. ENDOTHELIAL PHALANX CELL 
 
When tissue equilibrium is restored, secretion of pro-angiogenic factors 
will cease and endothelial cells will again assume a quiescent state (phalanx 
cells, Figure 1). Establishment of a tight EC barrier is mediated through cell 
adhesion molecules such as vascular endothelial-Cadherin (VE-Cadherin) and 
tight junction protein ZO1. Mechanistically, several signaling molecules contribute 
to maintenance of EC quiescence such as VEGF (for EC survival) and Ang1 (see 
also above) (Welti et al., 2013). Furthermore, prolyl hydroxylase domain 
containing protein 2 (PHD2) haplodeficiency promoted EC quiescence through 
Hypoxia-inducible factor 2 (HIF2) driven up-regulation of VEGFR1 and VE-
Cadherin (Mazzone et al., 2009). Lastly, increased Notch signaling also 
promotes EC quiescence (Maes et al., 2014; Noseda et al., 2004). The main 
function of quiescent ECs is to ensure blood flow and transport of oxygen and 
nutrients to the adjacent tissue. Endothelial cells can remain in this quiescent 
state for years but are able to very rapidly switch to angiogenesis when 
necessary.  
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Figure 1. Scheme of tip-stalk-phalanx cells in a vascular sprout 
 
Schematic representation of a vascular sprout, showing the endothelial tip cell 
(green) - containing filopodia - followed by proliferating stalk cells (purple). 
Whenever a vascular sprout is fully formed, the endothelial cells revert to a 
quiescent state (Phalanx cells, in grey) and for structural purpose they are 
supported by pericytes (orange) and basement membrane (red).  
Adapted from (Geudens and Gerhardt, 2011) 
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1.3. ANTI-ANGIOGENESIS 
 
 1.3.1. VESSEL PRUNING 
 
Excessive angiogenesis is a hallmark of cancer, inflammation and ocular 
diseases. Therefore, blocking angiogenesis has become an attractive therapeutic 
strategy (Carmeliet and Jain, 2011a). The rational of these anti-angiogenic 
therapies is to starve the tumor from oxygen and nutrients by pruning the blood 
vessels. Many pro-angiogenic molecules have been identified of which VEGF-A 
is best known, as it is the most essential growth factor for angiogenesis. Indeed 
mice haplodeficient or overexpressing VEGF are embryonically lethal due to 
severe vascular abnormalities (Carmeliet et al., 1996). Furthermore, numerous 
reports have demonstrated the critical role of VEGF in normal and abnormal 
angiogenesis. VEGF was found to be up-regulated in the hypoxic tumor 
environment and blocking VEGF using neutralizing anti-bodies showed promising 
results in pre-clinical mouse tumor models (Ferrara, 2009). Therefore, the 
majority of anti-angiogenic therapies target VEGF. 
 
 Many strategies to block VEGF or its signaling, have been developed: 
VEGF neutralizing antibodies (fi bevacizumab) and tyrosine kinase inhibitors (fi 
sunitinib, sorafenib) (Ferrara, 2009; Jain et al., 2006). For treatment of ocular 
diseases, such as the wet form of age related macular degeneration, anti-VEGF 
treatments have been successful (Carmeliet and Jain, 2011a). However for 
treatment of cancer, the effects in the clinic were not as anticipated. Some types 
of cancer never respond to anti-angiogenic therapy while others initially respond 
but eventually develop resistance or suffer from toxic side effects. Overall the 
outcome is a prolongation of progression free survival by a few months (Allegra 
et al., 2011; Escudier et al., 2010; Jain et al., 2006; Jain et al., 2009). Indeed, 
ECs also rely on VEGF for survival, resulting in toxic side effects of VEGF 
blockade. Furthermore, VEGF is only one of the pro-angiogenic molecules 
secreted by the tumor. Upon VEGF blockade, the tumor can secrete other growth 
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factors to re-initiate angiogenesis, thereby developing resistance to the anti-
VEGF therapy (Bergers and Hanahan, 2008). To overcome this limitation, agents 
against other pro-angiogenic molecules are being developed but the tumor 
secretes a wide variety of pro-angiogenic factors, thus the question arises 
whether this strategy will be more successful.  
 
Additionally, it has been suggested that the current anti-angiogenic 
strategies might cause cancer cells to become more malignant. The pruning of 
tumor vessels increases tumor hypoxia, which can promote invasion and 
metastasis. While some cells will try to escape the hypoxic environment, others 
will try to adapt to survive. Indeed, cancer stem cells home in the hypoxic 
environment where they sustain self-renewal (Loges et al., 2010; Zhao et al., 
2011). Eventually, these cancer stem cells contribute to the reoccurrence of 
cancer in patients (Loges et al., 2010; Zhao et al., 2011). However, only some 
pre-clinical studies support these findings while other reports contradict these 
data. Furthermore, no evidence to support this hypothesis can be found in the 
clinic, as anti-angiogenic therapy was not clearly associated with increased 
metastatic disease (Carmeliet and Jain, 2011a; Welti et al., 2013).  
 
 
 1.3.2. VESSEL NORMALIZATION 
 
Nevertheless, the limited success of current anti-angiogenic therapies for 
cancer treatment warrants the search for novel strategies. The hostile tumor 
microenvironment (hypoxia, inflammation and mechanical stress) results in the 
production of an overload of pro-angiogenic factors (Bergers and Benjamin, 
2003; Carmeliet and Jain, 2000). The vessels formed in response to this stimulus 
are functionally and structurally abnormal. The tumor vasculature is leaky, 
tortuous, dilated and lacks organization. Functionally these vessels can never 
fulfill the nutrient and oxygen demands of the tumor cells. A cycle begins where 
tumor cells continuously secrete pro-angiogenic factors to form more abnormal 
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blood vessels that do not function normally and cannot fulfill the needs of the 
tumor. The result is a hostile tumor microenvironment with high interstitial 
pressure and hypoxia, two features that promote metastasis, which is facilitated 
by the leaky vessels. 
 
A novel hypothesis is therefore not to prune the tumor vessels but to make 
them more normal, both structurally and functionally (Carmeliet and Jain, 2011b). 
Normalized tumor vasculature would allow adequate transport of nutrients and 
oxygen, fulfilling the demands of the tumor and preventing metastasis (Figure 2). 
Furthermore, it would increase the effectiveness of chemo- and radiotherapy as 
their efficacy depends on proper perfusion of the tumor. Indeed chemotherapy 
often does not reach the core of the tumor due to leaky vessels and radiotherapy 
is less efficient due to poor tumor oxygenation.  
 
Genetic studies in mice demonstrated that PHD2 haplodeficiency 
normalizes the tumor vasculature. Tumor perfusion and oxygenation were 
increased, which resulted in reduced metastasis and increased efficacy of 
chemotherapy (Mazzone et al., 2009). Furthermore, an FDA approved anti-
malaria agent (Chloroquine) was recently shown to induce vessel normalization 
through increased Notch signaling (Maes et al., 2014). Chloroquine treatment not 
only reduced metastasis but also improved response to chemotherapy. Thus this 
novel hypothesis clearly warrants further investigation as anti-angiogenic 
strategie (Figure 2). 
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Figure 2. Anti-aniogiogenesis: vessel pruning versus vessel normalization 
 
The normal vasculature is highly organized and the balance between pro- and 
anti-angiogenic factors is tightly controlled. In contrast, tumor vessels are highly 
disorganized caused by an overload of pro-angiogenic factors. The current anti-
angiogenic strategies aim to prune the tumor vessels thereby starving the tumor. 
However this strategy potentially results in a more hostile tumor micro-
environment and reduced efficacy of chemoradiation. Therefore a novel proposal 
for anti-angiogenesis is to normalize the tumor vessels, thereby stabilizing the 
tumor microenvironment. This strategy aims to induce a more benign tumor 
behavior and better response to chemoradiation (Adapted from Jain et al, 
Scientific American, 2008). 
 
 
Anti-angiogenic strategies:
 “vessel pruning” versus “vessel normalization”
pruning
impaired perfusion
malignant
highly invasive
more metastasis
poor 
chemoradiation 
response
normalization
increased perfusion
benign
encapsulated
less metastasis
strong 
chemoradiation 
response
Jain, Scientific Am 2008
tumornormal
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2. METABOLISM AS ANTI-ANGIOGENIC TARGET? 
 
We decided to approach angiogenesis from a different perspective. Secreted 
growth factors activate quiescent ECs to initiate angiogenesis. We postulate that 
quiescent ECs must alter their metabolism to support their increased metabolic 
needs during angiogenesis. Indeed migration of ECs requires ATP for 
cytoskeletal remodeling and proliferation requires the production of biomass 
building blocks. Thus we hypothesized that growth factor signaling in ECs 
converges onto metabolism and that the angiogenic switch must be 
accompanied by a metabolic rewiring. Instead of targeting the different growth 
factors and their signaling pathways, we considered the alternative strategy of 
targeting the metabolic rewiring, thereby possibly circumventing the resistance to  
current anti-angiogenic strategies. Even more, by restoring the quiescent 
metabolic phenotype in ECs, we hypothesized that the tumor vasculature will 
normalize, resulting in increased functionality of the vessels and less metastasis. 
 
 In order to target metabolism, we must first understand how metabolism is 
reprogrammed when ECs switch from quiescence to angiogenesis. Currently, 
little is known on metabolism of ECs apart from observations that they are highly 
glycolytic. Thus we first focused on the glycolytic pathway and its specific 
function for the endothelial tip cells. Next we evaluated the role of fatty acid 
oxidative metabolism in ECs. More specifically we focused on its novel role 
related to nucleotide synthesis. An overview of the state of the art on EC 
metabolism is provided in the next sections. 
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3. GLYCOLYSIS 
 
3.1. GLYCOLYSIS: PATHWAY AND FUNCTIONS 
 
Glycolysis is the conversion of glucose to lactate, which does not require 
consumption of oxygen. This metabolic pathway is of vital importance and thus 
controlled at different levels. Rate limiting enzymes of glycolysis are hexokinase 
(HK, converts glucose to glucose-6-phosphate) and phosphofructokinase 1 
(PFK1, converts fructose-6-phosphate to fructose-1,6-phosphate). Well known 
regulators of PFK1 are the phosphofructokinase-fructose-2,6-bisphosphatase 
enzymes (PFKFB), which produce fructose-2,6-bisphosphate, an allosteric 
activator for PFK1 (Van Schaftingen et al., 1982). Four different PFKFB isoforms 
have been described of which PFKFB3 has the highest kinase to phosphatase 
activity and thus activates PFK1. 
 
 The vital importance of glycolysis relates to the different functions it can 
serve. The conversion of glucose to lactate produces net two molecules of ATP. 
Additionally, glycolysis also feeds into several side pathways (Figure 3): i) 
Glucose-6-phosphate can enter the oxidative pentose phosphate pathway 
(oxPPP), which serves multiple functions. First of all, oxPPP generates two 
molecules of NADPH, needed for redox homeostasis or lipid synthesis. 
Additionally, oxPPP generates ribose-5-phosphate, an essential carbon source 
for nucleotide synthesis. ii) Fructose-6-phosphate can fuel the hexosamine 
biosynthesis pathway, which supports glycosylation of proteins.  iii) Glycolysis 
also feeds the non-oxidative pentose phosphate pathway (non-oxPPP), which 
also generates ribose-5-phosphate for nucleotide synthesis. iv) Further down the 
glycolytic cascade, glucose fuels serine and glycine biosynthesis. These amino 
acids are essential for protein and nucleotide synthesis but also for redox 
homeostasis. v) Glycolysis also feeds polyamine biosynthesis, however its 
function in ECs remains unknown. vi) Finally, one of the last intermediates of the 
glycolytic pathway is pyruvate, an essential fuel for the tricarboxylic acid (TCA) 
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cycle, which is also a rich source of macromolecules. Overall, it is not surprising 
that glycolysis is essential for proliferation.   
 
 
 
Figure 3: Schematic representation of the metabolic functions of 
glycolysis. Schematic representation of the glycolytic pathway showing the ATP 
producing steps as well as the different side pathways which support biomass 
production (ribose-5-P for nucleotides, serine and glycine for protein synthesis) 
and redox homeostasis (oxidative pentose phosphate pathway, serine pathway). 
Additionally glycolysis can also support protein glycosylation and polyamine 
biosynthesis. Lastly, pyruvate produced in the end steps of glycolysis can fuel the 
krebs cycle and in turn be a source of ATP, amino acids and nucleotides. 
(Adapted from Eelen et al., Circulation Research 2015) 
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 3.2. STATE OF THE ART: GLYCOLYSIS IN ENDOTHELIAL CELLS 
 
During quiescence, ECs are exposed to the highest concentrations of oxygen in 
the blood. Strikingly, ECs were reported to be highly glycolytic, even resembling 
cancer cells in this respect. (Culic et al., 1997; De Bock et al., 2013c; Krutzfeldt 
et al., 1990). However, when glucose concentrations decrease, oxidation of 
nutrients (glucose, palmitate and amino acids) is stimulated. ECs thus switch to a 
more oxidative metabolism when glycolysis is impaired, an effect which is called 
the Crabtree effect (Krutzfeldt et al., 1990). Furthermore, anaerobic glycolysis in 
ECs is stimulated during pathological conditions such as latent infection with 
Kaposi Sarcoma associated Herpes virus or pulmonary hypertension (Delgado et 
al., 2010; Fijalkowska et al., 2010). 
 
 Regulation of glycolytic flux depends on the environment as well as 
molecular signals. It has been shown that pulmonary microvascular ECs are 
highly glycolytic while the pulmonary arterial ECs consume more oxygen (Parra-
Bonilla et al., 2010). This was in line with the higher proliferation rate of the 
microvascular cells when compared to the arterial ECs. Furthermore, 
hemodynamic forces also stimulate glycolysis (Doddaballapur et al., 2015; 
Suarez and Rubio, 1991). 
 
 Since ECs are exposed to high oxygen levels, it seems paradoxical that 
they are highly glycolytic. Compared to glycolysis, oxidative phosphorylation can 
generate ATP more efficiently. Indeed, glycolysis generates four molecules of 
ATP while oxidation can generate up to 36 molecules. However, ECs proliferate 
and migrate into avascular areas. Therefore relying on anaerobic glycolysis as 
energy source is much more efficient in an oxygen-depleted milieu, especially 
since the levels of oxygen drop faster over the distance from the vessel to the 
core of an avascular area then the levels of glucose (Buchwald, 2011; Gatenby 
and Gillies, 2004). In line with these findings, ECs are resistant to hypoxia only 
when glucose is present (Mertens et al., 1990). One could speculate on other 
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possible advantages of glycolysis over oxidative metabolism. First, by consuming 
little oxygen, they can transfer more oxygen to perivascular cells. Second, when 
sprouting into avascular tissues, ECs become exposed to low levels of oxygen 
and glucose. Because glucose diffuses further away from vessels than oxygen 
(Buchwald, 2011; Gatenby and Gillies, 2004), ECs can still rely on anaerobic 
glycolysis to form vessels. Third, by maintaining a low oxidative metabolism, ECs 
minimize the production of reactive oxygen species, thereby providing protection 
against their high-oxygen milieu. Fourth, glycolysis generates ATP more rapidly 
than oxidative metabolism, allowing ECs to meet the energy demands for 
dynamic rapid changes in motility. Finally, the glycolysis side pathways are 
necessary for the biosynthesis of macromolecules needed for cell mass 
duplication during cell division. 
 
 
 3.3. GLYCOLYSIS AND MIGRATION 
 
Filopodia and lamellipodia are essential for tip cells and migration. Contraction 
and protrusion of these structures rely on actin cytoskeleton remodeling and 
require hydrolysis of large amounts of ATP. Mitochondria (0.5 to >4.0 µm) are too 
bulky to fit into thin filopodia and lamellipodia (250 nm wide and high, 
respectively) and are mostly present in the perinuclear cytosol, distant from the 
filopodial tip, which can be up to 10 µm long. Diffusion of ATP from distant 
mitochondria in the perinuclear cytosol may thus not be able to support the high 
and rapidly changing ATP demands for sustained motor activity at the tip.  
 
 Compartmentalization of glycolysis with F-actin can offer many 
advantages. By creating a “glycolytic hub”, glycolytic enzymes are arranged on a 
cytomatrix in an assembly line, where metabolic substrates are passed from one 
enzyme to the next. Glycolytic enzymes are activated by actin, and help in 
assembling actin microfilaments (Real-Hohn et al., 2010). The enzyme proximity 
and activation by actin favor maximal rates of reaction (al-Habori, 1995). Also, 
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rapid extension–retraction of filopodia and lamellipodia may create an ATP drain 
for the cell body. Localizing ATP supply to compartments where ATP is 
consumed can prevent catastrophic ATP depletion.  
 
 The link between glycolysis and actin is evolutionarily conserved, as 
glycolysis fuels other motile structures such as flagella of micro-organisms, 
tentacles of hydra, or cilia of eukaryotic cells (Baquer et al., 1975; Hereng et al., 
2011; Pavlova, 2010). The relevance of this link is underscored by findings that 
expression of aldolase, incapacitated to bind actin, paralyzes fruit flies (Wojtas et 
al., 1997).  
 
 
4. FATTY ACID OXIDATION 
 
 4.1. METABOLIC FUNCTIONS OF FAO 
 
Fatty acid oxidation (FAO) is one of the major metabolic pathways in a cell. By 
shuttling cytosolic long chain fatty acids through the outer mitochondrial 
membrane, carnitine palmitoyltransferase 1 (CPT1) constitutes a first rate-limiting 
step of FAO (Figure 4). Three different isoforms of CPT1 have been described: 
CPT1a (liver isoform), CPT1b (muscle isoform) and CPT1c (brain isoform). The 
importance of these transporters is demonstrated by the lethality of CPT1a knock 
out mice as well as the pathologies of patients deficient for CPT1a (Goetzman, 
2011; Olpin, 2013). Next, CPT2 will transport fatty acids over the inner 
mitochondrial membrane into the mitochondria where they are converted to 
acetyl-CoA, which subsequently enters the TCA cycle.  
 
 FAO can serve various purposes (Figure 5). Best known is its function to 
generate large amounts of ATP. The large amounts of acetyl-CoA generated by 
FAO enter the TCA resulting in the generation of reducing equivalents NADH and 
FADH2, which are used for oxidative phosphorylation. This function of FAO is 
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critical in highly energy-dependent tissues such as the heart, muscle, kidney and 
liver, and explains why inherited FAO gene defects in mice and humans cause 
energy deficits in these organs (Goetzman, 2011; Olpin, 2013).  
 
 Second, FAO has been implicated in redox homeostasis. On one hand, 
cells can use FAO to generate reactive oxygen species (ROS), as documented in 
macrophages for bactericidal killing of pathogens (Hall et al., 2009). On the other 
hand, FAO is involved in ROS scavenging. Indeed, FAO promotes the formation 
of redox equivalents (NADPH) by providing acetyl-CoA, which is converted in the 
tricarboxylic acid (TCA) cycle to citrate and malate, metabolites that are 
substrates for the NADPH-producing malic enzyme and isocitrate 
dehydrogenase-1 and -2, respectively. Stressed cancer cells use this redox 
mechanism for survival (Carracedo et al., 2013; Jeon et al., 2012). It remains 
unknown whether ECs use FAO for vessel sprouting and, if so, whether they use 
FAO for ATP production, redox balance or another metabolic purpose 
 
 
 
Figure 4: Schematic representation of CPT1 and CPT2 function.  
CPT1 enzymes are located in the outer membrane for transport of fatty acids into 
the intermembrane space. CPT2 then takes over to transport fatty acids into the 
mitochondrial matrix for subsequent beta-oxidation. (Adapted from: 
https://hrcbiochem.wordpress.com) 
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Figure 5: Schematic representation of the metabolic functions of fatty acid 
odixation. Fatty acids are oxidized to acetyl-CoA and enter the TCA cycle. 
Previously described roles of FAO are the production of NADPH for redox 
homeostasis and ATP production in the electron transport chain (ETC). We now 
describe a novel role of FAO: the production of biomass (Amino acids and 
nucleotides) 
 
 
4.2. STATE OF THE ART: THE ROLE OF FAO IN ECS 
 
Fatty acid oxidation (FAO) is critical for many cell types (see above), but its role 
in ECs during vessel sprouting is largely undefined. Indeed, apart from a few 
contradictory in vitro reports (Dagher et al., 2001b; De Bock et al., 2013a; Spahr 
et al., 1989a; Spolarics et al., 1991a), the role and importance of FAO in ECs 
during angiogenesis in vivo is undefined. In vitro, it has been reported that FAO 
is necessary for bio-energetic supply in ECs, mostly when carnitine was present 
in the medium (Dagher et al., 1999; Dagher et al., 2001b; Hulsmann and 
Dubelaar, 1988; Hulsmann and Dubelaar, 1992) or when glucose was absent 
(Dagher et al., 2001a; Krutzfeldt et al., 1990). In case of the latter, increased fatty 
acid oxidation compensates reduced glycolytic ATP production. It was also 
shown that ECs oxidize extra- and intra-cellular fatty acids, but the importance of 
A Bctrl shCPT1a C
sp
ro
ut
s/
sp
he
ro
id
20
15
0
ctrl to
ta
l s
pr
ou
t l
en
gt
h 
(m
m
)
shCPT1a
D 2.0
1.5
0
ctrl
1.0
*
10
5
shCPT1a
*
0.5
shCPT1a - +
0
20
40
60
80
m
ig
ra
tio
n 
(%
)


shCPT1a - +
0
10000
5000
15000
th
ym
id
in
e 
in
co
rp
or
at
io
n
*
E F G HWT CPT1acKO
PALMITATE 
ATP 
AMINO ACIDS 
NUCLEOTIDES 
ETC 
CPT1a 
TCA cycle 
NADPH 
PROLIFERATION 
I
	   29	  
fatty acid oxidation for ATP production as compared to the importance of 
glycolytic ATP production is debated (Dagher et al., 1999; Dagher et al., 2001b; 
Delgado et al., 2010; Dobrina and Rossi, 1983; Polet and Feron, 2012; Spolarics 
et al., 1991a).  
 
 The activity of CPT1 is inhibited by malonyl-CoA, which is generated by 
acetyl-CoA carboxylase (ACC). AMP-activated protein kinase (AMPK) increases 
fatty acid oxidation in ECs through inhibition of ACC (Dagher et al., 2001a; 
Fisslthaler and Fleming, 2009). Other studies also connected lipid transporters 
downstream of growth factor signaling. Fatty acid binding protein 4 (FABP4) was 
shown to be a target of VEGF and regulates proliferation of EC (Elmasri et al., 
2009). Also, expression of the lipid transporters fatty acid transport protein 3/4 
(FATP3/4) was induced by VEGF-B, which promoted transport of lipids across 
the endothelium (Hagberg et al., 2010). 
 
 In a recent study, we showed that FAO is responsible for only 5% of the 
total ATP production in ECs (De Bock et al., 2013c). These data already question 
a possible role for FAO as energy source during angiogenesis. Even more, not a 
single report available supports any possible role for FAO during vessel 
sprouting. We therefore investigated the role of FAO in ECs during vessel 
sprouting in vivo, and characterized how fatty acid metabolism determines EC 
behavior. Our study uncovered an unexpected role of fatty acid carbons for de 
novo nucleotide synthesis during EC proliferation in sprouting vessels.  
 
 
5. OTHER METABOLIC PATHWAYS 
 
5.1. GLUTAMINE METABOLISM 
     
Glutamine metabolism was only minimally studied in ECs. ECs take up glutamine 
but are also capable of producing glutamine themselves through glutamine 
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synthetase (Lohmann et al., 1999). When glutamine is taken up by ECs, it is 
converted to glutamate thereby producing ammonia (Wu et al., 2000).  
Glutaminase constitutes the first step of glutaminolysis, its activity in ECs was 
shown to be 20-fold higher compared to lymphocytes, which already have high 
glutaminolysis (Leighton et al., 1987). However, it remains debated whether 
glutamine metabolism supports ATP production in ECs (Wu et al., 2000; 
Spolarics et al., 1991; Krützfeld et al.). Furthermore, pharmacological inhibition of 
glutaminolysis reduced EC proliferation and resulted in senescent-like behavior 
(Unterluggauer et al., 2008). A high rate of glutamine metabolism in ECs could 
potentially serve many purposes. Even though debated, mitochondrial glutamine 
oxidation mighy be a source of ATP. Furthermore, glutamine metabolism can 
also support nitrogen production, which is critical for several biosynthesis 
processes. Glutamine itself is also a critical nitrogen source for de novo 
nucleotide synthesis. Furthermore, glutamine oxidation can contribute to the TCA 
cycle, which in turn is a source of macromolecular precursors needed for 
biomass production. Indeed various amino acids are converted from TCA 
intermediates for protein synthesis but also for nucleotide synthesis (aspartate, 
see below). Thus, glutamine is a rich carbon and nitrogen source needed for 
different biosynthetic processes during cell division. 
 
 
 5.2. NUCLEOTIDE BIOSYNTHESIS 
 
Nucleotide synthesis is necessary to support proliferation of cells. Apart from 
duplicating their DNA (consisting of deoxyribonucleotides), cells also have a 
constant need for ribonucleotides, which constitute the RNA that is critical for 
subsequent protein synthesis.  
 
Nucleotides can be produced by two different pathways: the de novo 
synthesis and the salvage synthesis pathways. De novo synthesis involves 
nucleotide synthesis from carbon and nitrogen sources (glucose, glutamine), 
	   31	  
while salvage synthesis involves the breakdown of existing nucleotides after 
which the breakdown products are used to rebuild new nucleotides. Briefly, the 
de novo synthesis of nucleotides commences when ribose-5-phoshate (a product 
of the oxPPP and non-oxPPP) is phosphorylated to produce 
phosphoribosylpyrophosphate (PRPP), the backbone for uridine monophosphate 
(UMP) and inosine monophosphate (IMP). For the conversion of PRPP to UMP, 
glutamine is a crucial nitrogen source while aspartate is a critical carbon source. 
Conversion of PRPP to IMP requires either glutamine or aspartate as nitrogen 
source. Once UMP and IMP are generated they give rise to pyrimidine (UTP, 
TTP and CTP) and purine nucleotides (ATP and GTP) respectively (Figure 6). 
 
 
 
 
 
Figure 6: Schematic representation of de novo nucleotide synthesis. 
Ribose-5-phosphate is phosphorylated to form PRPP, the backbone for IMP and 
UMP. For this conversion, glutamine and aspartate are essential carbon and 
nitrogen sources. UMP and IMP can then be converted to pyrmidine and purine 
nucleotides respectively.  
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 Literature on cancer metabolism considers glucose and glutamine as the 
major sources for the de novo nucleotide synthesis (Thompson, 2014). If fatty 
acids are mentioned at all, it is for lipid synthesis and not for oxidation. Also in 
other cell types, a role for fatty acid oxidation in nucleotide biosynthesis has not 
been described so far (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: State of the art: carbon source for de novo nucleotide synthesis 
in cancer cells. Glucose metabolism generates ribose-5-phosphate and glycine 
while glutamine metabolism is a major source of aspartate. Together, these 
intermediates fuel de novo nucleotide synthesis to support cancer cell 
proliferation. Lipid metabolism in cancer cells is only mentioned in the context of 
lipid synthesis, not oxidation. 
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Chapter 2 
 
Objectives 
The mechanism of vessel sprouting has been studied extensively. A wealth of 
information is available on the various genetic signals that regulate angiogenesis. 
However, it remains unknown whether other signals can control angiogenesis. 
The cancer cell field has been investigating the role of metabolism for cancer cell 
proliferation for years, however its potential in stromal cells remains 
understudied. We therefore aimed to characterize EC metabolism and to 
elucidate how metabolism regulates vessel sprouting. Furthermore we also 
aimed to uncover any possible translational potential of our findings. 
 
Traditional anti-angiogenic treatments block the signaling of pro-angiogenic 
factors. For treatment of ocular diseases, this strategy is successful but for 
cancer treatment it is largely failing. Indeed, in this setting, current anti-
angiogenic strategies are suffering from insufficient efficacy, resistance and 
toxicity (De Bock et al., 2011). There is thus an urgent need for novel anti-
angiogenic strategies. We now propose an innovative anti-angiogenesis strategy 
by starving ECs from specific nutrient sources.  
 
Vessel sprouting critically relies on two types of ECs: (i) the non-proliferative 
migrating tip cell at the forefront of the sprout; and (ii) the proliferating stalk cells 
that trail behind and elongate the sprout. Both EC types likely have different 
metabolic needs, but the specific role of glycolysis and fatty acid oxidation herein 
is entirely unknown. In this PhD thesis, we have studied the role of both 
pathways during angiogenesis. More specifically, we had three main objectives: 
 
1) To elucidate the role of PFKFB3 driven glycolysis during vessel 
sprouting and more specifically its role for tip cell function. 
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2) To elucidate the role of fatty acid oxidation during vessel sprouting and 
more specifically its role for stalk cell proliferation. 
3) To generate proof of principle that blocking metabolic pathways can 
become a promising anti-angiogenic strategy. For this we have 
employed pre-clinical in vivo models of physiological and pathological 
angiogenesis. 
 
NOTE: All the research in this PhD thesis was the result of extensive teamwork.  
During the process of the Cell publication, I had the opportunity to learn many 
experimental approaches including cell culture based procedures such as 
primary culture of HUVECs (e.g. isolation, transduction, transfection, etc.); 
angiogenesis assays (e.g. spheroid sprouting assay, migration, etc.); metabolism 
assays (e.g. radioactive tracer experiments); standard molecular assays (e.g. 
RT-PCR, western blot) and flow cytometry. Additionally, I also learned various in 
vivo mouse models of angiogenesis (e.g. retinal vessel sprouting and hindbrain). 
More specialized techniques related to zebrafish experiments; SIM imaging and 
mass spectrometry were executed by specific expert core facilities. For this 
paper, I thus contributed mostly by performing and analyzing experiments and 
had the opportunity to learn how to design experiments and to interprete results 
by working in a team with an experienced post-doc and senior PhD student. 
After the Cell publication, the data on pharmacological blockade of PFKFB3 were 
published in Cell Metabolism and Cell Cycle. The knowledge gathered during the 
Cell publication was necessary to finalize these revisions together with a new 
post-doc in the lab. Furthermore, various new animal models of pathological 
angiogenesis were implemented (choroidal neovascularization, retinopathy of 
prematurity and inflammation models). I contributed to the design, execution and 
analysis of these experiment and in addition, received support from our animal 
core facility for specialized animal work (e.g. techniques requiring years of 
training) as well as from our microscopy core for histological and imaging related 
experiments. 
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Lastly, for the Nature publication, I contributed to the design, execution, and 
analysis of the experiments. For the specialized 13C metabolic tracer techniques, 
we collaborated with Dr. Sarah-Maria Fendt and Dr. Bart Ghesquière who are 
experts in mass spectrometry. My role during the process of this publication 
gradually grew toward the coordination of team members and the project (design 
experiments, critical interpretation of result, etc.). In the listed publications, all 
colleagues who contributed were acknowledged as a co-author. 
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Chapter 3 
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SUMMARY
Vessel sprouting by migrating tip and proliferating
stalk endothelial cells (ECs) is controlled by genetic
signals (such as Notch), but it is unknown whether
metabolism also regulates this process. Here, we
show that ECs relied on glycolysis rather than on
oxidative phosphorylation for ATP production and
that loss of the glycolytic activator PFKFB3 in ECs
impaired vessel formation. Mechanistically, PFKFB3
not only regulated EC proliferation but also
controlled the formation of filopodia/lamellipodia
and directional migration, in part by compartmen-
talizing with F-actin in motile protrusions. Mosaic
in vitro and in vivo sprouting assays further re-
vealed that PFKFB3 overexpression overruled the
pro-stalk activity of Notch, whereas PFKFB3 defi-
ciency impaired tip cell formation upon Notch
blockade, implying that glycolysis regulates vessel
branching.
INTRODUCTION
Vessel sprouting relies on the induction of endothelial cells (ECs)
into specialized subtypes, each performing specific functions.
Tip cells at the forefront of the vascular branch extend long filo-
podia and navigate but rarely proliferate, whereas trailing stalk
cells proliferate to elongate the branch (Geudens and Gerhardt,
2011; Potente et al., 2011). Once the vessel is perfused, ECs
become quiescent phalanx cells. Several genetic factors coordi-
nate tip, stalk, and phalanx cell phenotypes (Geudens and Ger-
hardt, 2011; Potente et al., 2011). For instance, Notch signaling
potently controls vessel branching by stimulating the stalk cell
phenotype (Potente et al., 2011). Hence, blockade of Notch
signaling induces vascular hypersprouting, while activation of
the Notch pathway causes the opposite effect. However, a role
for metabolism in vessel sprouting has not been studied to date.
Cell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc. 651
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Only a limited number of reports have characterized the meta-
bolic pathways in ECs in vitro, and even fewer reports have stud-
ied how EC metabolism regulates angiogenesis in vivo (Dobrina
and Rossi, 1983; Harjes et al., 2012; Laing et al., 1992; Mertens
et al., 1990; Peters et al., 2009). Despite immediate access to
oxygen in the blood, ECs have been reported to rely on glycolysis
(Dobrina and Rossi, 1983; Kru¨tzfeldt et al., 1990; Mertens et al.,
1990). However, other studies have claimed that glutamine and
fatty acids weremore essential substrates, suggesting an impor-
tant role for oxidative phosphorylation andmitochondrial respira-
tion (Leighton et al., 1987; Spolarics et al., 1991). How critical
glycolysis versus respiration is for ECbehavior in vivo is unknown.
One of the rate-limiting checkpoints of the glycolytic flux is
the conversion of fructose-6-phosphate (F6P) to fructose-1,6-
bisphosphate (F1,6P2) by 6-phosphofructo-1-kinase (PFK-1).
Phosphofructokinase-2/fructose-2,6-bisphosphatase (PFKFB)
enzymes synthesize fructose-2,6-bisphosphate (F2,6P2), an
allosteric activator of PFK-1 and the most potent stimulator of
glycolysis (Van Schaftingen et al., 1982). Of all PFKFB iso-
enzymes, PFKFB3 has a much higher kinase activity than
bisphosphatase activity (700-fold), thus favoring the production
of intracellular F2,6P2 levels and controlling its abundance (Yalcin
et al., 2009b). By contrast, the PFKFB4 isoenzyme has a much
weaker kinase activity and has been reported to stimulate or
inhibit glycolysis (Goidts et al., 2012; Ros et al., 2012). Silencing
as well as pharmacological inhibition of PFKFB3 in tumor cells
reduces tumor cell glycolysis and growth (Chesney et al., 1999;
Clem et al., 2008). However, aside from a single study docu-
menting its expression in ECs (Bando et al., 2005), the role of
PFKFB3 in angiogenesis has not been studied. Here, we investi-
gated whether PFKFB3-driven glycolysis regulates vessel
sprouting and whether it affects tip versus stalk cell formation.
RESULTS
Endothelial Cells Are Highly Glycolytic
We first explored whichmetabolic pathway is critical for ECs and
measured the flux of metabolic pathways using radioactive
tracer-labeled substrates in EC monolayers. Arterial, venous,
lymphatic, and microvascular ECs were highly glycolytic (Fig-
ure 1A). Glycolysis was even higher in hemangioma and angio-
sarcoma cells (Figure 1B). Glycolysis levels in ECs were largely
comparable to those in tumor cells but much higher than in
various other healthy cells (Figures 1A and 1B). For most exper-
iments, human umbilical venous endothelial cells (HUVECs) were
used (further denoted as ‘‘ECs’’). Notably, when compared to
glucose oxidation (GO), fatty acid oxidation (FAO), and glutamine
oxidation (QO), glycolytic flux was >200-fold higher (Figure 1C).
Mitochondrial respiration was lower in ECs than in other oxida-
tive cell types (Figure 1D). Calculation of the amount of ATP
showed that glycolysis generated up to 85% of the total cellular
ATP content. Overall, glycolysis is the predominant bioenergetic
pathway for ECs.
PFKFB3 Regulates Glycolysis in ECs
To explore the functional importance of glycolysis in ECs, we
focused on PFKFB3, the most abundant isoenzyme in various
EC subtypes (Figures S1A–S1D available online). PFKFB3
silencing in EC monolayers with a lentiviral vector encoding a
PFKFB3 small hairpin RNA (shRNA) (PFKFB3KD) lowered PFKFB3
protein levels by 76% (Figure S1E). PFKFB3 knockdown
decreased F2,6P2 levels (Figure S1F); it also reduced glycolytic
flux but by no more than 35% (Figure 1E). Similar effects
were obtained when using PFKFB3-selective RNA interference
(RNAi) oligomers, which lowered PFKFB3 protein levels by 84%
(Figure S1G) and reduced glycolysis by 40% (Figure 1E). PFKFB3
silencing also reduced glycolysis in arterial and microvascular
ECs, as well as in hemangioma and angiosarcoma cells (Fig-
ure 1E). Furthermore, PFKFB3 knockdown decreased F2,6P2
levels in arterial ECs (by 60%) and in hemangioma cells (by 66%).
PFKFB3 Stimulates Vessel Sprouting In Vitro
To study the role of PFKFB3 in vessel formation in vitro, we first
used EC spheroids. PFKFB3KD decreased sprout numbers and
shortened sprout length (Figures 1F–1I). Conversely, overex-
pression of PFKFB3 using a lentiviral vector encoding PFKFB3
(PFKFB3OE) enhanced glycolysis and increased sprout numbers
and length (Figures S1H–S1L). The reduced sprouting of
PFKFB3-silenced ECs was partly due to an impairment of EC
proliferation (Figure 1J) (see below for effects on EC motility).
In contrast, poisoning mitochondrial respiration by using
inhibitors at concentrations that lower oxygen consumption did
not inhibit vessel sprouting (Figures 1K and 1L; Figure S1M).
Conversely, supplements of pyruvate or NADH at concentrations
that increased the oxygen consumption rate failed to affect
vessel sprouting and did not rescue sprouting upon PFKFB3
silencing (Figures 1M and 1N; Figure S1N). Thus, loss- and
gain-of-function studies highlighted that glycolysis, rather than
respiration, regulates vessel sprouting.
PFKFB3 Gene Deletion in ECs Causes Vascular Defects
In Vivo
We then studied the effects of PFKFB3 deficiency on vessel
formation in the postnatal mouse retina. We generated
PFKFB3lox/lox mice and crossed them with VE-cadherin(PAC)-
CreERT2 mice, an EC-specific Cre-driver line (Benedito et al.,
2009), termed PFKFB3vDEC mice. To evaluate the recombination
efficiency, we crossed PFKFB3vDEC mice with mT/mG mice, a
double-fluorescent Cre reporter line that expresses mem-
brane-targeted Tomato (mT) prior to Cre-mediated excision
and GFP (mG) after excision. Treatment of triple-transgenic
pups with tamoxifen at postnatal days 1–4 inactivated PFKFB3
in 50%–85% of ECs, and the PFKFB3-lox allele was correctly
recombined (Figure S2A). EC loss of PFKFB3 diminished the
number of branch points, distal sprouts with filopodia and filopo-
dia (Figures 2A–2H). Distal sprouts in PFKFB3vDEC mice also had
fewer side connections. The radial expansion of the vascular
plexus was reduced in PFKFB3vDEC mice (Figure 2I) to similar
levels as in other models with sprouting defects (Graupera
et al., 2008; Phng et al., 2009). Similar results were obtained
when using Pdgfb-CreERT2 mice, another EC-selective inducible
Cre-driver line (Claxton et al., 2008) (Figures S2A–S2G), termed
PFKFB3pDEC mice. In PFKFB3DEC mice, vessel regression was
increased because collagen IV staining showed that there were
more empty sleeves of basement membrane without ECs (Fig-
ures 2J–2L), whereas EC proliferation was reduced, as revealed
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by the injection of EdU (Figures 2M–2O). However, EC depletion
of PFKFB3 did not alter the coverage by NG2+ pericytes (Figures
S2H–S2J).
We also analyzed the role of PFKFB3 in vessel formation in the
hindbrain, another model used to study angiogenesis (Fantin
et al., 2013). To assess whether PFKFB3 deficiency affected
this process, we generated high (>90%) chimeric mice by inject-
ing mCherryRed+ wild-type (WT) or PFKFB3!/! ES cells in CD-1
blastocysts. The vascular area in the ventricular zone was
reduced by 40% in embryonic day 10.5 (E10.5) somite-matched
PFKFB3!/! chimeras (Figures 2P–2R), indicating that PFKFB3
regulated vessel sprouting.
PFKFB3 Silencing Impairs Lamellipodia Formation
We then explored whether the vascular defects in mice lacking
endothelial PFKFB3 were also due to EC motility defects, aside
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Figure 1. PFKFB3 Regulates Glycolysis and Vessel Sprouting In Vitro
(A) Glycolytic flux in venous (HUV), arterial (HA), lymphatic (HLy), or microvascular (HMV) ECs is higher than in other healthy cells (mean ± SEM; n = 3–5; *p < 0.05
versus HUV).
(B) Glycolysis in primary ECs (HUVEC) is lower than in murine angiosarcoma (SVR) and hemangioma (MS1) cells but comparable to various tumor cell lines (CT2A
mouse glioma, 4T1 mouse breast carcinoma, MDA-MB-231 human breast carcinoma, MCF7 human breast adenocarcinoma, U2OS human osteosarcoma,
B16F10.9 mouse melanoma, PancO2 mouse pancreatic carcinoma, and HCT116 human colon carcinoma) (mean ± SEM; n = 3; *p < 0.05 versus HUV).
(C) Flux analysis of ECs showing that glycolysis (Glyc) is higher than glucose oxidation (GO), fatty acid oxidation (FAO), or glutamine oxidation (QO) (mean ± SEM;
n = 3; *p < 0.001 versus Glyc).
(D) Oxygen consumption rate (OCR) showing lower respiration in ECs than in oxidative cell types (neurons, hepatocytes [HC], and cardiomyocytes [CM]) (mean ±
SEM; n = 11; *p < 0.01).
(E) Reduction in glycolysis in human arterial (HA), human microvascular (HMV), murine hemangioma (MS1), murine angiosarcoma (SVR), and human venous
(HUVECs) ECs upon genetic silencing by using shRNA (PFKFB3KD; sh) or small interfering RNA (si) (mean ± SEM; n = 3; *p < 0.05 versus shCtrl or siCtrl).
(F andG) Representative bright field photographs of EC spheroids showing that PFKFB3-silenced (PFKFB3KD) ECs formed fewer and shorter sprouts. Scale bars,
50 mm.
(H and I) Morphometric analysis revealing that PFKFB3 silencing (PFKFB3KD) reduced the number of sprouts per spheroid (H), as well as total sprout length (I)
(mean ± SEM; n = 30; *p < 0.01).
(J) 3H-thymidine incorporation assay showing that PFKFB3 silencing (PFKFB3KD) reduced proliferation of EC monolayers (mean ± SEM, n = 3, *p < 0.01).
(K and L) Morphometric quantification revealing that inhibition of mitochondrial respiration by oligomycin (oligo) or antimycin A (anti A) did not inhibit spheroid
sprouting (mean ± SEM; n = 30; *p < 0.05 versus untreated spheroids).
(M and N) Morphometric quantification revealing that stimulation of oxygen consumption by supplementation of pyruvate or NADH did not affect spheroid
sprouting or rescue the reduced sprouting upon PFKFB3 blockade (mean ± SEM; n = 30; *p < 0.05 in PFKFB3KD cells versus control cells).
See also Figure S1.
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from the aforementioned EC proliferation defects. Because
lamellipodia are critical for ECmotility, we quantified lamellipodia
formation. Time-lapse video imaging of GFP+ ECs revealed that
these cells formed lamellipodial projections over large areas and
had leading-edge projections with a front-to-back distribution,
resulting in cell body displacement (Figures 3A, 3D, and 3G;
Movie S1A). In contrast, PFKFB3-silenced cells formed smaller
lamellipodia and often only formed irregularly bulging protru-
sions (Figures 3B, 3E, and 3G; Movie S1B). Lamellipodia in
PFKFB3-silenced cells were also more transient, and the more
randomly projecting disoriented protrusions were unable to pro-
duce cell displacement (Figures 3C and 3F; Movie S1B). These
cells also formed fewer and shorter filopodia (Figures 3H–3M).
PFKFB3 silencing also impaired EC motility, as it reduced EC
migration and sprout formation in the presence of mitomycin C
(MitoC), which blocks EC proliferation (Figures 3N–3P), and
decreased the EC migration velocity (Figure 3Q). Moreover,
video imaging of random cell-motility tracks of individual ECs
revealed a greater directional persistence of movement for con-
trol than PFKFB3-silenced cells (Figures 3R and 3S), presumably
because PFKFB3-silenced ECs were unable to form sustained
lamellipodia.
Tip and Stalk Cell Signals Regulate PFKFB3 Levels
We then explored how PFKFB3 regulated vessel sprouting
mechanistically, and therefore first analyzed whether sprouting-
governing signals affected PFKFB3 expression. Indeed, sprout-
ing-inducingsignals (VEGF,FGF2) increasedPFKFB3expression
and glycolysis (Figure 4A), whereas the sprouting-limiting signal
DLL4 (activating Notch) caused opposite effects (Figure 4B).
However, PFKFB3 levels did not alter the genetic tip versus stalk
cell signature of ECs in baseline conditions (Figures 4C and 4D).
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Figure 2. PFKFB3 Gene Deletion in ECs Causes Vascular Defects In Vivo
(A and B) Confocal images of isolectin-B4-stained (gray) retinal vessels of postnatal day 5 (P5) pups showing reduced vascular branching in mice with endothelial
PFKFB3 deficiency (PFKFB3vDEC) (B) as compared to wild-type (WT) mice (A). Scale bars, 50 mm.
(C and D) Quantification of the number of branch points at the front (C) or rear (D) in the retinal vasculature of PFKFB3vDEC mice (mean ± SEM; n = 20; *p < 0.03).
(E and F) High-magnification confocal images of retinal vessels at the vascular front in WT (E) or PFKFB3vDEC (F) pups showing fewer filopodia in PFKFB3vDEC
pups. Scale bars, 20 mm.
(G and H) Quantification of distal sprouts with filopodia (G) and the number of filopodia (H) in the retinal vasculature of PFKFB3vDEC mice (mean ± SEM; n = 7–9;
*p < 0.05).
(I) Quantification of retinal vascular outgrowth showing that endothelial PFKFB3 gene deficiency (PFKFB3vDEC) reduces radial expansion (mean ± SEM; n = 8–9;
*p = 0.001).
(J–L) Isolectin-B4 (red) and collagen IV (green) staining of WT (J) and PFKFB3DEC (K) mice showing that PFKFB3DEC ECs had more isolectin-B4! collagenIV+
empty sleeves (arrows). Scale bars, 50 mm. (L) The quantification of the collagenIV+ empty sleeves is shown (mean ± SEM; n = 5–7; *p = 0.002).
(M–O) Staining for EdU (red) and Isolectin-B4 (green), revealing fewer proliferating ECs in PFKFB3DEC (N) than WT (M) mice. Scale bars, 50 mm. (O) The quan-
tification of the proliferating ECs is shown (mean ± SEM; n = 9; *p < 0.05).
(P–R) Confocal images of isolectin-B4-stained (green) hindbrains showing reduced vascularization in the ventricular zone of PFKFB3!/! (Q) as compared to WT
(P) chimeras. Scale bars, 50 mm. (R) The quantification of the vascular area is shown (mean ± SEM; n = 4; *p = 0.04).
See also Figure S2.
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Furthermore, PFKFB3 levels did not alter themolecular signature
of ECs that were genetically or pharmacologically instructed to
the tip or stalk cell phenotype. Indeed, we pretreated ECs with
DAPT to promote a tip cell phenotype, as evidenced by the upre-
gulation of VEGFR2/KDR (tip-cell-enriched gene) by 69% and
downregulation of VEGFR1 (stalk-cell-enriched signal) by 38%.
However, PFKFB3 silencing did not alter the molecular signature
of Notch-silenced cells (Figure 4C). Conversely, we also overex-
pressed the Notch intracellular domain (NICD) to promote a stalk
cell phenotype, as evidenced by the upregulated Notch-target
genes (Figure 4D). In stalk-promoted cells, PFKFB3 overexpres-
sion did not alter gene expression (Figure 4D).
PFKFB3 Levels Influence the Tip Cell Position
We then assessed whether PFKFB3 levels influenced the cell-
autonomous ability of ECs to form tip cells. We therefore gener-
ated mosaic spheroids by mixing ECs expressing normal or
silenced levels of PFKFB3 and assessed which ECs were pre-
sent at the tip. PFKFB3 silencing was achieved by lentiviral
transduction of shPFKFB3 and EGFP (PFKFB3KD/GFP). These
cells were mixed in a 1:1 ratio with WT cells expressing
mCherry (WTRED). In control spheroids, generated by mixing
WTRED and EGFP-positive WT cells (WTGFP), comparable
numbers of each genotype were identified at the tip (Figures
4E and 4G). However, when PFKFB3KD/GFP and WTRED cells
were mixed, PFKFB3KD/GFP cells were less frequently present
at the tip (Figures 4F and 4G). Similar results were obtained
when using MitoC-treated ECs, indicating that the reduced
tip cell behavior of PFKFB3KD/GFP cells was not due to impaired
proliferation (Figure S3A). Even when PFKFB3KD/GFP and WTRED
cells were mixed at a 9:1 ratio, fewer PFKFB3KD/GFP cells were
found at the tip (Figure S3B). Conversely, elevated PFKFB3
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Figure 3. PFKFB3 Blockade Impairs
Lamellipodia Formation
(A–G) Snapshot images of time-lapse video
imaging of GFP+ ECs (Movie S1) are shown to
illustrate the dynamic shape and size changes of
the lamellipodia and cellular protrusions in control
(A and D) and PFKFB3-silenced (B, C, E, and F)
cells. Arrows denote the migration direction.
Lamellipodia in (A), (B), (D), and (E) are the gray
veil-like structures; the nucleus and surrounding
cell organelles are intense white. In control cells,
note the presence of large lamellipodia uniformly
forming over broad sections of the cell’s perimeter
(arrowheads in A andD). In PFKFB3-silenced cells,
note the presence of smaller, more localized
lamellipodia (arrowheads in B and E) or the irreg-
ularly bulging small protrusions (arrowheads in C
and F). (G) The quantification of the lamellipodia
area is shown (mean ± SEM; n = 5 independent
experiments each containing >20 cells analyzed;
*p < 0.05).
(H–M) Micrograph of ECs, stained with CellMask
(gray) and nuclear DAPI (blue), showing filopodia
(arrows) in control cells (H and I), but not in
PFKFB3KD cells (J and K). (I and K) Shown are
higher magnifications of the boxes in (H) and (J),
respectively. (L and M) The quantification of the
number of filopodia (L) and their length (M) is
shown (mean ± SEM; n = 5; *p < 0.05).
(N) Quantification of MitoC-treated ECmigration in
scratch wound assays showing reduced migration
upon silencing of PFKFB3 (PFKFB3KD) (mean ±
SEM; n = 3; *p < 0.05).
(O and P) Morphometric analysis of MitoC-treated
sprouting EC spheroids revealing that the effect of
PFKFB3 silencing (PFKFB3KD) in reducing total
sprout length (O) as well as the number of sprouts
per spheroid (P) is independent of proliferation
(mean ± SEM; n = 30; *p < 0.01).
(Q) Quantification of migration speed showing
reduced migration velocity upon silencing
of PFKFB3 (PFKFB3KD) (mean ± SEM; n = 5;
*p < 0.05).
(R and S) Analysis of random cell-motility tracks by time-lapse imaging of GFP+ ECs. Cell tracks were determined by cell nuclei position and migration origin was
superimposed at the zero-cross point. Compared to the more directional persistence of cell movement in control cells (R), cell movements were more random in
PFKB3-silenced (PFKFB3KD) cells (S).
See also Movie S1.
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Figure 4. The Role of PFKFB3 in Tip Cell Formation
(A) Glycolytic flux analysis and western blotting showing that VEGF and FGF2 increased glycolysis (top) and PFKFB3 protein levels (bottom). Ratio represents the
densitometric quantification of PFKFB3 over lamin A/C immunoreactive bands (mean ± SEM; n = 3; *p < 0.05).
(B) Glycolytic flux analysis and western blotting showing that DLL4 reduced glycolysis (top) and PFKFB3 levels (bottom). Ratio represents the densitometric
quantification of PFKFB3 over lamin A/C immunoreactive bands (mean ± SEM; n = 3; *p < 0.05).
(C) Microarray analysis showing that silencing of PFKFB3 (PFKFB3KD) in baseline conditions or after DAPT treatment did not affect the expression of sprouting-
governing genes (n = 3). *p < 0.05 versus control; p was not significant for DAPT versus DAPT + PFKFB3KD. Immunoblotting showed that VEGFR2 protein and
tyrosine phosphorylation levels were not affected (data not shown).
(D) Microarray analysis showing that overexpression of PFKFB3 (PFKFB3OE) did not affect the sprouting-governing gene signature in baseline conditions or after
overexpression of the Notch intracellular domain (NICDOE) (n = 3; *p < 0.05 versus control; &p < 0.05 versus NICDOE).
(E–G) Representative fluorescence photographs of EC spheroids containing a 1:1 mixture of WTRED and WTGFP ECs showing a comparable fraction of WTred and
WTGFP ECs at the tip position (E). In contrast, in spheroids containing a 1:1 mixture of WTRED ECs and ECs with silenced PFKFB3 (PFKFB3KD/GFP), a reduced number
of PFKFB3KD/GFP ECswas present at the tip position (F). (G) The quantification of the fraction of tip cells with the indicated PFKFB3 genotype is shown, revealing the
competitive disadvantage of PFKFB3KD/GFP ECs to reach the tip (n = 30; *p < 0.01). Scale bars, 50 mm.
(H and I) Morphometric quantification of spheroid sprouting showing that Notch1 silenced (NOTCH1KD) ECs form more (H) and longer (I) sprouts but that
hypersprouting was abolished when both Notch and PFKFB3 were silenced (NOTCH1KD/PFKFB3KD) (mean ± SEM; n = 30; *p < 0.05 versus control (gray), &p <
0.0005 versus NOTCH1KD).
(J) Mosaic EC spheroids containing a 1:1 mixture of WTRED and NOTCH1KD/GFP cells showing a larger fraction of NOTCH1KD/GFP cells at the tip (left). However,
compared to WTRED cells, NOTCH1KD/ PFKFB3KD/GFP cells no longer have a tip cell advantage (n = 30; *p < 0.05).
(K and L) EC spheroid sprouting showing that overexpression of the Notch intracellular domain NICD (NICDOE) reduced sprout number (K) and length (L) but that
PFKFB3 (PFKFB3OE) overcomes the impaired sprouting of NICDOE cells (mean ± SEM; n = 30; *p < 0.01 versus ctrl; &p < 0.01 versus PFKFB3OE).
(M–O) Representative fluorescence photographs of mosaic EC spheroids containing a 1:1 mixture of mCherry wild-type (WTRED) and GFP-labeled NICD over-
expressing (NICDOE/GFP) ECs (M) or combined NICD plus PFKFB3-overexpressing (NICDOE/PFKFB3OE/GFP) ECs (N), revealing that NICDOE/PFKFB3OE/GFP cells were
found more frequently at the tip position (N) than NICDOE/GFP cells (M). (O) The quantification of the fraction of tip cells with the indicated genotype is shown,
revealing that PFKFB3 overexpression overcomes the disadvantage of NICDOE/GFP ECs to reach the tip (n = 30; *p < 0.05). Scale bars, 50 mm.
See also Figure S3.
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levels improved tip cell formation, though only modestly
(Figure S3C).
PFKFB3 Silencing Impairs Tip Cell Activity
To further document the importance of PFKFB3 during tip
cell competition, we inhibited Notch signaling (which favors
the tip cell phenotype) and examined whether PFKFB3
silencing affected their tip position. Spheroids of ECs in which
Notch signaling was blocked by RNAi-mediated silencing
(NOTCH1KD/GFP) or DAPT treatment formed more numerous and
longer sprouts (Figures 4H and 4I; Figures S3D and S3E), but
PFKFB3 silencing in NOTCH1KD/GFP or DAPT-treated cells
reduced the number and length of the vascular sprouts induced
by Notch inhibition (Figures 4H and 4I; Figures S3D and S3E).
We also used mosaic spheroids containing a 1:1 mixture
of WTRED and NOTCH1KD/GFP cells. NOTCH1KD/GFP cells were
more often detected at the tip (Figure 4J). However, when
PFKFB3 was silenced in NOTCH1KD/GFP cells, the double-
silenced cells were no longer preferentially present at the tip
(Figure 4J). Thus, ECs lacking the genetic determinant of the
stalk phenotype were less able to reside at the tip when their
PFKFB3 levels were reduced. Similar results were obtained
after treatment with MitoC, indicating that the observed find-
ings were not only attributable to differences in proliferation
(Figure S3F).
PFKFB3 Overexpression Improves Tip Cell Behavior
We further analyzed whether elevated PFKFB3 levels could
overrule the stalk-cell-inducing activity of NICD. Vascular
sprouting was impaired in spheroids of ECs overexpressing
NICD (NICDOE) (Figures 4K and 4L). Notably, however, overex-
pression of PFKFB3 in NICDOE cells overcame NICD’s activity
and restored vascular sprouting (Figures 4K and 4L), indicating
that increased PFKFB3-driven glycolysis promoted sprouting,
even when ECs were genetically instructed to adopt a stalk cell
phenotype. Compared to tip cells, stalk cells have fewer and
smaller filopodia and lamellipodia. Formation of lamellipodia
was indeed impaired in NICDOE cells but was restored to near-
normal levels in NICDOE/PFKFB3OE cells (Figure S3G). We also
used mosaic spheroids containing a 1:1 mixture of mCherry+
(WTRED) and GFP+ NICD-overexpressing (NICDOE/GFP) ECs.
Compared to WTred cells, NICDOE/GFP cells were found less
frequently at the tip (Figures 4M and 4O). However, NICDOE/GFP/
PFKFB3OE/GFP cells were present more frequently at the tip (Fig-
ures 4N and 4O). Mitotically inactivated ECs showed similar
responses (Figure S3H).
PFKFB3 Promotes the Tip Cell Position In Vivo
We analyzed the hindbrain vasculature of E10.5 somite-
matched chimeras generated by injecting mCherryRed+ WT
or PFKFB3!/! ES cells into CD-1 blastocysts. Hindbrains were
stained for isolectin-B4 and the EC-specific transcription factor
Erg to label ECs, and tip cells were identified as ECs with protru-
sions from where filopodia emerged. Compared to mosaic
mCherryRed+ WT ECs, 33% fewer mCherryRed+ PFKFB3!/!
ECs were present at the tip (Figures 5A–5E). We also used the
zebrafish model to explore whether endothelial overexpression
of PFKFB3 could overcome the stalk cell phenotype induced
by overexpression of NICD. Using EC-selective fli1-promotor
constructs, we generated transgenic Fli1:EGFPy1 zebrafish over-
expressing mCherryRed and either NICD (NICDOE/RED), PFKFB3
(PFKFB3OE/RED), or both transgenes (NICDOE/PFKFB3OE/RED). All
constructs expressed comparable transgene messenger RNA
levels (data not shown), and the percentage of mosaic inter-
somitic vessels (ISVs) with an mCherryRed+ cell at the tip
was determined. Compared to 50% in control embryos, 60%
of the mosaic ISVs contained an mCherryRed+ tip cell in
PFKFB3OE/RED embryos (Figures 5F–5M and 5V), showing that
PFKFB3 overexpression provides a modest tip cell advantage
in this assay. In NICDOE/RED embryos, only 22% of the ISVs con-
tained an mCherryRed+ tip cell while, notably, up to 67% of
the ISVs contained an mCherryRed+ tip cell in NICDOE/
PFKFB3OE/RED embryos (Figures 5N–5V). Thus, PFKFB3 was
able to overcome NICD’s pro-stalk activity.
Compartmentalization of PFKFB3
The aforementioned results show that PFKFB3 silencing
affected EC motility, a process requiring remodeling of the cyto-
skeleton. Because respiration did not affect sprouting, we
explored a possible link between glycolysis and the actin cyto-
skeleton. To analyze the cellular distribution of mitochondria
in tip cells in vivo, we generated a transgenic MitoEC: mouse
expressing GFP in EC mitochondria. Isolectin-B4 staining of
retinal ECs in vivo showed that mitochondria in tip cells were
present in the perinuclear cytosol and in cytoplasmic protrusions
at the base from where filopodia projected but were excluded
from filopodia (Figures 6A–6C). Staining for the mitochondrial
marker TOMM20 (Figure 6D) and time-lapse video imaging
of mCherry+ ECs in which mitochondria were labeled with
Mito:EGFP (Movie S2) confirmed that mitochondria were
excluded from lamellipodia.
We then analyzed the subcellular localization of glycolytic
enzymes (including PFKFB3) by immunostaining. In spontane-
ously moving ECs, PFKFB3 was detectable in the cell body
and lamellipodia (Figure 6E). Abundant PFKFB3 immunoreac-
tivity was detected in the perinuclear cytosol. When analyzing
PFKFB3 immunoreactive levels in a 300 nm single optical stack
after pseudocolor conversion, PFKFB3-immunoreactive levels
were comparable in lamellipodia and the cell body (Figure 6F).
Quantification of PFKFB3 and F-actin immunoreactivity levels
in single-stack images showed that PFKFB3 was enriched with
F-actin in membrane ruffles at the leading front of lamellipodia,
known to contain a meshwork of polymerized actin filaments
(Figures 6G and 6H). Additional glycolytic enzymes, including
the ATP-generating pyruvate kinase (PK) and phosphoglycerate
kinase (PGK) and others, also colocalized with F-actin in lamelli-
podial ruffles (Figures S4A–S4H). Notably, unlike PKM2, PKM1,
which is involved in ATP production rather than biosynthesis of
macromolecules, also colocalized in lamellipodia (Figures S4I
and S4J). Immunoprecipitation of PFKFB3 followed by immuno-
blotting for b-actin (Figure 6I) or mass spectrometry (Table S1)
confirmed that PFKFB3 interacts with actin. Moreover, PFKFB3
was detectable in both the G- and F-actin cellular fractions
(Figure 6J) but was more abundant in the F-actin fraction of
motile than quiescent contact-inhibited ECs (Figure 6K).
Notably, PFKFB3 was present in the perinuclear cytosol in
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contact-inhibited ECs but was relocated into the lamellipodia,
protrusions, and cell-cell bridges in motile ECs (Figures S4K
and S4L).
Furthermore, time-lapse video imaging after transfecting the
ATP biosensor GO-ATeam in spontaneouslymotile ECs revealed
high ATP levels in lamellipodia in leading membrane ruffles (Fig-
ure 6L; Movie S3). Compared to control cells, PFKFB3-silenced
cells had 55% ± 5% fewer lamellipodial ATP hotspots, which
were also 49% ± 9% smaller and contained 57% ± 2% lower
levels of ATP (n = 4–5; p < 0.001) (Figure 6M). However, respira-
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Figure 5. PFKFB3 Influences the Tip
Position In Vivo
(A–E) Representative fluorescent image of the
hindbrain vasculature in chimericWT (A and B) and
chimeric PFKFB3!/! (PFKFB3KO) embryos (C and
D) showing that mCherry+ WTRED ECs contribute
more frequently to the tip position than mCherry+
PFKFB3KO/RED ECs (arrowheads). Staining for Iso-
lectin-B4 is shown is green, mCherry in red, and
Erg in blue. (E) The quantification of the WTRED and
PFKFB3KO/RED tip cells is shown (mean ± SEM;
n = 9–13; p < 0.02). Scale bars, 50 mm.
(F–V) Confocal images of GFP+ vessels in 24 hpf
transgenic mosaic fli1:EGFPy1 embryos express-
ing only mCherryRed (ctrlRED; F–I), coexpressing
mCherry and PFKFB3 (PFKFB3OE/RED; J–M), coex-
pressing mCherry and NICD (NICDOE/RED; N–Q),
or mCherry and NICD plus PFKFB3 (NICDOE/
PFKFB3OE/RED; R–U) showing that overexpression
of PFKFB3 promotes tip cell contribution and can
overcome the NICD-induced tip cell disadvantage.
(G, I, K, M, O, Q, S, U) Shown is a higher magnifi-
cation of the boxes in (F), (H), (J), (L), (N), (P), (R),
and (T). The arrowheads indicate mCherryRed+
ECs that reached the tip position. The dotted lines
indicate the localization of the dorsal aorta and
posterior cardinal vein (bottom) and the dorsal roof
level (top). Scale bars, 50 mm. (V) The fraction
of mosaic ISVs with the indicated tip cell geno-
type in fli1:EGFPy1 zebrafish embryos mosai-
cally overexpressing NICD (NICDOE/RED), PFKFB3
(PFKFB3OE/RED), or both transgenes (NICDOE/
PFKFB3OE/RED) is shown. Compared to controls,
NICDOE/RED ECs were less frequently present at the
tip, while PFKFB3OE/RED or NICDOE/PFKFB3OE/RED
ECs were present more frequently at the tip
position, indicating that PFKFB3 overexpression
overrules the NICD effect (n = 3–4 experiments
with 55 ISVs/experiment; *p < 0.05 versus control;
&p < 0.05 versus NICDOE/RED).
tion blockers did not reduce lamellipodia
ATP levels in the membrane ruffles
(Figure 6N).
Cellular Adaptation to PFKFB3
Silencing
Finally, we explored whether the effects
of PFKFB3 blockade were due to a gen-
eral energy hypometabolism. However,
PFKFB3 silencing did not alter the
energy charge and ATP levels (Figures 7A and 7B), nor did it
induce cell death as analyzed by measuring activated caspase
3 (Figures 7C and 7D) or LDH release (data not shown).
PFKFB3-silenced cells showed no signs of endoplasmic reticu-
lum, energy, or oxidative stress or of autophagy (Figures 7E–
7H). PFKFB3 silencing did also not increase glucose oxidation
and did not induce a switch to fatty acid oxidation or respiration
(Figures 7I and 7J), which would be expected to occur when
cells suffer severe energy deprivation from the blockage of
glycolysis and need to compensate for such cellular energy
658 Cell 154, 651–663, August 1, 2013 ª2013 Elsevier Inc.
	   45	  
 
 
stress. PFKFB3-silenced ECs were thus not in energy distress
but rather adapted to a new metabolically balanced state. To
maintain ATP levels, PFKFB3-silenced ECs decreased ATP con-
sumption, as evidencedby a lower ADP/ATP ratio (Figure 7K) and
reduced protein synthesis (Figure 7L) and EC proliferation (see
above), all high-energy-demanding processes. Nonetheless,
PFKFB3 silencing maintained extracellular matrix production
(Figure 7M), promoted ECquiescence (Figure 7N), and increased
the oxidative pentose phosphate pathway (oxPPP) (Figure 7O),
thus showing that PFKFB3 knockdown did not cause general
energy hypometabolism but rather suppressed the hypermetab-
olism induced by vessel sprouting. In conditions of stress,
PFKFB3-silenced ECs even increased fatty acid oxidation (Fig-
ure 7P), likely to ensure redox homeostasis (Jeon et al., 2012).
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(A–C) High-magnification images of tip cells in the
retina of transgenic P4 MitoEC reporter mice (A),
stained for isolectin-B4 (B and C), revealing that
mitochondria (green; arrows) are present in the
cytosol and large cytosolic protrusions, but not
inside filopodia (arrowheads). (C) Magnification of
the boxed region in (A) and (B) (merger).
(D) High-magnification SIM images of ECs stained
for the mitochondrial marker TOMM20 revealing
that mitochondria are present in the central peri-
nuclear cell body but excluded from the lamelli-
podia (denoted by a white dotted line).
(E and F) SIM imaging of sparsely seeded ECs
immunostained for PFKFB3 revealing positive
signal in the cell body and lamellipodia. (F)
PFKFB3 pseudocolor conversion (from low
[purple] to high [red]) in a 300 nm single optical
stack is shown, revealing comparable levels in
lamellipodia and the cell body. Arrows denote the
migration direction.
(G and H) Quantification of the relative PFKFB3
and F-actin immunoreactive levels in single-stack
images showing that PFKFB3 colocalized with
F-actin inmembrane ruffles.The line in (H) indicates
the distance over which the immunoreactive levels
were quantified (from point ‘‘a’’ to point ‘‘b’’).
(I) Immunoblotting (IB) for b-actin after immuno-
precipitation (IP) of PFKFB3 from EC extracts
using Dynabead-bound anti-PFKFB3 antibody
(aPFKFB3), indicating that PFKFB3 interacts with
actin (lane 3). Lane 1 and 2 show negative con-
trols using naked beads and beads incubated
with irrelevant B16F10.9 control antibody,
respectively.
(J) Immunoblotting for PFKFB3 after ultracentri-
fugation-based separation of G-actin- and
F-actin-enriched fractions showing that PFKFB3
is present in both fractions.
(K) Immunoblotting for PFKFB3 after ultracentri-
fugation-based separation of G-actin- and
F-actin-enriched fractions showing that PFKFB3
is more abundantly associated with F-actin
in proliferating/migrating than contact-inhibited
cells.
(L–N) Snapshot pseudocolored images of time-
lapse videos (Movie S3) of ECs expressing the
ATP-biosensor GO-ATeam showing that mem-
brane ruffles of lamellipodia (arrowheads) contain
high ATP levels in control cells (L), but not in
PFKFB3-silenced cells (PFKFB3KD; M). Lamelli-
podial ATP levels remained unaffected by
treatment with the mitochondrial respiration
blocker oligomycin (N). Color bars indicate the
orange fluorescent protein/GFP emission ratio
(pseudocolor).
SeealsoFigureS4,MoviesS2andS3, andTableS1.
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DISCUSSION
Endothelial Cells Are Highly Glycolytic
ECs generated up to 85% of their ATP from glycolysis and were
more glycolytic than other healthy cell types. In line with reports
that ECs have a smaller mitochondrial volume fraction (5%) than
oxidative hepatocytes (30%) and that mitochondria in ECs func-
tion as signaling hubs rather than metabolic powerhouses
(Groschner et al., 2012), the flux through glucose, fatty acid,
and glutamine oxidation in ECs was <1% of the glycolytic flux.
The importance of glycolysis for ECs was illustrated by findings
that PFKFB3 silencing reduced vessel sprouting, whereas inhibi-
tion or stimulation of respiration had no effect.
The dependence of ECs on glycolysis is at first sight surprising
because quiescent ECs are in immediate contact with oxygen in
the blood. Hence, ECs are exposed to sufficient oxygen for
oxidative metabolism, yet they prefer aerobic glycolysis. This is
likely due to various reasons. First, by consuming little oxygen,
they can transfer more oxygen to perivascular cells. Second,
when sprouting into avascular tissues, ECs become exposed
to low levels of oxygen and glucose. Because glucose diffuses
further away from vessels than oxygen (Buchwald, 2011; Gate-
nby and Gillies, 2004), ECs can still rely on anaerobic glycolysis
to form vessels. Third, by maintaining a low oxidative meta-
bolism, ECsminimize the production of reactive oxygen species,
thereby providing protection against their high-oxygen milieu.
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Figure 7. Adaptation to PFKFB3 Silencing
(A) PFKFB3 silencing did not affect the energy
balance ([ATP] + 1/2 [ADP] / [ATP] + [ADP] +
[AMP]) (mean ± SEM; n = 3; *p < 0.05).
(B) Quantification of ATP content showing
that ATP levels were not affected in PFKFB3-
silenced (PFKFB3KD) cells (mean ± SEM, n = 6;
p = nonsignificant [NS]).
(C and D) Caspase-3 immunostaining (red) in
combination with TO-PRO3 nuclear staining
(blue) showing that PFKFB3 silencing (D) did not
cause apoptosis. Scale bar, 50 mm.
(E) Immunoblotting showing that PFKFB3
silencing did not alter expression levels of
the ER stress markers BiP and CHOP. Tunica-
mycin treatment was used as positive control.
Densitometric quantifications are shown below
the lanes (mean ± SEM; n = 3; p = NS).
(F) Immunoblotting showing that PFKFB3
silencing did not alter the phospho-AMPK/AMPK
ratio. Densitometric quantifications are shown
below the lanes (mean ± SEM; n = 3; p = NS).
(G) Immunoblotting showing that PFKFB3
silencing did not alter the phospho-ATM/ATM
ratio. Densitometric quantifications are shown
below the lanes (mean ± SEM; n = 3; p = NS).
(H) Immunoblotting showing that PFKFB3
silencing did not induce autophagy, assessed
via the LC3-II/LC3-I ratio. Densitometric quanti-
fications are shown below the lanes (mean ±
SEM; n = 3; p = NS).
(I) PFKFB3 silencing did not alter glucose oxida-
tion or fatty acid oxidation (mean ± SEM; n = 3;
p = NS).
(J) PFKFB3 silencing did not alter oxygen
consumption rates (OCR) (mean ± SEM; n = 11;
p = NS).
(K) PFKFB3 silencing reduced the ADP/ATP ratio
(mean ± SEM; n = 3; *p < 0.05).
(L) Protein synthesis (HPG fluorescence intensity)
was reduced in PFKFB3-silenced ECs (mean ±
SEM; n = 3; *p < 0.05).
(M) 3H-proline incorporation assay (103 dpm/hr/
mg protein) showing that PFKFB3 silencing did
not affect collagen synthesis (mean ± SEM; n = 3;
p = NS).
(N) Fluorescence-activated cell sorting analysis of ECs, stained for Hoechst 33342 and EdU, showing a larger fraction of Hoechst2NEduneg cells in G0 phase in
PFKFB3-silenced cells (mean ± SEM, n = 5; *p < 0.001).
(O) PFKFB3 silencing increased the flux through the oxidative pentose phosphate pathway (oxPPP) (mean ± SEM; n = 3; p < 0.05).
(P) PFKFB3 silencing increased fatty acid oxidation under low-glucose (1 mM and 0.1 mM) conditions (mean ± SEM; n = 5; *p < 0.05).
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Fourth, glycolysis generates ATP more rapidly than oxidative
metabolism, allowing ECs to meet the energy demands for
dynamic rapid changes in motility. Finally, the glycolysis side
pathways are necessary for the biosynthesis of macromolecules
needed for cell mass duplication during cell division.
PFKFB3-Driven Glycolysis Regulates Sprouting
Silencing of PFKFB3 impaired vessel sprouting. These defects
are due to effects on both migrating tip and proliferating stalk
cells. In agreement with findings that cell proliferation requires
glycolysis (Lunt and Vander Heiden, 2011), PFKFB3 inactivation
reduced EC proliferation, implying that the impaired vessel
formation was at least partially due to proliferation defects.
However, PFKFB3 is also important for EC motility. First,
the tip-cell-activating signal VEGF upregulated the levels of
PFKFB3 and glycolysis, whereas the pro-stalk cell signal Notch
had opposite effects. Second, PFKFB3 blockade suppressed
whereas PFKFB3 overexpression stimulated the sprouting of
mitotically inactivated ECs in spheroids. Furthermore, PFKFB3
silencing impaired the motility, lamellipodia/filopodia formation,
and directional migration of EC monolayers, which could
contribute to the impaired vessel outgrowth and branching in
mice with endothelial PFKFB3 deficiency. Third, in mosaic
competition assays in vitro (using mitotically inactivated cells)
and in vivo, ECs with silenced PFKFB3 levels were underrepre-
sented at the tip in baseline and in tip-cell-favoring conditions,
whereas PFKFB3 overexpression promoted the ability of ECs
to form tip cells in baseline conditions in some assays and
promoted tip cell formation of cells overexpressing the pro-stalk
cell signal NICD.
Notably, relative PFKFB3 levels did not alter the relative
expression levels of tip or stalk cell genes, implying that a change
in PFKFB3-driven glycolysis alone sufficed to promote tip cell
activity. It is worth noting that no other signal has so far been re-
ported to overcome NICD’s potent pro-stalk cell activity, raising
the question whether regulation of metabolism is a (perhaps
even ‘‘the’’) key activity of Notch driving stalk cell formation.
Given that tip and stalk cells dynamically interchange positions
(Jakobsson et al., 2010), we speculate that an increased level
of glycolysis does not permanently convert stalk cells into a fixed
tip cell phenotype, but rather that varying levels of glycolysis
dynamically codetermine the fluid tip versus stalk cell pheno-
type. These findings also raise other intriguing questions, such
as for instance whether tip cells can only stay at the tip for as
long as they have sufficient glycolysis. In any case, in parallel
to control by genetic signals, PFKFB3-driven glycolysis also
regulates vessel sprouting.
Compartmentalization of Glycolysis with Actin
Cytoskeleton Remodeling
Filopodia and lamellipodia are essential for tip cells. Contraction
and protrusion of these structures rely on actin cytoskeleton
remodeling and require hydrolysis of large amounts of ATP.
Mitochondria (0.5 to >4.0 mm) are too bulky to fit into thin filopo-
dia and lamellipodia (250 nmwide and high, respectively) but are
mostly present in the perinuclear cytosol, distant from the filopo-
dial tip, which can be up to 10 mm long. Diffusion of ATP from
distant mitochondria in the perinuclear cytosol may thus not be
able to support the high and rapidly changing ATP demands
for sustained motor activity at the tip.
Several lines of evidence suggest that glycolytic enzymes are
compartmentalized with F-actin in lamellipodia during vascular
sprouting. First, PFKFB3 and other glycolytic enzymes (including
those generating ATP) were relocated from the perinuclear
cytosol in contact-inhibited ECs into lamellipodia and cell protru-
sions and were enriched in leading membrane ruffles of motile
cells. Interestingly, the pyruvate kinase isoenzyme involved
in ATP production (PKM1) rather than macromolecular bio-
synthesis (PKM2) was present in lamellipodia. Second, ATP
biosensor imaging revealed that lamellipodia contained ‘‘ATP
hotspots,’’ which were reduced when PFKFB3 was silenced,
but not when respiration was blocked. Third, vessel branching
was affected by inhibiting or stimulating glycolysis, but not
by altering respiration. Fourth, PFKFB3 was associated with
F-actin, and this fraction increased during EC migration.
The use of glycolysis to generate energy for motile structures
may seem counterintuitive, as nearly 20-fold less ATP is pro-
duced per unit of glucose by glycolysis than by oxidative
phosphorylation. Several reasons can explain this phenomenon.
First, despite a low intrinsic yield, the yield of ATP generation by
glycolysis can exceed that by glucose oxidation, as long as
glucose is not limiting (DeBerardinis et al., 2008; Vander Heiden
et al., 2009). Second, compartmentalization of glycolysis with
F-actin offers advantages. By creating a ‘‘glycolytic hub,’’ glyco-
lytic enzymes are arranged on a cytomatrix in an assembly line,
where metabolic substrates are passed from one enzyme to
the next. Glycolytic enzymes are activated by actin and help in
assembling actin microfilaments (Real-Hohn et al., 2010). The
enzyme proximity and activation by actin favor maximal rates
of reaction (al-Habori, 1995). Third, rapid extension/retraction
of filopodia and lamellipodia may create an ATP drain for the
cell body. Localizing the ATP supply to compartments where
ATP is consumed can prevent catastrophic ATP depletion.
The link between glycolysis and actin is evolutionarily
conserved, as glycolysis fuels other motile structures such as
flagella of micro-organisms, tentacles of hydra, or cilia of eukary-
otic cells (Baquer et al., 1975; Hereng et al., 2011; Pavlova,
2010). The relevance of this link is underscored by findings that
expression of aldolase, incapacitated to bind actin, paralyzes
fruit flies (Wojtas et al., 1997). PFKFB3 blockade might reduce
angiogenesis also via other mechanisms. For instance, lactate
stimulates angiogenesis via activation of HIF-1a and upregula-
tion of VEGFR2 (Hunt et al., 2007) or via inhibition of the oxygen
sensor PHD2, activating a proangiogenic nuclear factor kB/inter-
leukin-8 program (Ve´gran et al., 2011). The reduced lactate levels
upon PFKFB3 blockade could thus also suppress angiogenesis
via these mechanisms. Also, PFKFB3 has been proposed
to control cell proliferation via glycolysis-independent nuclear
activities (Yalcin et al., 2009a). While perhaps relevant to explain
the effects on EC proliferation, the effects of PFKFB3 on EC
motility are more likely due to compartmentalization of glycolytic
enzymes in the lamellipodia.
General Implications
To date, only genetic signals have been considered to control
vessel sprouting. Our findings add an extra dimension to this
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traditional concept and imply that metabolism also controls
vessel sprouting. Aside from a genetic signature, tip and stalk
cells thus likely also have a metabolic signature. While our study
documented a role for glycolysis, other metabolic pathways
might also influence vessel formation. In addition, it will be inter-
esting to explore whether targeting PFKFB3 can reduce patho-
logical angiogenesis.
EXPERIMENTAL PROCEDURES
More details can be found in the Extended Experimental Procedures.
Cell Culture and In Vitro Functional Assays
Freshly isolated primary HUVECs were used for metabolic evaluation, prolif-
eration, migration, motility, and spheroid capillary sprouting assays and in
cell-cycle assessments.
RNA and Protein Analysis
RNA expression analysis was done by quantitative RT-PCR. Immunoblotting
of proteins and immunohistochemistry was performed using the antibodies
listed in the Extended Experimental Procedures.
Metabolic Assays
Glycolysis and oxidation of other substrates were determined using radioac-
tively labeled tracers.
Animal Models of Angiogenesis
Tg(fli1:EGFP)y1 zebrafish (Lawson and Weinstein, 2002) were subjected to
Tol2-based transgenic overexpression. Quantification of sprouting of ISVs
was done as explained in the Extended Experimental Procedures. Tamoxifen
was injected intraperitoneally in mouse pups daily from postnatal day 1 to
day 4. Eyes were fixed at postnatal day 5, and retinal flat mounts were
prepared for vascular analysis as described (Phng et al., 2009). Embryonic
hindbrain angiogenesis was assessed in E10.5–E11.5 embryos as described
(Fantin et al., 2013). Experimental animal procedures were approved by the
Institutional Animal Care and Research Advisory Committee of the University
of Leuven.
Statistics
Data represent mean ± SEM of representative experiments unless otherwise
stated. Unless otherwise indicated, statistical significance was calculated by
standard t test (Prism v4.0b), and phenotype severity distributions were
analyzed by the chi-square test. Estimated means, SEMs, and significance
levels were calculated with the general linearmodel univariate statistical model
(SPSS), considering experiment as covariate. p < 0.05 was considered as
statistically significant.
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Supplemental Information
EXTENDED EXPERIMENTAL PROCEDURES
Chemicals and Reagents
Collagen type 1 (rat tail) was fromMillipore or Novagen (Merck, Germany). Recombinant hDLL4 extracellular domain, hVEGF165 and
rFGF-2 were from R&D Systems. Endothelial Cell Growth Supplements (ECGS), heparin, mitomycin C (mitoC), antimycin A, oligomy-
cin C, NADH, polybrene and dimethyl sulfoxide (DMSO) were from Sigma-Aldrich (Bornem, Belgium). Hoechst 33342, TO-PRO3,
Calcein-AM, MitoTracker Green FM and Click-iT EdU Cell Proliferation kit were from Molecular Probes and L-glutamine, sodium
pyruvate and penicillin/streptomycin were from GIBCO and 40,6-diamidino-2-phenylindole, dihydrochloride (DAPI) and proteinase
K were from Invitrogen (Invitrogen, Life Technologies, Ghent, Belgium). The g-secretase inhibitor N-[N-(3,5-Difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester (DAPT) was from Merck Millipore (Overijse, Belgium). Click-iT EdU Cell Prolifertion kit was
from Invitrogen (Life Technologies, Ghent, Belgium).
Cell Culture
Primary Cells
Human umbilical vein endothelial cells (HUVECs) were freshly isolated from different donors as described (Jaffe et al., 1973) and used
between passage 1 and 5. HUVECs were cultured in M199 medium (1 mg/ml D-glucose) supplemented with 20% fetal bovine serum
(FBS), 2 mM L-glutamine, 30 mg/l endothelial cell growth factor supplements (EGCS), 10 units/ml heparin, 50 IU/ml penicillin and
50 mg/ml streptomycin, or in endothelial basal medium (EBM-2) supplemented with endothelial growth medium SingleQuots
(Clonetics, Lonza, Braine-l’Alleud, Belgium). Human aortic ECs (HAECs), adult human dermal blood microvascular ECs (HMVEC-
dBlAd) and dermal lymphatic cells (DLy) were purchased from Clonetics, Lonza (Braine-l’Alleud, Belgium) and cultured in the recom-
mended medium supplemented with SingleQuots (EGM-2 or EGM-2 MV; Clonetics, Lonza, Braine-l’Alleud, Belgium). Cells were
routinely maintained in 5%CO2 and 95% air at 37!C. Mitotic inactivation was achieved by culturing the cells for 24 hr in the presence
of 1 mg/mlMitoC andwas confirmed using a [3H]-Thymidine proliferation assay (see below).Murine hepatocytes were isolated using a
two-step collagenase perfusion technique and fixed after short-term culture for 6 hr as described (Dirkx et al., 2007). Murine mac-
rophages were collected from the peritoneal cavity and cultured in RPMI (Invitrogen, Life Technologies, Ghent, Belgium) containing
10%FBS. Murine adipocytes were isolated from epididymal/gonadal fat pads using 0.1% collagenase II, separated from the stromal
vascular fraction via centrifugation and were cultured in DMEM/F12 supplemented with 10% FBS (Pospisilik et al., 2010). Neuron
cultures were prepared from the cortices of embryonic day 14 (E14) mice andmaintained in serum-free NeuroBasal medium (GIBCO)
containing 25 mM glucose (Thathiah et al., 2009). After 4 days in culture, 8 mM cytosine arabinoside was added to prevent nonneuro-
nal proliferation. These cultures contained > 95%neurons. Glial cells were isolated from the ventral part of the spinal cords of 14-day-
old Wistar rat embryos and plated in L15 medium supplemented with glucose (3.6 mg/ml), sodium bicarbonate (0.2%), penicillin
(100 IU/ml), streptomycin (50 mg/ml) and fetal bovine serum (10%). In these cultures, glial cells rapidly proliferate and reach conflu-
ency after 1 – 2 weeks in vitro. These cells were used after 7 days in culture. Pericytes were isolated from human placenta using
gentleMACS tissue dissociator (Miltenyi Biotec) and incubation with collagenase 0.2% (GIBCO) and Dnase 80 U/ml (Life technolo-
gies) for 30 min at 37!C followed by Percoll gradient 5 (GE Healthcare) centrifugation, or from human adipose tissue using collage-
nase 0.2% in 0.9% NaCl and 2 mM CaCl2 for 1 hr 37
!C. Thereafter, the cell suspension was immunomagnetically sorted by using
CD31 and CD146 antibodies conjugated with microbeads (Miltenyi Biotec). CD146+/CD31" sorted cells were seeded in aMEM
plus 10% FBS and 5 nM PDGFBB. Cardiomyocytes were isolated as described (Sreejit et al., 2008). Human dendritic cells were
generated as described (Ferreira et al., 2013).
Tumor Cell Lines
Murine melanoma B16 clone F10.9 and human breast cancer MDA-MB-231 cells were obtained from American Type Culture Collec-
tion (ATCC; LGC Standards, Molsheim Cedex, France) and maintained in DMEM containing 10% FBS and 2 mM glutamine. PancO2
murine pancreatic carcinoma cells (provided by B. Wiendenmann, Charite´, Berlin, Germany) were cultured in RPMI containing 10%
FBS. Human osteosarcoma U2OS cells, MCF7 (human breast cancer), HCT116 (human colon carcinoma), and 4T1 (mouse mam-
mary carcinoma) were cultured in DMEM containing 10% FBS, 2 mM glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin.
CT2A murine glioblastoma cells were cultured in DMEM containing 10% FBS and 2 mM glutamine (Invitrogen, Life Technologies,
Ghent, Belgium) supplemented with conditioned medium obtained from CT2A cells. Murine endothelial cells, infected with an eco-
tropic retrovirus encoding SV40 large T 58-3 allele (MS1 hemangioma) and subsequently infected with a second retrovirus encoding
activated H-ras (SVR angiosarcoma) were obtained from Dr. Arbiser and cultured in DMEM with glutamine and 10% FBS (Arbiser
et al., 1997). All cells were routinely maintained in 5% CO2 and 95% air at 37!C.
Knockdown Strategies
Lentiviral Transductions
To generate a lentiviral expression vector for PFKFB3, the Notch intracellular domain (NICD; gift fromM. Potente), and the GO-Ateam
biosensor (Nakano et al., 2011), the respective cDNAs were cloned in the pRRLsinPPT.CMV.MCS MM W prevector (Michieli et al.,
2004). To generate shRNA vectors against PFKFB3, oligonucleotides were cloned into the pLVX-shRNA2 vector (No. PT4052-5;
Clontech, Westburg BV, Leusden, the Netherlands) (oligonucleotide sequence is available upon request). A nonsense scrambled
shRNA sequence was used as a negative control. Production of lentiviruses by transfection into 293T cells was performed as
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described (Carlotti et al., 2004). For transductions, amultiplicity of infection (MOI) of 10 was used in all shRNA experiments and aMOI
of 5 for PFKFB3 overexpression. Transduction with mCherry Red and NICD overexpression was performed at MOI 10. Cells were
transduced overnight in the presence of 0.5 mg/ml polybrene and re-fed with fresh medium the next day. Transduced cells were
used in functional assays at least 3 to 4 days posttransduction.
RNA Interference
To silence PFKFB3 or NOTCH1 expression, cells were transfected with a validated pool of siRNA duplexes directed against human
PFKFB3 (Trifekta Kit, IDT), or a validated Stealth RNAi against human Notch1 (Invitrogen). A scrambled siRNA was used as control.
HUVECs were transfected with the indicated siRNA (50 nM) using Lipofectamine RNAi Max (Invitrogen).
In Vitro Assays
Proliferation was quantified by incubating cells for 2 hr with 1 mCi/ml [3H]-thymidine. Thereafter, cells were fixedwith 100%ethanol for
15 min at 4!C, precipitated with 10% trichloroacetic acid and lysed with 0.1 N NaOH. The amount of [3H]-thymidine incorporated into
DNA was measured by scintillation counting.
Scratch Wound Migration Assay
A scratch wound was applied on a confluent HUVECmonolayer using a 200 ml tip, 24 hr after seeding (75,000 cells per well in 24-well
plates) and after cells were mitotically arrested (1 mg/ml MitoC overnight). After scratch wounding and photography (T0), the cultures
were further incubated for the indicated time periods in defined M199 medium with or without glucose supplemented with growth
factors and dialyzed serum (containing minimal traces of glucose), and photographed again (Tx). Migration distance (gap area at
T0 minus gap area at Tx) was measured with NIH Image J software package and is expressed in arbitrary units.
Growth Factor Stimulation
Cells were seeded sparsely and upon adherence were washed and refed with growth factor depleted starvation medium containing
only 0.1% FBS. After overnight starvation, cells were stimulated for the indicated time points with or without 100 ng/ml hVEGF165 or
50 ng/ml rFGF-2.
Dll4 Stimulation
To activate the Notch pathway, cells were grown for 24 hr on plates coated for 24 hr at 4!Cwith recombinant Dll4 extracellular domain
at a final concentration of 1 mg/ml, using BSA coated plates as control. Pharmacological inhibition of Notch activation was achieved
by culturing the cells in the presence of DAPT (10 mM).
Motility Assay
Sparse HUVEC cultures were assessed for spontaneousmotility after plating on glass bottom 24-well plates (PAA, Pasching, Austria)
in complete EBM-2medium. Images were acquired at intervals of 4 min overnight at 37!C using a Zeiss LSM 510Meta NLO confocal
microscope (oil objectives: x 40 with NA 1.3, x 63 with NA 1.4, x 100 with NA 1.3) (Carl Zeiss, Munich, Germany). Cell movement was
tracked using Imaris software by tracking nucleus position over time and by superimposing migration origin at the zero-cross point
(Lim et al., 2010) or is expressed as migration rate in mm/hr. Experiments were performed with or without genetic shRNA PFKFB3
silencing.
Lamellipodia Formation Assay
The number and area of lamellipodia was measured on still photos of the time-lapse recordings using the Axiovision morphometric
analysis software (Carl Zeiss, Munich, Germany) with in-house developed macros. Lamellipodia area is expressed in percent of total
cell area.
Spheroid Capillary Sprouting Assay
HUVECs (1,000 cells with or without lentiviral overexpression of NICD, PFKFB3 or shPFKFB3 or transfectedwith NOTCH1RNAi) were
incubated overnight in hanging drops in EGM-2 medium containing 20% methylcellulose (Sigma-Aldrich, Bornem, Belgium) to form
spheroids. Formitotic inactivation,MitoC (500ng/ml)wasadded to thismedium. Toassess tip cell competition, cellsweremixedat the
indicated ratio. Spheroidswere then embedded in collagen gel as described (Korff et al., 2004) and cultured for 24 hr to induce sprout-
ing. Compounds were added at the indicated concentrations during the collagen gel culture step, using corresponding vehicle con-
centrations as control. Cultures were fixed with 4% PFA at room temperature and images were captured with a Zeiss LSM 510 Meta
NLOconfocalmicroscope (oil objectives: x 40withNA1.3, x 63withNA1.4, x 100withNA1.3) (Carl Zeiss,Munich,Germany) or a Leica
laser-scanning SP5 confocal microscope (Leica, Manheim, Germany). Analysis of the number of primary sprouts and the total sprout
length (cumulative length of primary sprouts and branches per spheroid) was done using the NIH Image J software package.
Cell Death Assay
Cell death was measured by determining the LDH release in the medium using the Cytotoxicity Detection Kit (Roche applied
sciences).
Immunocytochemistry/Histochemistry
Cells grown for 24 hr on coverslips were fixed with 4%PFA for 10min at 37!C and processed for immunocytochemistry andmounted
in mounting medium containing DAPI (Invitrogen, Life Technologies, Ghent, Belgium). Primary antibodies used: anti-PFKFB3 (Riera
et al., 2002) (gift from Dr. Bartrons, Barcelona, Spain), anti-VE-cadherin (R&D), anti-HKII (Cell Signaling Technology), anti-PGI
(Abgent), anti-PFKI (Santa Cruz Biotechnology), anti-GAPDH (Abcam), anti-aldolase (Abgent), anti-PGM (Abgent), anti-enolase
(Abgent), anti-PKM (Abcam), anti-PKM2 (Schebo Biotech) anti-TOMM20 (Abcam), anti-caspase 3 (Abcam), and anti-PGK
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(Santa Cruz Biotechnology). The actin cytoskeleton was visualized using Alexa-488 Fluor conjugated phallloidin (Invitrogen, Life
Technologies, Ghent, Belgium). Imaging was performed using a Zeiss LSM 510 Meta NLO or Zeiss LSM 780 confocal microscope
(oil objectives: x 40 with NA 1.3, x 63 with NA 1.4, x 100 with NA 1.3) (Carl Zeiss, Munich, Germany). 3D projections were recon-
structed with ZEN software (Carl Zeiss, Munich, Germany). Morphometry was done with NIH Image J and AxioVision (Carl Zeiss,
Munich, Germany) software packages. Colocalization of glycolytic enzymes with F-actin was calculated using the Colocalization
plug-in of ZEN software (Carl Zeiss, Munich, Germany). Super-resolution imaging was performed using a Zeiss Elyra Structured Illu-
minationmicroscope (SR-SIM) (Carl Zeiss,Munich, Germany) equippedwith an oil x 63 Plan-Apochromat objective with NA 1.4, three
SIM grid rotations and each line was scanned 4 times and the 4 scans of each pixel are averaged.
Live Cell Stainings and Imaging
Cells grown for 24 hr on coverslips were stainedwith Cell Mask DeepRed plasmamembrane stain (Invitrogen) and fixedwith 4%PFA
for 10 min at room temperature, mounted in mounting medium containing DAPI (Invitrogen, Life Technologies, Ghent, Belgium) and
imaged with a Zeiss LSM 510 Meta NLO confocal microscope (oil objectives: x 40 with NA 1.3, x 63 with NA 1.4, x 100 with NA 1.3)
(Carl Zeiss, Munich, Germany). Cells expressing a mitochondrial targeted GFP were used for time-lapse imaging of mitochondria.
Real time monitoring of the ATP levels was performed using the GO-ATeam biosensor (Nakano et al., 2011). Images were acquired
continuously for > 30 min at 37!C using a Zeiss LSM 510 Meta NLO confocal microscope (oil objectives: x 40 with NA 1.3, x 63 with
NA1.4, x 100 with NA 1.3).
RNA and DNA Analysis
RNA expression analysis was performed by Taqman quantitative RT-PCR as described (Carmeliet et al., 2001), using in house-
designed primers and probes or premade primer sets (Applied Biosystems, Carlsbad, CA). Sequences or premade primer set ID
numbers are available upon request. Microarrays: Total RNA extracted from 500,000 ECs was reverse transcribed into cRNA and
biotin-UTP labeled using the Illumina TotalPrep RNA Amplification kit (Ambion). RNA was hybridized to the Illumina HumanHT-12
v4 Expression BeadChip using standard protocols (Illumina). Image data were converted to unnormalized sample probe profiles
using the Illumina GenomeStudio Software and analyzed by Ingenuity Pathway Analysis software. Image data were converted
into unnormalized sample probe profiles and subsequently was background corrected, both by using the Illumina GenomeStudio
Software. Data were further preprocessed by applying variance stabilizing transformation (Lin et al., 2008), quantile normalization
(Bolstad et al., 2003) and probe filtering. Statistical comparative analysis was performed with the limma package of Bioconductor
(Smyth, 2004) and the resulting p values were corrected for multiple testing with Benjamini-Hochberg (Benjamini et al., 2001) to
control the false discovery rate. Pathway analysis was done with Ingenuity Pathway Analysis software.
Immunoblot Analysis
Protein extraction and immunoblot analysis were performed using a modified Laemli sample buffer (125 mM Tris-HCl, pH 6.8 buffer
containing 2% SDS and 10% glycerol) (Carmeliet et al., 2001) in the presence of protease and phosphatase inhibitors (Roche,
Vilvoorde, Belgium). F-actin separation was performed by ultracentrifugation at 150,000 g for 90 min. Lysates were separated by
SDS-PAGE under reducing conditions, transferred to a nitrocellulose or PVDFmembrane, and analyzed by immunoblotting. Primary
antibodies used were rabbit anti-VEGFR2 (SC-504, Santa Cruz Biotechnologies, California, U.S.A/C (No. 2032)), rabbit anti-Lamin
A/C (No. 2032), rabbit anti-b-actin (13E5) rabbit anti-BiP (No. 3183), mouse anti-CHOP (No. 2895), anti-total AMPK (No. 2532), rabbit
anti-AMPK Thr172 (No. 2531 Cell Signaling Technology, Bioke´, Leiden, the Netherlands), anti-ATM (Abcam, ab2631), anti-ATM
Ser1981 (Abcam, ab36810) and anti-PFKFB3 (Riera et al., 2002). Autophagy was analyzed via western blot determination of LC3
II/I ratio (No. 3868, Cell Signaling Technology) to reveal the on-state of autophagy (autophagic flux). Equal loading was verified by
Ponceau Red staining. Appropriate secondary antibodies were from Dako (Enschede, the Netherlands). Signal was detected using
the ECL system (Amersham Biosciences, GE Healthcare, Diegem, Belgium) according to the manufacturer’s instructions. Densito-
metric quantifications of bands were done with NIH Image J software.
Immunoprecipitation of PFKFB3 fromHUVEC extracts was performed using anti-PFKFB3 antibodies (Abgent) covalently bound to
Dynabeads as per manufacturer’s specifications (Invitrogen). Immunoprecipitated extracts were used for immunoblot detection of
actin using anti-b-actin antibody (Cell Signaling) under denaturing conditions by SDS-PAGE, as described above, or for mass spec-
trometry analysis of putative binding partners (see below). Immunoprecipitation of PFKFB3was also confirmed using anitbodies from
Proteintech and polyclonal rabbit anti-PFKFB3 (Riera et al., 2002).
In Vitro Actin Binding Assay
GST-coupled recombinant human PFKFB3 (Sino Biological Inc.) was used in conjunction with the Actin Binding Protein Spin-Down
Assay Biochem Kit (human platelet actin; Cytoskeleton, Inc.), as per manufacturer’s protocols.
Mass Spectrometry
Detection of Immunoprecipitated Proteins
The pH of immunoprecipitated proteins was adjusted to pH 8.0 using 1 M Tris-HCl pH 8.0. Proteins were denatured by heating them
for 10 min at 95!C followed by immediate cooling down on ice. To 10 mg of immunoprecipitated proteins, 0.2 mg of trypsin
(Sequencing Grade Trypsin, Promega, Wisconsin, US) was added (w/w ratio of 1/50) for digestion of proteins overnight at 37!C. Prior
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to analysis on the mass spectrometer, the reaction mixtures were acidified using acetic acid (0.5% final concentration). 10 mg of
digested proteins were loaded onto an Ultimate 3000 nanoLC (Thermo Scientific, Waltham, MA, US) equipped with a C18
pepMap100 5 mm 100 A˚ precolumn with dimensions 300 mm x 5 mm (Thermo Scientific) and an Acclaim C18 PepMap100 3 mm
100 A˚, 75 mm x 15 cm analytical column (Thermo Scientific). Peptides were eluted using a gradient from solvent A (0.1% formic
acid) to solvent B (0.1% formic acid in acetonitrile (BioSolve, Valkenswaard, The Netherlands)), practically from 0-35 min an increase
from 5% to 35% solvent B was applied, from 35-44 min an increase to 45% solvent B and from 44-48 min an increase to 95% B. The
column was then re-equilibrated by running 10 min on 5% solvent B. The Ultimate 3000 nanoLC was in-line connected to a Finnigan
LTQ linear ion trap (Thermo Scientific). The mass spec was operated in full scan mode LTQ linear ion trap. Top 5 candidates of each
spectrum were subjected to fragmentation (MS2, using a minimal MS1 count of 7500, isolation width 2 m/z, collision energy 35 eV).
Exclusion of fragmented parent ions was applied (2 counts/15 s, excluded for 180 s, charge rejection: + 1). Raw data files were con-
verted into mascot generic files (mgf) using software provided by the manufacturer. MS/MS peak lists were searched with Mascot
using theMascot Daemon interface (version 2.2.0, Matrix Science). Spectra were searched against the Swiss-Prot database (version
56.4) and taxonomy was set to Homo sapiens (20,328 entries). Variable modifications were set to acetylation of the protein’s N ter-
minus and methionine oxidation. No fixed modifications were selected. Mass tolerance of the precursor ions was set to ± 0.5 Da and
of fragment ions to ± 0.5 Da. The peptide charge was set to 2+, or 3+ and onemissed tryptic cleavage site was allowed. Only peptides
that met the 95% Mascot confidence interval were retained for further data analysis.
Flow Cytometry
Cell-Cycle Analysis
Cells in G0 were identified as a 2N DNA population lacking 5-ethynyl-20-deoxyuridine (EdU, Invitrogen) incorporation, as described.
Briefly, cells were labeled with 10 mM EdU over 24 hr, collected by trypsinization and fixed (4% PFA). The incorporated EdU was
detected by a ‘‘click-It reaction’’ with Alexa fluor 647 according to the manufacturer’s instructions. Alexa fluor 647 was excited
with a 604 nm red laser and emission was recorded at 660 nm, while Hoechst 33342 was excited with a 405 nm Violet Diode laser
and emission was recorded at 450 nm.
Protein Synthesis
HUVEC were incubated in methionine free medium for 1 hr to deplete intracellular methionine reserves. Cells were then labeled with
50 mM Click-IT L-Homopropargylglycine (HPG, Molecular Probes) in methionine free medium for 4 hr to allow incorporation during
protein synthesis. After fixation of the trypsinized cells with 4% PFA, the incorporated HPG was detected by a ‘‘click it reaction’’ with
Alexa fluor 647 according to the manufacturer’s instructions. Flow cytometry was performed on a FACS CANTOII (BD Biosciences,
Erembodegem, Belgium) and data were analyzed with FlowJo software (TreeStar Inc., Olten, Switzerland).
Metabolism Assays
Lactate concentration in the medium was determined at the Leuven University Hospital.
Glycolysis
Cells were incubated for 2 hr in growth medium containing 0.4 mCi/ml [5-3H]-D-glucose (PerkinElmer). Thereafter, supernatant was
transferred into glass vials sealed with rubber stoppers. 3H2O was captured in hanging wells containing a Whatman paper soaked
with H2O over a period of 48 hr at 37!C to reach saturation (Aragone´s et al., 2008). Radioactivity was determined in the paper by liquid
scintillation counting.
14C-Glucose Oxidation
Cells were incubated for 6 hr in growth medium containing 0.55 mCi/ml [6-14C]-D-Glucose. Thereafter, 250 ml of 2 M perchloric acid
was added to each well to stop cellular metabolism and wells were immediately covered with a 1 x hyamine hydroxide-saturated
Whatman paper. Overnight absorption of 14CO2 released during the oxidation of glucose into the paper was performed at room tem-
perature, and radioactivity in the paper was determined by liquid scintillation counting (Schafer et al., 2009).
Oxidative Pentose Phosphate Pathway
The contribution of the oxidative pentose phosphate pathway (oxPPP) to total glucose utilization was measured as 14CO2 formation
using 0.55 mCi/ml [6-14C]-D-glucose (14CO2 formation only in the TCA cycle) or 0.55 mCi/ml [1-
14C]-D-glucose (14CO2 formation both
in the TCA cycle and the oxPPP) and then subtracted the [6-14C]-glucose flux from the [1-14C]-glucose flux. This value was corrected
for total glucose utilization, as previously described (Ashcroft et al., 1972).
Fatty Acid Oxidation
ECs were incubated in serum free M199 medium supplemented with 100 mMunlabeled palmitic acid bound to BSA and 50 mMcarni-
tine. Oxidation was measured analogously to glycolysis (cf supra) using 2 mCi/ml [9,10-3H]-palmitic acid (Dagher et al., 2001).
14C-Glutamine Oxidation
Cells were incubated for 6 hr in growthmedium containing 0.5 mCi/ml [U-14C]-glutamine. Thereafter, 250 ml of 2M perchloric acid was
added to eachwell to stop cellularmetabolism and 14CO2was collected as described above for glucose oxidation (Wang et al., 2011).
Fructose-2,6-Bisphosphate Levels
Cells were lysed in 100 mM NaOH and centrifuged (20,000 g for 20 min). An aliquot of the homogenate was used for protein deter-
mination and the remaining sample was heated at 80!C for 5 min, centrifuged (20,000 g for 20 min) and the resulting supernatant was
used for the determination of F2,6P2 concentration as described (Van Schaftingen et al., 1982).
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Oxygen Consumption
Cells were seeded at 40,000 cells per well on Seahorse XF24 tissue culture plates (Seahorse Bioscience Europe, Copenhagen,
Denmark). The assay medium was unbuffered DMEM supplemented with 5 mMD-glucose and 2mM L-glutamine, pH 7.4. The mea-
surement of oxygen consumption was performed at 10min intervals (2minmixing, 2min recovery, 6minmeasuring) for 3 hr using the
Seahorse XF24 analyzer. Inhibitors and substrates were used at the following concentrations: oligomycin (1.2 mM), antimycin (1 mM),
NADH (500 mM), and pyruvate (10 mM).
Calculation of ATP Production
ATP production was calculated from the rate of glycolysis, glucose oxidation, fatty acid oxidation and glutamine oxidation. Here, it
was assumed that 2 moles of ATP are generated per mole of glucose that entered glycolysis, 30 mole of ATP per mole glucose
oxidized, 129 mole of ATP per mole of fatty acid oxidized, and 20-32 mole ATP per mole of glutamine oxidized.
Energy Balance Assessment
A total of 2 3 106 cells were harvested in ice cold 0.4 M perchoric acid supplemented with 0.5 mM EDTA. ATP, ADP and AMP were
measured using ion-pair RP-HPLC as previously described (Peeters et al., 2011). NAD+/NADH ratio wasmeasured in cell lysates from
1 3 106 cells using the Fluoro NAD/NADH Detection Kit from Cell Technology Inc. (Gentaur, Kampenhout, Belgium). ATP content:
Measurement of ATP in HUVECwas performed using the ATP lite Luminescence ATP detection assay system (Perkin Elmer) accord-
ing to the manufacturer’s instructions and corrected for DNA content.
Extracellullar Matrix Synthesis
A total of 35,000 cells were seeded in 24-well plates in completeM199medium supplemented with ascorbic acid. At day 7, cells were
incubated for 12 hr with M199 containing 5 mCi/ml 3H-L-proline (PerkinElmer). Thereafter, the supernatant was collected, and an
equal volume 20% TCA was added, after which samples were vortexed, left on ice for 1 hr and centrifuged (30 min, 13,000 rpm,
4!C). The precipitate waswashedwith 500 ml 10%TCA, centrifuged, and the pellet was resuspended in 250 ml 1MNaOH and neutral-
ized with 250 ml 1 M HCl. In parallel, cells were washed with PBS, and 500 ml ice cold acetate buffer (for 100 ml: 250 mg BSA, 11.5 ml
acetate) was added. Thereafter, the plate was freeze/thawed 3 times and centrifuged (10 min, 3,000 rpm, 4!C). To the supernatant,
20%TCAwas added, and themixturewas vortexed, incubated on ice for 15min and centrifuged (20min, 14,000 rpm, 4!C). The pellet
was washed with 400 ml 10% TCA and solubilized in 250 ml 1 N NaOH and neutralized with 250ml 1 N HCl. Radioactivity was deter-
mined by liquid scintillation counting.
Zebrafish Models of Angiogenesis
Transient overexpression of zebrafish NICD (zNotch1a-intra) (Scheer and Campos-Ortega, 1999) and/or murine PFKFB3 along with
anmCherryRed reporter, all under the control of the fli1 enhancer, was performed in Tg(fli1:EGFP)y1 embryos (Zebrafish International
Resource Center, ZIRC, Oregon, USA) (Jin et al., 2005; Traver et al., 2003) using Tol2 transposon transgenesis with Tol2kit-based
vectors (Kwan et al., 2007) generated via Invitrogen’s Multi-Site Gateway Pro technology. Briefly, NICD or PFKFB3 cDNAwas cloned
upstream and mCherryRed cDNA downstream of a bidirectional fli1 promoter (basfli1 ep) using the entry vector [pE(R4R3)basfli1ep]
in the second position of a 3-way LR reaction with the Tol2 destination vector [pDESTTol2pA(R1R2)pA]. Simultaneous expression of
NICD and PFKFB3 along with mCherryRed was achieved with a NICD-T2A-Pfkfb3 fusion cloned upstream and mCherryRed down-
stream of the bidirectional basfli1 ep promoter, using the [pE(R4R3)basfli1ep] entry vector in the third position of a 4-way LR reaction.
The bidirectional basfli1ep promoter was generated by adding the sequence for the carp beta-actin minimal promoter, in a reverse
orientation, to the 50 end of the fli1ep enhancer/promoter (Villefranc et al., 2007). NICD and PFKFB3 gene expression by the Tol2 vec-
tors was verified in vitro by qRT-PCR after transfection of the vectors into the zebrafish fibroblast cell line ZF4 (ATCC, LGCStandards,
Molsheim Cedex, France) in which the fli1 promoter shows some expression. Live screening and quantification of ISV abnormalities
in the trunkwas performed on Tricaine-anaesthetized embryos (Tricaine, Sigma-Aldrich, Bornem, Belgium) at 24-28 hpf. Competition
for tip location by NICD+:mCherry+, PFKFB3+:mCherry+ or NICD+:PFKFB3+:mCherry+ overexpressing ECs was quantified by count-
ing the fraction among mosaic mCherryRed+ ISVs, grown beyond the midline, but not fused yet at the dorsal roof level, that showed
mCherryRed+ signal in the tip, but not in the base. Multiphoton or confocal imaging of fli1:EGFPy1 embryos was performed using a
Zeiss LSM 510 Meta NLO confocal microscope (oil objectives: x 40 with NA 1.3, x 63 with NA 1.4, x 100 with NA 1.3) (Carl Zeiss,
Munich, Germany); embryoswere anaesthetized and positioned on a coverslip in a drop of 0.5% lowmelting point agarose. All exper-
imental animal procedures were approved by the Institutional Animal Care and Research Advisory Committee of the University of
Leuven.
Mice
Generation of MitoEC Mice
Micewith conditional reporter expression associated withmitochondria were generated by knock-in into theRosa26 locus of a cDNA
encoding a fusion of green fluorescent protein (AcGFP1) and amitochondrial targeting sequence (Mito) derived from the precursor of
subunit VIII of human cytochrome C oxidase (Rizzuto et al., 1995; Rizzuto et al., 1989). Therefore, the NheI-NotI fragment from the
pAcGFP1-Mito vector (Clontech Laboratories, Inc., Westburg, Leusden, the Netherlands), was inserted into the multiple cloning site
downstream of the floxed neomycineR:stop cassette of pBigT (Srinivas et al., 2001) into which the ubiquitous CAGGS promoter (Di-
vision of Stem Cell Regulation Research, Osaka University Graduate school of Medicine, Japan) was first inserted upstream of the
floxed neomycineR:stop cassette (pBigT-CAGGS). Subsequently, the entire loxP-neomycineR:stop-loxP-AcGFP1-Mito fragment
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was excised with Pac1 and AscI and cloned into the targeting vector pRosa26-pA (Addgene plasmid 21271) (Srinivas et al., 2001).
The targeting vector was then used to generate conditional R26lsl-GFP-Mito mice by homologous recombination in embryonic stem
cells as described (Aragone´s et al., 2008). The R26lsl-GFPmito mice were then crossed with Tie2:Cre transgenic mice (Kisanuki et al.,
2001), to obtain mice with selective expression of the AcGFP1-Mito reporter in endothelial cells (MitoEC mice). PFKFB3EC mice: For
postnatal EC-specific loss of function studies, VECadherin(PAC)-CreERT2 (provided by R. Adams) and Pdgfb(PAC)-CreERT2 (Clax-
ton et al., 2008) were intercrossed with PFKFB3lox/lox mice and named PFKFB3vdEC and PFKFB3pdEC, respectively. A description on
the generation of the PFKFB3lox/lox will be reported elsewhere. In addition, PFKFB3dEC mice were intercrossed with mT/mG mice for
determination of recombination efficiency.
Generation of PFKFB3!/! Embryonic Stem Cells
PFKFB3+/!mice (C57Bl6/129) were mated and blastocysts were collected from plugged female mice 3.5 days postcoitus. Individual
blastocysts were cultured in ES cell culture medium (see below), and after 5-8 days the inner cell mass outgrowth was selectively
removed from the trophectoderm, trypsinized and replated on a mitoC-arrested murine fibroblast monolayer. ES cells were
passaged every 2–4 days onto freshly prepared feeder layers, and were fed every day with new ES cell culture medium consisting
of Knockout DMEM medium (Life Technologies), supplemented with 2 mM L-glutamine (Life Technologies), fetal bovine serum
(Hyclone, ThermoScientific), MEM nonessential amino acids 100X (GIBCO/Invitrogen), 0.01mM b-mercaptoethanol (Sigma-Aldrich),
1 mM sodium pyruvate, 100 IU/ml penicillin and 100 mg/ml streptomycin, and 2,000 U/ml Leukemia Inhibitory Factor (Merck,
Millipore).
Mouse Mosaics
Chimeric embryos were generated by injecting 15-20 wild-type or PFKFB3!/! ES cells stably transfected with DsRed, into CD-1 host
blastocysts. Injected blastocysts were transplanted into 2.5 day pseudo pregnant CD-1 foster mothers.
Mouse Models of Angiogenesis
C57BL/6 mice were from Charles River, Belgium. Housing and experimental procedures were approved by the animal care and use
committee of the university of Leuven.
Postnatal Retinal Angiogenesis
Endothelial cell specific inactivation of PFKFB3 in neonatal mice was achieved by intraperitoneal injection of 10 mg/kg Tamoxifen
solution (Sigma T5648; dissolved in 1:10 EtOH:corn oil solution) once daily from P1 to P4 in PFKFB3vDEC mice and following single
injection at P2 in PFKFB3pDEC mice. At P5, eyes were enucleated, fixed with 2% PFA and prepared for vascular analysis. For detec-
tion of cell proliferation, EdU (Invitrogen) was injected 2 hr before dissection. Radial vascular area, branching points, and number of
filopodia were analyzed using the NIH Image J software package and the AxioVision morphometric analysis software (Carl Zeiss,
Munich, Germany) with in-house developed macros. Primary antibodies used: isolectin GS-IB4-Alexa 488, isolectin GS-IB4-Alexa
568, isolectin GS-IB4- Alexa 647 (Molecular Probes), anti-Erg (Santa Cruz Biotechnology), anti-NG2Chondroitin Sulfate Proteoglycan
(Chemicon), anti-GFP (Molecular Probes), anti-caspase 3 (Abcam), and anti-collagen IV (Southern Biotech), and anti-F4/80 (Serotec
MCA497). Alexa-488, !568 or !633 conjugated secondary antibodies were used (Molecular Probes). EdU staining was performed
according to manufacturer’s instructions. Other stainings were performed as described previously (Jakobsson et al., 2010).
Embryonic Hindbrain Angiogenesis
Embryos were harvested at E10.5-11.5 and hindbrains were dissected, stained and analyzed as described previously (Fantin
et al., 2013).
Statistics
Data represent mean ± SEM of representative experiments unless otherwise stated. For in vitro experiments with freshly isolated
HUVECs, every experiment was performed at least three times using different donors. Unless otherwise indicated, statistical signif-
icance between groups was calculated by standard t test (Prism v4.0b). Phenotype severity distributions were analyzed by Chi-
square test. Estimatedmeans, SEMs and significance levels were calculatedwith the general linearmodel univariate statistical model
(SPSS), considering experiment as covariate. p < 0.05 was considered as statistically significant.
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Figure S1. PFKFB3 Drives Glycolysis in ECs and Stimulates Vessel Sprouting In Vitro, Related to Figure 1
(A–D)Messenger RNA expression analysis of the phosphofructokinase-2/fructose-2,6-bisphosphatase isoenzymes showing that PFKFB3 is themost abundantly
expressed isoenzyme in venous (HUV) (A), arterial (HA) (B), microvascular (HMV) (C), and hemangioma (MS1) (D) ECs (mean ± SEM; n = 3; *p < 0.05).
(E) Immunoblotting, showing reduced PFKFB3 protein levels in cells after silencing with LV-shPFKFB3. Densitometric quantification is shown below the lanes
(mean ± SEM; n = 3; *p < 0.05).
(F) Quantification of fructose-2,6-bisphosphate (F2,6P2) content showing reduced F2,6P2 levels after PFKFB3 silencing (PFKFB3
KD) (mean ± SEM; n = 3;
*p < 0.05).
(G) Immunoblotting, showing reduced PFKFB3 protein levels in cells after siRNA mediated silencing of PFKFB3. Densitometric quantification is shown below the
lanes (mean ± SEM; n = 3; *p < 0.05).
(H) Glycolytic flux analysis showing that overexpression of PFKFB3 (PFKFB3OE) increases glycolysis in ECs (mean ± SEM; n = 5-6; *p = 0.01).
(I and J) Representative bright field photographs of EC spheroids showing that PFKFB3-overexpressing (PFKFB3OE) ECs formedmore and longer sprouts. Scale
bars, 50 mm.
(K and L) Morphometric analysis of sprouting EC spheroids, revealing that overexpression of PFKFB3 (PFKFB3OE) enhanced the number of sprouts per spheroid
(K) as well as total sprout length (L) (mean ± SEM; n = 30; *p < 0.01).
(M) Decreased oxygen consumption in the presence of the mitochondrial respiration inhibitors oligomycin or antimycin A (mean ± SEM; n = 3; *p < 0.05).
(N) Supplementation of NADH and pyruvate increases oxygen consumption rates (OCR) (mean ± SEM; n = 3; *p < 0.05).
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Figure S2. PFKFB3 Gene Deletion in ECs Causes Vascular Defects In Vivo, Related to Figure 2
(A) PCR of tail genomic DNA from PFKFB3vDEC and PFKFB3pDEC pups, showing recombination of the floxed PFKFB3 allele following tamoxifen induction of
VE-cadherin-driven (vDEC) or Pdgfb-driven (pDEC) Cre-activity in endothelial cells.
(B and C) Confocal images of isolectin B4-stained (gray) retinal vessels of neonatal pups showing branching defects in PFKFB3pDEC (C) as compared to WT (D)
mice. Scale bars, 50 mm.
(D and E) Quantification of the branching points at the front (D) and rear (E) showing reduced branch points in PFKFB3pDEC mice (mean ± SEM; n = 29; *p < 0.03).
(F and G) Quantification of the number of distal sprouts with filopodia (F) and the number of filopodia (G) in the retinal vasculature of PFKFB3pDEC mice (mean ±
SEM; n = 6-8; *p < 0.05).
(H–J) Double staining of retinal vessels for Isolectin B4 (red) and the pericyte differentiation marker NG2 (green), showing comparable pericyte coverage in
PFKFB3DEC (I) and WT (H) mice. Scale bars, 50 mm. (J) shows the quantification of pericyte coverage (mean ± SEM; n = 16 and n = 11; *p = NS).
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Figure S3. Role of PFKFB3 in Tip Cell Formation, Related to Figure 4
(A) Quantification of the fraction of MitoC-treated ECs at the tip position with the indicated genotype, revealing that the competitive disadvantage of
PFKFB3KD/GFP ECs as compared to WTred ECs to reach the tip is independent of proliferation (n = 30; p < 0.01 of WT: PFKFB3KD/GFP versus WT:WT by
Chi-square).
(B) Mosaic EC spheroid experiments using a 9-fold excess of WTgfp over WTred ECs, showing that up to 80% of tip cells were WTgfp cells. In contrast, when a
9-fold excess of PFKFB3KD/GFP over WTred ECs was used, only 66% of tip cells were PFKFB3KD/GFP cells. Quantification of the fraction of tip cells with the
indicated PFKFB3 genotype is shown (n = 31-42; *p < 0.01 WT:PFKFB3KD/GFP versus WT:WT by Chi-square).
(C) Mosaic EC spheroid experiments, containing a 1:1 mixture of WTred ECs and GFP-labeled PFKFB3-overexpressing ECs (PFKFB3OE/GFP), revealing a modest
competitive advantage of PFKFB3OE/GFP ECs to reach the tip. Quantification of the fraction of tip cells with the indicated PFKFB3 genotype is shown (n = 30; *p <
0.05 WT: PFKFB3OE/GFP versus WT:WT by chi-square test).
(D and E) Morphometric quantification of spheroid sprouting, showing that DAPT increases the number (D) and length (E) of the sprouts, but that hypersprouting
was abolished when PFKFB3was silenced in DAPT-treated cells (DAPT/PFKFB3KD) (mean ±SEM; n = 30; *p < 0.05 versus control (gray), &p < 0.005 versus DAPT
for number of sprouts (D) and *p < 0.01 versus control (gray), &p < 0.0001 versus DAPT for total vessel length (E)).
(F) Quantification of the fraction of MitoC-treated ECs at the tip position with the indicated genotype, revealing that the competitive advantage of NOTCH1KD/GFP
ECs as compared to NOTCH1KD/GFP/PFKFB3KD/GFP cells to reach the tip is independent of proliferation (n = 30; *p < 0.05 of WT: NOTCH1KD/GFP versus WT:
NOTCH1KD/GFP/PFKFB3KD/GFP).
(G) Morphometric quantitation of sparsely seededGFP+ ECs showing that lamellipodia formation was impaired in NICDOE cells and restored to near normal levels
in NICDOE/PFKFB3OE cells (mean ± SEM; n = 30; *p < 0.001 versus control (gray), &p < 0.001 versus NICDOE).
(H) Quantification of the fraction of MitoC-treated ECs at the tip position with the indicated genotype, revealing that the competitive advantage of NICD/
PFKFB3OE/GFP ECs over NICDOE/GFP cells to reach the tip is independent of proliferation (n = 30; *p < 0.05 of WT: NICDOE/GFP versus WT: NICD/PFKFB3OE/GFP).
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Figure S4. Localization of Glycolytic Enzymes in Lammelipodia, Related to Figure 6
(A–J) Staining of the indicated glycolytic enzymes, revealing the presence of glycolytic enzymes in both the perinuclear cytosol as well as in membrane ruffles of
lamellipodia. Each row presents the immunostaining in gray scales (left panel), the double staining for the indicated glycolytic enzyme (red) and F-actin (green)
(middle panel), and a pseudocolor conversion enlarged inset of the immunostained glycolytic enzyme (right panel). GAPDH: glyceraldehyde 3-phosphate
dehydrogenase, HKII: hexokinase II, PFK1: phoshofructokinase 1, PFKFB3: PFK-2/fructose bisphosphatase 3, PGI: phosphoglucose isomerase, PGK: phos-
phoglycerate kinase, PGM, phosphoglucomutase, PKM1&2: pyruvate kinase 1&2.
(K and L) Double staining for PFKFB3 (gray; left panel) and VE-Cadherin (green; K middle panel) or phalloidin (green; L middle panel) revealing that glycolytic
enzymes are present in the perinuclear cytosol in contact-inhibited quiescent ECs (K) but relocalize to lamellipodia, cell protrusions and cell-cell bridges in motile
ECs (L). The right panels show a higher magnification.
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SUMMARY
Strategies targeting pathological angiogenesis have
focused primarily on blocking vascular endothelial
growth factor (VEGF), but resistance and insufficient
efficacy limit their success, mandating alternative
antiangiogenic strategies. We recently provided
genetic evidence that the glycolytic activator phos-
phofructokinase-2/fructose-2,6-bisphosphatase 3
(PFKFB3) promotes vessel formation but did not
explore the antiangiogenic therapeutic potential of
PFKFB3 blockade. Here, we show that blockade
of PFKFB3 by the small molecule 3-(3-pyridinyl)-1-
(4-pyridinyl)-2-propen-1-one (3PO) reduced vessel
sprouting in endothelial cell (EC) spheroids, zebra-
fish embryos, and the postnatal mouse retina by in-
hibiting EC proliferation and migration. 3PO also
suppressed vascular hyperbranching induced by in-
hibition of Notch or VEGF receptor 1 (VEGFR1) and
amplified the antiangiogenic effect of VEGF
blockade. Although 3PO reduced glycolysis only
partially and transiently in vivo, this sufficed to
decrease pathological neovascularization in ocular
and inflammatory models. These insights may offer
therapeutic antiangiogenic opportunities.
INTRODUCTION
Angiogenesis stimulates the progression of numerous disorders.
Hence, targeting this process by blocking angiogenic signals
such as vascular endothelial growth factor (VEGF) has become
a clinically attractive strategy (Singh and Ferrara, 2012). Howev-
er, insufficient efficacy and resistance limit its success (Ebos and
Kerbel, 2011; Potente et al., 2011). Although combination treat-
ment with multiple agents blocking distinct angiogenic signals
might offer benefit, a concern remains that angiogenesis re-
lapses through compensation by other angiogenic factors. We
therefore explored a fundamentally different antiangiogenic
strategy.
Targeting endothelial cell (EC) metabolism for antiangiogene-
sis has received little attention (De Bock et al., 2013a; Harjes
et al., 2012). Since angiogenic signaling pathways converge
onto metabolism, and ECs rely on glycolysis for generating
most (85%) of their ATP (De Bock et al., 2013b), we hypothesized
that targeting glycolysis might provide an alternative therapeutic
opportunity for reducing pathological neovascularization. How-
ever, given that previous antiglycolytic, anticancer therapies
were not always successful (Granchi and Minutolo, 2012; Raez
et al., 2013), it was unknown if antiglycolytic strategies could
inhibit pathological angiogenesis.
We focused on phosphofructokinase-2/fructose-2,6-bi-
sphosphatase-3 (PFKFB3), since silencing in vitro or inactiva-
tion in vivo of this glycolytic activator reduced glycolysis and
impaired vessel sprouting (De Bock et al., 2013b). This enzyme
is an activator of a key glycolytic enzyme, 6-phosphofructo-1-
kinase (PFK-1), which converts fructose-6-phosphate (F6P)
to fructose-1,6-bisphosphate (F1,6P2). PFKFB isoenzymes
synthesize fructose-2,6-bisphosphate (F2,6P2), an allosteric
activator of PFK-1 and potent stimulator of glycolysis (Van
Schaftingen et al., 1982). Of all PFKFB isoenzymes, PFKFB3
has a much (700-fold) higher kinase than bisphosphatase activ-
ity and promotes production of F2,6P2 and glycolysis (Yalcin
et al., 2009). PFKFB3 is also the most abundant isoenzyme in
ECs (De Bock et al., 2013b). Here, we characterized the antian-
giogenic therapeutic potential of a PFKFB3 inhibitor.
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RESULTS
PFKFB3 Blockers Reduce Glycolysis in EC Monolayers
In Vitro
To explore if pharmacological blockade of the kinase activity of
PFKFB3 reduced glycolysis in human umbilical venous endothe-
lial cells (HUVECs, abbreviated as ECs) and affected vessel
sprouting, we used the small molecule compound 3-(3-pyri-
dinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) (Chesney et al.,
1999; Clem et al., 2008). Key findings were confirmed by us-
ing 7,8-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one (YN1),
another PFKFB3 blocker (Seo et al., 2011). 3PO and YN1 dose
dependently reduced glycolysis in ECs, but by no more than
35%–40% (Figure 1A; Figure S1A available online). 3PO evoked
comparable effects in arterial ECs (Figure S1B). PFKFB3
blockade thus reduced glycolysis incompletely, i.e., less than
the nonmetabolizable glucose analog 2-deoxy-D-glucose
(2DG), which reduced glycolysis by !80% (Figure S1C). 3PO
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Figure 1. 3PO Inhibits Glycolysis in ECs
(A) Glycolytic flux in control or PFKFB3-silenced ECs, showing that 3PO reduced glycolysis in control cells but was ineffective in further reducing glycolysis in
PFKFB3-silenced cells (mean ± SEM; n = 3; *p < 0.05 versus vehicle; &p < 0.05 versus control).
(B) Quantification of fructose-2,6-bisphosphate (F2,6P2) content, showing reduced F2,6P2 levels after PFKFB3 inhibition by 3PO (mean ± SEM; n = 3; *p < 0.05).
(C) PFKFB3 blockade by 3PO did not affect the energy charge ([ATP] + ½[ADP]) / ([ATP] + [ADP] + [AMP]) (mean ± SEM; n = 3; p = not significant [NS]) at 24 hr.
(D) Enzymatic activity of glycolytic enzymesmeasured in extracts of ECs, treated with a concentration of 3PO or YN1 that effectively inhibited glycolysis, showing
that these PFKFB3 blockers failed to affect their enzymatic activity (mean ± SEM; n = 3; *p < 0.05). HK, hexokinase; G6PD, glucose 6-phosphate dehydrogenase;
TKT, transketolase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PK, pyruvate kinase; LDH, lactate dehydrogenase.
(E) Glucose uptake in vivo, showing that a first injection of 3PO (vertical arrow 1) lowered 2-[1-14C]-DG uptake in the diaphragm modestly and transiently during
the first 6 hr, but not after 24 hr. A second administration of 3PO after 24 hr (vertical arrow 2) reduced glucose uptake again to the same level as the first
administration (mean ± SEM; n = 3; *p < 0.05).
(F) GC-MS analysis of 13C enrichment in lactate, showing that lactate production from [U-13C]-glucose in the blood was transiently reduced upon 3PO treatment
after 1 hr, but not any longer after 24 hr (mean ± SEM; n = 4 for ctrl and n = 5 for 3PO; *p < 0.05 versus vehicle at the same time point).
(G) [6-14C]glucose incorporation assay, showing that 3PO reduced the synthesis of RNA in EC monolayers (mean ± SEM; n = 3; *p < 0.01).
(H) [3H]thymidine incorporation assay, showing that 3PO reduced proliferation of EC monolayers (mean ± SEM; n = 3; *p < 0.01).
(I) FACS quantification of 5-ethynyl-20-deoxyuridine (EdU") ECs, showing that 3PO treatment increased the fraction of quiescent ECs. Upon reseeding in the
absence of 3PO, ECs reinitiate proliferation (mean ± SEM; n = 3; *p < 0.05).
(J) Glycolytic flux is lower in quiescent ECs (81% ± 3% synchronized in G0/G1 by contact inhibition [CI]) than in proliferating (prol) ECs (35% ± 1% in G0 upon
replating) (mean ± SEM; n = 3; *p < 0.05).
(K) Quantification of MitoC-treated EC migration in scratch wound assays over time (10 and 24 hr), showing reduced migration upon PFKFB3 blockade (3PO).
When 3PO was removed from the medium 10 hr after the initiation of the treatment, ECs resumed migration (mean ± SEM; n = 3; *p < 0.05). See also Figure S1.
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also lowered F2,6P2 levels by 41% (Figure 1B). 3PO, however,
did not lower the energy charge (Figure 1C) and, unlike 2DG,
did not increase oxygen consumption (Figure S1D).
3PO and YN1 did not inhibit the enzymatic activity of a panel of
glycolytic enzymes when analyzing EC lysates (Figure 1D) or
purified enzymes (Figures S1E–S1I). When measuring glycolytic
flux by using D-[5-3H]-glucose, 3PO did not further reduce
glycolysis in ECs in which PFKFB3 was silenced to nearly unde-
tectable protein levels (Figure 1A). YN1 reduced glycolysis in
PFKFB3-silenced cells slightly more (Figure S1A), in agreement
with its partial effect on PFKFB4 (Seo et al., 2011).
PFKFB3 Blockade Reduces Glycolysis Partially
and Transiently In Vivo
We also determined the effect of 3PO on glycolysis in vivo in
mice by measuring 2-[1-14C]-deoxy-D-glucose (2-[1-14C]-DG)
uptake as an indirect parameter of glycolysis. 3PO lowered
2-[1-14C]-DG uptake by 38% and 41% in the diaphragm and
heart, but only transiently during 6 hr (Figure 1E). However, a sec-
ond administration of 3PO 24 hr later comparably reduced
2-[1-14C]-DG uptake (Figure 1E). Intravenous injection of
[U-13C]-glucose and analysis of 13C-lactate enrichment in the
blood by gas chromatography-mass spectrometry (GC-MS)
confirmed the transient reduction in glycolysis upon 3PO injec-
tion (Figure 1F).
PFKFB3 Blockers Reduce EC Proliferation
and Migration In Vitro
In ECmonolayers, 3PO reduced [6-14C]-glucose incorporation in
RNA, a process involving the nonoxidative branch of the pentose
phosphate pathway (non-oxPPP) that generates pentoses for
nucleotide synthesis (Figure 1G). 3PO also decreased EC prolif-
eration (Figure 1H), in agreement with PFKFB3 silencing data (De
Bock et al., 2013b). Instead, 3PO increased the fraction of quies-
cent ECs (Figure 1I). This effect was reversible, as removal of
3PO restored the fraction of cycling cells (Figure 1I). In accor-
dance, glycolysis was 40% lower in contact-inhibited quiescent
ECs than in cycling ECs (Figure 1J). To study EC migration in the
absence of confounding effects of proliferation, we treated ECs
with mitomycin C (MitoC) to inhibit proliferation. 3PO reduced
MitoC-treated EC migration in a scratch wound and modified
Boyden chamber assay, and the effects were reversible upon
washout of 3PO (Figure 1K; Figure S1J). Similar data were ob-
tained for YN1 (Figures S1K and S1L).
PFKFB3 Blockers Impair Vessel Sprouting In Vitro
To study the effect of PFKFB3 blockers on vessel sprouting, we
used EC spheroids. Similar to that in vivo, a tip cell with filopodia-
like protrusions takes the lead, while proliferating stalk cells elon-
gate the sprout. PFKFB3 was essential for vessel outgrowth, as
both 3PO and YN1 shortened sprout length and decreased
sprout numbers (Figures 2A–2D; Figures S2A, S2B, S2D, and
S2E), similar to the effect induced by PFKFB3 silencing (De
Bock et al., 2013b). 2DG also reduced vessel sprouting (Figures
S2C–S2E), but unlike 3PO-treated spheroids that retained a
healthy morphology, 2DG-treated spheroids disintegrated and
eventually died, as revealed by TO-PRO 3 staining (Figures
S2F–S2H), indicating that near-complete inhibition of glycolysis
causes cellular demise and death. Counting of Hoechst 33342-
stained nuclei revealed that 3PO reduced EC numbers in
vascular sprouts (Figures 2E–2G). 3PO also decreased the incor-
poration of bromodeoxyuridine (BrdU) in spheroid sprout ECs
(Figure 2H), indicating that blockade of PFKFB3 impairs sprout-
ing at least partially via reducing EC proliferation. 3PO also
impaired ECmigration, as it reduced sprouting after MitoC treat-
ment (Figures 2I and 2J). Furthermore, 3PO impeded capillary
tube formation (Figures S2I and S2J).
PFKFB3 increases glycolysis but decreases the oxidative
pentose phosphate pathway (oxPPP) flux (Herrero-Mendez
et al., 2009). This pathway with its rate-limiting enzyme glucose-
6-phosphate dehydrogenase (G6PD) generates NADPH, used
to reduce oxidized glutathione for antioxidant defense. Notably,
3PO increased the oxPPP flux (Figure 2K) and, consistent with
previous reports that the oxPPP promotes angiogenesis (De
Bock et al., 2013a; Leopold et al., 2003), blocking the oxPPP by
6-aminonicotinamide (6AN) decreased vessel sprouting (Figures
2L and 2M). However, this increase did not explain the impaired
vessel sprouting phenotype by 3PO, since blocking the oxPPP
by 6ANdid not abrogate the antisprouting activity of 3PO (Figures
2L and 2M). Furthermore, addition of sodium pyruvate at a con-
centration that increases oxygen consumption (De Bock et al.,
2013b) did not rescue the impaired vessel sprouting in 3PO-
treated spheroids (Figures S2K and S2L), indicating that
diminishing glycolysis by 3PO did not reduce vessel sprouting
by diminishing entry of glycolytic intermediates into the tricarbox-
ylic acid (TCA) cycle for oxidative glucose metabolism.
PFKFB3 Blockade Does Not Alter the Expression
of Tip- or Stalk-Enriched Genes
We analyzed if PFKFB3 impeded tip or stalk cell formation by
reducing the expression of VEGF receptor 2 (VEGFR2) and
Dll4, known to influence tip versus stalk cell formation, respec-
tively (Geudens and Gerhardt, 2011; Potente et al., 2011). How-
ever, RT-PCR analysis revealed that 3PO did not alter the
expression of tip or stalk cell-enriched genes (Figure 2N).
Indeed, 3PO did not affect transcript levels of Dll4 or of the
Notch1 target genes HES1, HEY1, and HEY2. Expression of
VEGFR2 was also not affected by 3PO at the mRNA or protein
level (Figure 2N; Figure S2M). Since 2DG interferes with glyco-
sylation by affecting the hexosamine biosynthetic pathway, a
side pathway of glycolysis, we examined if 3PO had similar
effects. However, VEGFR2 was detected as a fully glycosylated
230 kDa form in 3PO-treated ECs (Figure S2M), suggesting that
glycosylation was not impaired. Fluorescence-activated cell
sorting (FACS) analysis also failed to reveal a difference in
VEGFR2 levels on the cell surface (Figure S2N). Overall, consis-
tent with PFKFB3 loss-of-function studies in ECs (De Bock
et al., 2013b), the impaired vessel sprouting by 3PO was not
attributable to a change in the expression of tip versus stalk
cell signature.
PFKFB3 Blockers Impair Vessel Sprouting in Zebrafish
To explore the functional in vivo relevance of PFKFB3 inhibition,
we used fli1:EGFPy1 zebrafish embryos expressing GFP in ECs
and focused on intersomitic vessels (ISVs), which branch off
from the dorsal aorta in a ventral-to-dorsal direction and estab-
lish the dorsal longitudinal anastomosing vessel (DLAV). We
analyzed only viable embryos without developmental defects
Cell Metabolism
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Figure 2. Pharmacological Blockade of PFKFB3 by 3PO Impairs Sprouting In Vitro
(A and B) Representative bright-field micrographs of control (A) and 3PO-treated (B) EC spheroids, showing reduced vascular sprouting in spheroids in the
presence of the PFKFB3 inhibitor 3PO (B). Scale bars: 50 mm.
(C and D) Morphometric quantification of EC spheroid sprouting, revealing that blockade of PFKFB3 by 3PO reduced the number of sprouts per spheroid (C) and
total sprout length (D) (mean ± SEM; n = 30; *p < 0.01).
(E and F) Representative fluorescence photographs of Hoechst 33342-stained EC spheroids (E), showing a reduced number of EC nuclei in the sprouts of 3PO
treated spheroids (F).
(G) Quantification of Hoechst 33342-stained ECs, showing that 3PO treatment reduces the number of nuclei per sprout (mean ± SEM; n = 30 spheroids; *p <
0.001).
(H) Quantification of BrdU+ ECs in spheroid sprouts, showing reduced proliferation upon PFKFB3 blockade by 3PO (mean ± SEM; n = 23 spheroids; *p < 0.005).
(I and J) Morphometric quantification of EC spheroid sprouting, revealing that blockade of PFKFB3 by 3PO reduced the total sprout length (I) and number of
sprouts per spheroid (J) even after MitoC-induced mitotic arrest (mean ± SEM; n = 30; *p < 0.05 versus ctrl and &p < 0.05 versus MitoC).
(K) Quantification of oxPPP, showing increased flux upon 3PO treatment (mean ± SEM; n = 4; *p < 0.04).
(L and M) Morphometric quantification of vessel sprouting from EC spheroids upon 6AN treatment, showing that blockade of the oxPPP affects neither the 3PO-
induced reduction of the number of sprouts per spheroids (L) nor the total sprout length (M) (mean ± SEM; n = 20; *p < 0.0001).
(N) mRNA expression analysis of DLL4, HES1, HEY1, HEY2, and VEGFR2, showing unaltered expression after PFKFB3 blockade (mean ± SEM; n = 3; p = NS).
See also Figure S2.
Cell Metabolism
PFKFB3 Blockade Reduces Pathological Angiogenesis
40 Cell Metabolism 19, 37–48, January 7, 2014 ª2014 Elsevier Inc.
	   66	  
 
 
 
 
 
 
 
 
and with an intact circulation (Figure S3A–S3D). When treating
embryos with 3PO from 20 hr postfertilization (hpf) onward, just
prior to the onset of ISV sprouting, 3PO dose dependently
impaired ISV sprouting (Figures 3A–3D). At 40 mM, only <5% of
the embryos formed ISVs, but these vessels had perfusion de-
fects (see below). Time-lapse video imaging of 3PO-treated
embryos showed that the ISVs failed to grow out normally and
established only an incomplete DLAV (Movie S1). At the highest
concentration of 3PO (40 mM), a fraction of ISVs stalled midway,
exhibiting blunt ends without side branches or anastomoses,
and failed to form a DLAV (Figure 3D). Withdrawal of 3PO reiniti-
ated branching, showing that 3PO did not cause irreversible EC
demise (Figures S3E–S3G). Similar results were obtained for
YN1 (Figures S3H–S3J). Angiography after intracardiac injection
of rhodamine-labeled dextran showed that 3PO reduced
the number of perfused ISVs (Figures 3E–3J). Analysis of
Tg(kdrl:EGFP;GATA1:DsRed) zebrafish, in which vessels are
GFP+ and erythrocytes are DsRED+, confirmed these findings
(Figure 3K).
Counting of EC nuclei in fli1:nEGFPy7 zebrafish embryos, ex-
pressing GFP in endothelial nuclei, showed that 3PO
decreased EC numbers in the DLAV (Figures 3L–3N). In addi-
tion, time-lapse video imaging revealed that 3PO altered the
leading edge of the vascular front, where tip cells reside. In
contrast to the rapidly advancing and dynamically exploring
vascular front in control embryos, tip cells in 3PO-treated em-
bryos were less dynamic and exploratory and moved more
slowly, almost creeping forward (Movie S1). In control em-
bryos, tip cells were polarized in a rear-to-front direction, often
projecting at the leading edge two to three ‘‘foot-like’’ cyto-
solic protrusions (2–3 mm wide) from where multiple, rapidly
moving, and highly motile long filopodia extended (Figures
3O–3R). By contrast, in 3PO-treated embryos, tip cells pro-
jected shorter, thinner, and more blunt-ended ‘‘foot-like’’
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Figure 3. Pharmacological Blockade of PFKFB3 Impairs Vascular Development in Zebrafish Embryos
(A–D) Confocal images of GFP+ vessels in 35 hpf fli1:EGFPy1 embryos treatedwith DMSO (ctrl) (A), 3PO (20 mM) (B), 3PO (30 mM) (C), or 3PO (40 mM) (D) from 20 hpf
onward, showing impaired outgrowth of ISVs (arrows) and defective formation of the DLAV (arrowheads). Scale bars: 50 mm.
(E–J) Confocal images of 48 hpf fli1:EGFPy1 embryos after intracardiac angiography with rhodamine-labeled dextran, showing that compared to control embryos,
3PO treatment (40 mM; from 20 hpf onward) reduced ISV perfusion. Control, GFP signal (E); control, rhodamine-dextran signal (F); control, merge (G); 3PO treated,
GFP signal (H); 3PO treated, rhodamine-dextran signal (I); 3PO treated, merge (J).
(K) Quantification of perfused ISVs in Tg(kdrl:EGFP;gata1:DsRed) zebrafish (mean ± SEM; n = 3 for control and n = 4 for 3PO; *p < 0.001).
(L–N) Confocal images of GFP+ vessels in 35 hpf fli1:nEGFPy7 zebrafish embryos treated with DMSO (ctrl) (L) or 3PO (40 mM) (M) from 20 hpf onward, showing that
3PO reduced EC numbers in the ISVs (arrows) and in the DLAV (arrowheads), and quantification (N) (mean ± SEM; n = 8 for control and 6 for 3PO; *p < 0.0001).
(O and P) Pseudocolor lookup table (LUT) high-magnification confocal images of GFP+ ISVs in 35 hpf fli1:EGFPy1 zebrafish embryos showing that compared to
controls (O), embryos treated with 3PO (45 mM) have fewer and shorter filopodia (P).
(Q and R) Quantification of the filopodia length (Q) and number (R) (filopodia length: n = 30 for ctrl and n = 20 for 3PO; *p < 0.0001; filopodia number per ISV: n = 4;
*p < 0.005). See also Figure S3 and Movie S1.
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cytosolic protrusions and extended fewer and shorter filopodia
(Figures 3O–3R).
PFKFB3 Blockers Impair Vessel Sprouting in the Mouse
Retina
We also studied the effects of PFKFB3 blockade on vascular
sprouting in the postnatal retina, a widely used mouse model
to characterize tip and stalk cell phenotypes. Treatment of
pups with 3PO at postnatal days 1–4 (P1–P4) reduced the num-
ber of branch points (Figures 4A–4C), the radial expansion of the
vascular plexus (Figure 4D), and the number of distal sprouts
with filopodia (Figure 4E). YN1 also reduced vessel branching
in the retina (Figures S4A–S4D). Staining of retinal flat mounts
for isolectin B4, BrdU, and Erg (an EC-specific nuclear transcrip-
tion factor) revealed that fewer Erg+ BrdU+ ECs were present in
the vascular plexus in 3PO-treated mice, suggesting that EC
proliferation was impaired (Figures 4F–4H). Confirming the
gene expression data in EC monolayers, 3PO did not affect the
expression of the tip cell-enriched marker Pdgfb in retinal tip
cells (Figures S4E and S4F).
Blocking PFKFB3 Inhibits Vascular Hyperbranching
We then explored if PFKFB3 blockade counteracted vascular
hyperbranching. VEGFR1 (Flt1) is an inhibitor of vascular
branching and, consistent with previous findings (Krueger
et al., 2011), flt1 knockdown (flt1KD) caused ISV hyperbranching
(Figures 5A and 5B). 3PO normalized ISV hyperbranching in a
large fraction of flt1KD embryos and reduced the severity of
vascular overgrowth (Figures 5C and 5D). While 64% of con-
trol-treated flt1KD embryos exhibited signs of severe ISV hyper-
branching in at least 4 out of 10 ISVs per embryo, only 20% of
3PO-treated flt1KD embryos showed this phenotype, and up to
29% of them formed completely normal ISVs. 3PO also reduced
ISV side branches in flt1KD embryos (side branches per ISV:
100% ± 10% for flt1KD controls versus 54% ± 10% for 3PO-
treated flt1KD; n = 3 experiments, each with >8 embryos per
condition; p < 0.01 by univariate test). We also analyzed ISV
perfusion. In control embryos, intracardiac angiography with
rhodamine-labeled dextran showed that PFKFB3 blockade
impaired vessel lumen formation and perfusion (see above). In
contrast, ISVs in Flt1-silenced (flt1KD) embryos had an enlarged
lumen, but PFKFB3 blockade largely normalized ISV lumen size
in flt1KD embryos (Figures S5A–S5F) without impairing vessel
perfusion (Figure S5G).
We also induced vascular hyperbranching by blocking
Dll4/Notch signaling (Hellstro¨m et al., 2007). In EC spheroids,
N-(N-(3,5-Difluorophenacetyl)-L-alanyl)-S-phenylglycine t-butyl
ester (DAPT) increased the number and length of the vessel
sprouts, but this hypersprouting was abrogated by 3PO (Fig-
ures S5H–S5K). 3PO also rescued vascular hyperbranching in
zebrafish embryos upon silencing of Dll4 (Figures S5L–S5O)
or in the retina upon treatment of neonatal mice with DAPT (Fig-
ures 5E–5H).
PFKFB3 Blockade Amplifies the Antiangiogenic Effect
of VEGFR Blockers
VEGF blockade is a clinically approved antiangiogenic strategy.
The VEGFR tyrosine kinase inhibitor SU5416 caused dose-
dependent vascular defects in zebrafish embryos, character-
ized by progressive impairment and stalling of ISVs and lack
of DLAV formation. At a maximal concentration (1 mM),
SU5416 prevented the outgrowth of !30% of the ISVs (Fig-
ure 5I). These defects were not only more severe, but also
occurred at a higher incidence when increasing the dose of
SU5416 (Figure 5I).
To evaluate if PFKFB3 blockade enhanced the antiangiogenic
effect of VEGFR inhibition, we treated embryos with suboptimal
doses of SU5416 (0.1 or 0.5 mM) and 3PO (20 or 30 mM), which
alone only induced a negligible impairment of ISV outgrowth in
a minority of embryos (Figures 5J–5L). However, the combina-
tion of both compounds at suboptimal doses aggravated the
vessel defects in most embryos (Figures 5I and 5M). Even
when a high dose of SU5416 (1 mM) was used that prevented
the formation of half of the ISVs, the combination with 3PO
(30 mM) further aggravated this phenotype, abrogating ISV devel-
opment in nearly all embryos (Figure 5I). Overall, blockade of
glycolysis amplified the efficacy of targeted VEGF inhibition in
blocking angiogenesis.
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Figure4. PharmacologicalPFKFB3Blockade
Impairs Vascular Development in Mice
(A and B) Confocal images of isolectin-B4-stained
(gray) retinal vessels of postnatal day 5 (P5) pups at
high magnification, showing, as compared to
DMSO-treated mice (A), reduced vascular branch-
ing in 3PO-treated mice (50 mg/kg) (B). Scale bars:
50 mm.
(C–E)Quantificationof theeffectof3POtreatmenton
thenumberofbranchpoints (C), radial expansion (D),
and the number of distal sprouts with filopodia (E) in
the retinal vasculature of 3PO-treated mice (mean ±
SEM; n = 3 for ctrl and n = 5 for 3PO; *p < 0.001).
(F and G) Triple staining for Erg (blue), isolectin B4
(red), and BrdU (green) at the vascular front of the
retinal plexusof control (F) and 3PO-treated (G)mice
confirmed that ECproliferationwas reduced in 3PO-
treated mice (G) (mean ± SEM; n = 3; p < 0.05).
Arrows: proliferating ECs.
(H) Quantification of BrdU+ Erg+ cells/mm2 retinal area, revealing lower proliferation of retinal ECs after 3PO treatment (mean ± SEM; n = 3; *p < 0.05). Scale
bars: 50 mm. See also Figure S4.
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Blockade of PFKFB3 Reduces Pathological
Angiogenesis
We tested if PFKFB3 blockade inhibited choroidal neovasculari-
zation (CNV), amodel of age-relatedmaculardegeneration (AMD)
(Van de Veire et al., 2010). The lesions in this model are largely
vascular in nature, allowing us to assess antiangiogenic effects
of 3PO. Starting from 1 day after laser burn injury of the Bruch’s
membrane to induce CNV, mice received a daily dose of vehicle
or 3PO.Quantification of CNV lesions upon injectionwith fluores-
cein isothiocyanate (FITC)-conjugated dextran at 14 days after
laser injury showed that 3PO dose dependently reduced the
CNV lesion volume (Figures 6A–6C). We also evaluated if 3PO
amplified the antiangiogenic activity of the anti-VEGFR2 mono-
clonal antibody (mAb) DC101 (Van de Veire et al., 2010). When
using a suboptimal dose of DC101 (12.5 mg/kg, 33 per week),
CNV was reduced by 38%, while the combination of DC101
plus 3PO caused a decrease of CNV by 67% (Figure 6D).
We confirmed the antiangiogenic activity of 3PO by using other
models of pathological angiogenesis. We first used the oxygen-
inducedmodelof retinopathyofprematurity (ROP),which isbased
on the exposure ofmouse pups to hyperoxia during a phasewhen
their retinal vasculature is still developing, from P7–P12. This
causes capillary depletion and vascular rarefication and, upon re-
turn to room air, results in retinal ischemia and, subsequently, in
the formation of proliferative vascular tufts by P17–P21 (Scott
and Fruttiger, 2010). Like in CNV, the lesions in the ROP model
are primarily vascular in nature. Treatment of pups with 3PO dur-
ing thephaseof vascular proliferation fromP12 toP17reduced the
formation of vascular tufts at P17 (Figures 6E–6G).
We also used two inflammation models, e.g., a skin psoriasis
model and an inflammatory bowel disease model, since inflam-
matory disorders are characterized by increased angiogenesis
(Wynn et al., 2013). A previous study reported that 3PO treatment
reduced skin epithelial hyperplasia and inflammation, induced by
local application of the immune activator imiquimod (IMQ), but
this study did not analyze the effects on angiogenesis (Telang
et al., 2012). Confirming previous findings, 3PO reduced the
epidermal hyperplasia (Figure S6A), the spleen weight, another
measure of inflammation (Figure S6B), and the number of CD3+
lymphocytes in the lesions (Figure S6C). Importantly, 3PO also
decreased thedensity ofCD105+ vessels in the epidermal lesions
(Figures 7A–7D).
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Figure 5. PFKFB3 Blockade Inhibits
Vascular Hyperbranching In Vivo
(A–D) Confocal images of 72 hpf fli1:EGFPy1 em-
bryos. As compared to the normally patterned ISV
in a control embryo (A), ISVs hyperbranch in flt1KD
embryos (arrowheads in B). Treatment of flt1KD
embryos with 3PO (30 mM) largely normalized the
vascular hyperbranching phenotype (C). Shown in
(D) is the incidence of flt1KD embryos with no, mild,
or severe vascular hyperbranching, revealing that
3PO reduced vascular hyperbranching (n = 12;
*p < 0.00001). Scale bars: 50 mm.
(E–G) Confocal images of the retinal vasculature
after treatment with control (E), DAPT (F), or
DAPT + 3PO (G), showing that DAPT increased the
number of branch points and that 3PO abolished
the hyperbranching induced by DAPT.
(H) Quantification of the number of branches
(mean ± SEM; n = 5 for DAPT and 3PO+DAPT,
n = 8 for ctrl; *p < 0.001 versus control (gray), &p <
0.05 versus DAPT).
(I) Quantification of the average incidence of indi-
cated ISV phenotypes for 10 ISVs scored per em-
bryo upon single or combined treatment with the
indicated doses of 3PO and/or SU5416. Complete
ISV, ISVs formed normally and completely; partial
ISV (above midline), ISVs formed at least until or
partially above the horizontal midline without
reaching the dorsal roof level; partial ISV (below
midline), ISVs were severely underdeveloped and
failed to reach the horizontal midline; absent ISV,
ISVs completely failed to sprout. n values per
condition are indicated under the bars.
(J–M) Confocal images of GFP+ vessels in 35 hpf
fli1:EGFPy1 embryos, showing a control embryo (J)
and a minor impairment of ISV development when
treating embryos with a submaximal dose of 3PO
(K) or the VEGFR tyrosine kinase inhibitor SU5416
(L) but severe vascular defects and near-complete
abrogation of ISV formation in embryos treated
with the combination of both inhibitors (M). Scale
bars: 50 mm. See also Figure S5.
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Inflammatory bowel disease, induced by administration of
dextrane sulfate sodium (DSS), is also characterized by patho-
logical angiogenesis (Hindryckx et al., 2010). Quantification of
the disease activity index (DAI), which scores body weight
loss, stool consistency, and blood in the stool and anal region,
revealed that 3PO reduced disease severity (Figure 7H). Hema-
toxylin and eosin staining (H&E) showed that 3PO-treated mice
had less-severe acute colitis (Figures 7E–7G). To quantify the
histological signs of colitis, we used a histologic scoring method,
taking into account the severity of inflammatory cell infiltration
(dispersed, focal, or widespread), the extent of injury (mucosal,
submucosal, or transmural), and crypt damage (basal, luminal,
or entire crypt loss) (Cummins et al., 2008). This analysis
confirmed that 3PO reduced the severity of colitis (histological
score, median value: 10 for control versus 6 for 3PO; n = 11 for
control and n = 10 for 3PO; p = 0.0004), and decreased CD45+
cell infiltration in the (sub)mucosa and muscularis externa (Fig-
ure 7I). 3PO also decreased the area of CD105+ vessels in the in-
flamed mucosa, submucosa, and muscularis externa (Figures
7J–7M).
DISCUSSION
Glycolysis: An Overlooked Target in Angiogenesis?
ECs rely on glycolysis and derive up to 85% of their ATP from
glycolysis, while PFKFB3-driven glycolysis regulates EC prolifer-
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Figure 6. Blockade of PFKFB3 Reduces
Pathological Angiogenesis: Ocular Models
(A and B) FITC-dextran choroidal flatmounts of
control (A) or 3PO-treated mice (B), revealing
fewer choroidal neovessels after 3PO treatment
(B). The images are 3D isosurface renderings from
z stacks of all individual optical sections through
the neovascular lesion, as made by confocal laser
scanning microscopy. Scale bars: 50 mm.
(C) 3PO dose dependently reduced CNV volume
(estimated marginal mean ± SEM; n = 16 for ctrl,
n = 16 for 38 mg/kg 3PO, and n = 14 for 50 mg/kg
3PO; two independent experiments; *p < 0.04 by
general linear model univariate analysis, consid-
ering experiment as covariate).
(D) The combination treatment of 3PO (50 mg/kg)
plus a submaximal dose of the anti-VEGFR2 mAb
DC101 reduced the CNV neovascular area more
than eachmonotherapy alone (mean ±SEM; n = 18
for ctrl, n = 7 for 3PO, n = 9 for DC101, and n = 8 for
3PO+DC101; *p < 0.05 versus ctrl or as indicated).
(E and F) Retinal flatmounts of ROP mice treated
withDMSO (E) or 3PO (F) (70mg/kg) andstained for
isolectin B4, revealing reduced formation of
vascular tufts (arrowheads) after 3PO (70 mg/kg)
(F). Scale bars: 50 mm.
(G) Quantification of the vascular tuft area (mean ±
SEM; n = 11 for ctrl, n = 9 for 3PO; *p < 0.001).
ation and migration (De Bock et al.,
2013b). We now also show that ECs in-
crease glycolysis when shifting from
quiescence to proliferation andmigration.
Glycolysis is required for cell proliferation,
not only by providing ATP, but also by generating glycolytic inter-
mediates that are used for the synthesis of macromolecules
necessary for cell mass duplication during division (Lunt and
Vander Heiden, 2011). In addition, glycolysis is required for EC
motility, in part by compartmentalizing PFKFB3 and other glyco-
lytic enzymes in lamellipodia and by concentrating these glyco-
lytic enzymes with F-actin at leading membrane ruffles (De Bock
et al., 2013b). The high glycolytic flux in ECs, their dependence
on this pathway to generate most of the ATP, and the increased
glycolysis during EC proliferation and migration, together with
the genetic findings that loss of PFKFB3 in ECs affects tip and
stalk cells (De Bock et al., 2013b), render glycolysis an attractive
target for therapeutic inhibition of angiogenesis.
PFKFB3 Blockade Reduces Physiological
and Pathological Angiogenesis
We previously reported that genetic silencing of PFKFB3 re-
duces vessel formation in physiological conditions (De Bock
et al., 2013b), but it remained untested if pharmacological
blockade of PFKFB3 could also impair pathological angiogen-
esis. 3PO phenocopied the effects of PFKFB3 silencing in ECs
in vitro and of PFKFB3 inactivation in ECs in vivo (De Bock
et al., 2013b). Indeed, 3PO impaired vessel sprouting in EC
spheroids by reducing EC proliferation and migration, impeded
filopodia formation, and EC accumulation in ISVs in zebrafish
and caused vascular hypobranching and outgrowth in the
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mouse retina by decreasing EC proliferation and tip cell
behavior. The finding that 3PO impaired lumen formation (a pro-
cess requiring actin cytoskeleton changes; Sacharidou et al.,
2012) is in agreement with findings that PFKFB3 regulates actin
cytoskeleton remodeling processes (De Bock et al., 2013b).
3PO also reduced vascular hyperbranching induced by inhibi-
tion of Notch or VEGFR1 signaling in zebrafish embryos. In addi-
tion, 3PO largely normalized vascular hypersprouting in EC
spheroids and the mouse retina, induced by the Notch signaling
blocker DAPT. Moreover, 3PO reduced pathological neovascu-
larization in ocular and inflammatory models in the mouse and
amplified the antiangiogenic activity of a VEGF receptor tyrosine
kinase inhibitor and anti-VEGF receptor 2 in the zebrafish and
CNV mouse model, respectively. Together, inhibition of PFKFB3
by 3PO reduces vessel formation in physiological and patholog-
ical conditions in the models tested.
Partial and Transient Reduction of Glycolysis
Previous antiglycolytic anticancer strategies attempted to block
glycolysis completely and permanently, but these approaches
also caused adverse effects (Granchi and Minutolo, 2012). In
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Figure 7. PFKFB3 Blockade Reduces Path-
ological Angiogenesis: Inflammation
Models
(A–C) Representative images of CD105 staining of
untreated skin (A), IMQ-DMSO-treated skin (ctrl)
(B), and IMQ-3PO-treated skin (3PO) (C). Scale
bars: 100 mm.
(D) Reduced CD105+ vascular area in the dermis
upon 3PO treatment (mean ± SEM; n = 7 for un-
treated, n = 9 for IMQ-DMSO and IMQ-3PO; *p <
0.001).
(E–M) DSS-induced colitis model. Representative
H&E images of untreated healthy colon (E), DSS-
DMSO-treated colon (DSS-ctrl) (F), and DSS-3PO-
treated colon (50 mg/kg) (G). Scale bars: 200 mm.
(H) Reduced disease activity index (DAI) score
upon 3PO treatment (median; n = 11 for DSS-
DMSO, n = 10 for DSS-3PO; *p < 0.0001). (I)
Reduced CD45+ area in the mucosa, submucosa,
and muscularis externa of the colon upon 3PO
treatment (mean ± SEM; n = 3 for untreated, n = 11
for control, and n = 10 for 3PO; *p < 0.003). (J)
Reduced CD105+ vascular area in the mucosa,
submucosa, and muscularis externa of the colon
upon 3PO treatment (mean ± SEM; n = 3 for un-
treated, n = 11 for DSS-DMSO, and n = 10 for DSS-
3PO; *p < 0.004). Representative images of CD105
staining of untreated healthy colon (K), DSS-
DMSO-treated colon (DSS-ctrl) (L), and DSS-3PO-
treated colon (M). Scale bars: 100 mm. See also
Figure S6.
agreement, our 2DG experiments show
that more complete, sustained inhibition
of glycolysis induces toxic effects in
cultured ECs. In contrast, 3PO reduced
glycolysis only partially, inducing EC
quiescence without causing EC death
in vitro. Likewise, 3PO reduced glycolysis
only partially and transiently in vivo, but
without inducing permanent refractoriness, since a second
3PO administration 24 hr later reduced glycolysis again to the
same level as the first treatment. Thus, a partial and daily tran-
sient decrease of glycolysis sufficed to suppress pathological
neovascularization. It remains to be studied whether 3PO treat-
ment in vivo has acceptable tolerability.
The transient effect of 3PO is in agreement with its short half-
life (30 min), rapid clearance (2,312 ml/kg/min), low Cmax
(113 ng/ml) and low area under the concentration-time curve
from zero to infinity (AUC0-inf; 36 ng/hr/ml) (AUC0-inf refers to
the actual body exposure to 3PO after administration of a
dose of 3PO) (Clem et al., 2013). With the concentrations
used, 3PO blocked PFKFB3 completely, since 3PO failed to
further reduce glycolysis in ECs in which PFKFB3 was silenced
to nearly undetectable levels. Despite full blockade of PFKFB3,
glycolysis was only decreased by 35%–40%. Similar data were
obtained when silencing PFKFB3 (De Bock et al., 2013b). The
reason for the partial effect likely relates to the fact that 3PO
blocks an activator of a key enzyme in glycolysis (e.g.,
PFK-1). Hence, PFKFB3 blockade has a ceiling level in its abil-
ity to inhibit glycolysis.
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PFKFB3 Blockade: A Different Therapeutic
Antiglycolytic Paradigm
Past antiglycolytic therapies faced challenges of cross-inhibition
of other glycolytic targets, off-target effects, poor membrane
permeability, and inability of compounds to efficiently antago-
nize abundant glycolytic substrates (Granchi and Minutolo,
2012). For instance, 2DG must compete with mM levels of
glucose in the blood, necessitating delivery of high (toxic)
amounts (Granchi and Minutolo, 2012). Nonetheless, cancer
patients receiving 2DG had a progressive disease and suffered
adverse effects (Granchi and Minutolo, 2012; Raez et al.,
2013). Some of the side effects were attributed to the fact that
these strategies block not only glycolysis, but also other glucose
metabolism pathways (Granchi and Minutolo, 2012). Another
reason is that these approaches inhibit glycolysis nearly
completely and permanently, inducing ATP depletion and
toxicity (Granchi and Minutolo, 2012). Indeed, human genetic
studies reveal that a decrease in glycolysis due to hereditary mu-
tations in glycolytic genes is well tolerated, as long as the
decreased glycolysis levels do not deplete ATP levels (Climent
et al., 2009).
PFKFB3 blockade by 3PO differs from these antiglycolytic
approaches in various aspects. Firsty, it inhibits a defined
intracellular enzyme, requiring much lower (mM) inhibitor con-
centrations than the high (mM) concentrations of 2DG needed
to compete with the mM plasma glucose levels (Franc¸ois
et al., 1987). Second, unlike 2DG and related drugs, which
block glucose metabolism high up in the pathway, PFKFB3
blockade inhibits a defined downstream target, which specif-
ically reduces glycolytic flux, without abrogating glycolytic
side pathways such as the oxidative PPP (oxPPP), necessary
for the production of NADPH to secure redox homeostasis. In
fact, 3PO increased the oxPPP flux, but this change did not
explain the antiangiogenic activity of 3PO. Third, 3PO and
YN1 did not inhibit other glycolytic enzymes, tested by using
recombinant enzymes or 3PO-treated EC extracts. Fourth, the
KM of PFKFB3 for its substrate fructose-6-phosphate (F6P) is
97 mM, while the Ki for competitive inhibition by 3PO is
25 mM, and 3PO has no effect on PFK-1, which shares an iden-
tical substrate, F6P (Clem et al., 2008). Fifth, 3PO did not cause
EC death.
3PO Blocks Hyperglycolysis during EC Proliferation
and Migration
Of the maximal amount of glycolysis that ECs can generate,
they use 40% to proliferate and migrate, reserving 60% for
maintenance homeostasis, in line with findings that proliferation
only requires 30% of ATP production (Locasale and Cantley,
2010). Lowering glycolysis by 40% through 3PO treatment
impaired EC proliferation and migration. This, however, did
not cause EC death, but promoted reversible quiescence.
PFKFB3 blockade thus reduced the hypermetabolism that is
induced when ECs switch from quiescence to proliferation
and migration.
Possible Medical Implications
PFKFB3 blockade decreased pathological angiogenesis in in-
flammatory and ocular disease models. Choroidal neovasculari-
zation (a preclinical model of wet AMD) and retinopathy of
prematurity are blinding disorders, caused by excessive growth
of retinal vessels (Cavallaro et al., 2013; Miller et al., 2013; Stew-
art, 2012). Anti-VEGF therapy has beneficial effects in AMD and
ROP patients, but does not attain durable treatment-free cessa-
tion of the disease (Darlow et al., 2013; Niranjan et al., 2012; Ro-
fagha et al., 2013). In addition, one-third of patients with wet
AMD have poor visual outcome, and!13% lost more vision after
intraocular anti-VEGF treatment (Lalwani et al., 2009). Our find-
ings that 3PO reduces vascular lesions in both ocular disorders
and enhances the antiangiogenic effect of the anti-VEGFR2 in
theCNVmodelmaywarrant further study of a possible therapeu-
tic use of PFKFB3 blockers.
EXPERIMENTAL PROCEDURES
More detailed methods are described in the Supplemental Experimental
Procedures.
Cellular Assays
Freshly isolated primary HUVECswere used for evaluation of metabolism, pro-
liferation, migration, matrigel assay, spheroid capillary sprouting assays, and
cell cycle status. Except for Figure 1A, we used the maximal concentration
of 3PO that reversibly impaired in vitro EC responses, ranging between 15
and 20 mM.
RNA Expression Analysis
RNA expression analysis was performed by TaqMan qRT-PCR or in situ
hybridization.
Metabolism Assays
Glycolysis, glucose incorporation into RNA, and oxidative pentose phosphate
pathway flux were determined by incubating cells with radioactive-labeled
tracer glucose. Briefly, 3H2O formation was a measure for glycolytic flux.
14CO2 production was a measure for oxidative pentose phosphate pathway
flux, and 14C counts in isolated RNA was a measure for glucose incorporation.
Fructose-2,6-bisphosphate levels in cell lysates were determined as
described (Van Schaftingen et al., 1982). Oxygen consumption and lactate
production were measured using the Seahorse XF24 analyzer. Energy balance
was calculated as ([ATP] + ½[ADP]) / ([ATP] + [ADP] + [AMP]) based on high-
performance liquid chromatography (HPLC) measurement of AMP, ADP,
and ATP levels in cell extracts.
Proliferation
Proliferation was quantified by incubating cells with [3H]-thymidine. The
amount of [3H]-thymidine incorporated into DNA wasmeasured by scintillation
counting.
Migration
Migration was evaluated using scratch wound or Boyden chamber migration
assays. To evaluate responses in the absence of proliferation, MitoC-treated
ECs (0.5–1 mg/ml for 24 hr) were used.
Spheroid Capillary Sprouting Assay
ECs were incubated overnight in hanging drops to form spheroids, embedded
in collagen, and cultured for 24 hr (with addition of compounds as indicated) to
induce sprouting. Cultures were fixed with 4% paraformaldehyde (PFA) and
analyzed.
Matrigel Assay
ECs were plated on top of polymerized Matrigel Basement Membrane Matrix
in M119 full medium containing 3PO or vehicle. After 6 hr, the network was
fixed using 4% PFA.
Cell Cycle Analysis
Cell cycle analysis was determined by flow cytometry based on the DNA and
RNA content as stained for with Hoechst and Pyronin Y.
In Vivo Metabolism
Glycolytic flux in vivo was assessed by mass spectrometry detection of
13C-lactate in the plasma, collected 10 min after tail vein injection of [U-13C]
glucose. Glucose uptake in vivo was assessed by measuring the radiolabel
content of the heart and diaphragm, harvested 1 hr after intravenous bolus in-
jection of the mice with 2-deoxy-D-glucose, 2-[1-14C].
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Angiogenesis Models
Zebrafish
Tg(fli1:EGFP)y1 or Tg(fli1:nEGFP)y7 zebrafish were subjected to morpholino
oligonucleotide injection of Dll4 or Flt1 or to treatment with inhibitors (3PO,
YN1, SU5416). Assessment of sprouting and hyperbranching of ISVs, imaging,
and morphometric quantitation was as detailed in the Supplemental Experi-
mental Procedures.
Mouse Models of Ocular Angiogenesis
CNV was induced in C57BL/6 mice by laser burn. Mice were injected intraper-
itoneally (i.p.) with 38–50 mg/kg PFKFB3 inhibitor 3PO daily with or without
treatment with anti-VEGFR2 DC101 (12.5 mg/kg i.p., 33 per week). Eyes
were enucleated 2 weeks after the laser treatment and processed for immuno-
histochemistry and neovascular morphometric analysis as described in the
Supplemental Experimental Procedures. Oxygen-induced retinopathy was
induced by exposing C57BL/6 pups to 70% oxygen from P7–P12. Pups
were then returned to normoxia and injected daily with 70 mg/kg 3PO and
euthanized at P17. Retinal flat mounts were analyzed as described in the Sup-
plemental Experimental Procedures. For analysis of neonatal retinal angiogen-
esis, mice were injected with 50 mg/kg 3PO or vehicle between P2 and P4 and
euthanized at P4 or P5; eyes were enucleated and fixed, and retinal flatmounts
were prepared for vascular analysis as described in the Supplemental Exper-
imental Procedures.
Mouse Models of Inflammation
Skin inflammation was induced by daily topical application of 5% imiquimod
cream on the back of BALB/c mice. Mice received a daily i.p. dose of
50 mg/kg 3PO. After 4 days, skins were resected for analyses as described
in the Supplemental Experimental Procedures. Acute colitis was induced
with 2.5% dextran sodium sulfate (DSS) in the drinking water for 6 days.
Mice received a daily i.p. dose of 50mg/kg 3PO. Histological scoring was as
detailed in the Supplemental Experimental Procedures. All experimental ani-
mal procedures were approved by the Institutional Animal Care and Research
Advisory Committee of the University of Leuven.
Statistics
Data represent mean ± SEM of representative experiments, unless otherwise
stated. For all in vitro and in vivo experiments, every experiment was per-
formed at least three times. For analysis of the mousemodels of angiogenesis,
the investigator assessing the outcomewas blinded to the group allocation; for
analysis of zebrafish models of angiogenesis, assessment was done by an
investigator ignorant of potential outcome. Unless otherwise indicated, statis-
tical significance between groups was calculated by standard t test with F
testing to confirm equality of variance (Prism v4.0b). Phenotype severity distri-
butions were analyzed by chi-square test. Statistical significance of DAI and
histological scoring data were determined by Mann-Whitney test. p < 0.05
was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one movie and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2013.11.008.
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FIGURE S1, RELATED TO FIGURE 1: SPECIFICITY OF 3PO/YN1 AND EFFECT OF YN1 ON ECS 
A, Glycolytic flux in control or PFKFB3-silenced ECs, showing that YN1 dose dependently 
reduced glycolysis in control cells. In agreement with reports that YN1 also inhibited other 
PFKFB isoenzymes (minimally), YN1 reduced glycolysis slightly in PFKFB3-silenced cells 
(mean±SEM; n=3; *P<0.05 versus vehicle; &P<0.05 versus ctrl). B, Glycolysis assay 
showing that PFKFB3 blockade (3PO) reduced glycolysis in arterial ECs (mean±SEM; 
n=3; *P<0.05). C, Reduction in glycolytic flux upon pharmacological (3PO and YN1) 
blockage of PFKFB3 or treatment with the glycolysis inhibitor 2-deoxy-D-glucose (2DG) 
(mean±SEM; n=3; *P<0.05 versus vehicle). D, Increased oxygen consumption rates 
(OCR) upon treatment with 2DG but not 3PO (mean±SEM; n=7; *P<0.001 versus vehicle). 
E-I, Enzymatic activity of purified glycolytic enzymes in the presence of control vehicle or 
various concentrations of 3PO or YN1, showing that these PFKFB3 blockers failed to 
affect their enzymatic activity (mean±SEM; n=3; P=NS; GAPDH activity levels were near 
(one experiment) or below (two experiments) the threshold of detection). GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase, LDH: lactate dehydrogenase, PK: pyruvate 
kinase, PFK: phosphofructokinase, G6PDH: glucose 6-phosphate dehydrogenase. J, 
Modified Boyden chamber migration assay showing that PFKFB3 blockade by 3PO 
reduced migration (mean±SEM; n=3; #P=0.06). K, 3H-thymidine incorporation assay 
showing that PFKFB3 blockade (YN1) reduced proliferation of EC monolayers 
(mean±SEM, n=3, *P<0.01). L, Quantification of MitoC-treated EC migration in scratch 
wound assays, showing reduced migration upon PFKFB3 blockade  (YN1) (mean±SEM; 
n=3; *P<0.05).  
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FIGURE S2, RELATED TO FIGURE 2: PHARMACOLOGICAL BLOCKADE OF PFKFB3 BY YN1 
IMPAIRS SPROUTING IN VITRO  
A-C, Representative bright field micrographs of EC spheroids, showing reduced vascular 
sprouting in spheroids in the presence of the PFKFB3 inhibitor YN1 (B) and the glycolytic 
inhibitor 2DG (C) as compared to control (A). Scale bars: 50 µm. Note: Representative 
images are derived from the same experiment as shown in Figure 2. For this reason, the 
image for vehicle treated spheroid (ctrl) is the same. D,E, Morphometric quantification of 
EC spheroid sprouting, revealing that YN1 and 2DG reduced the number of sprouts (D) 
and total sprout length (E) per spheroid (mean±SEM; n=30; *P<0.01). F-H, Representative 
images of EC spheroids (merge of bright field and fluorescence for TO-PRO-3 (red) to 
visualize dead cells) after treatment with 3PO or 2DG for 24 hours, showing absence of 
cell death in ctrl spheroids (F), minimal cell death upon 3PO treatment (G) but markedly 
increased cell death in 2DG treated spheroids (H). Scale bars: 100 µm. I,J, Representative 
images of ctrl (I) and 3PO-treated (J) matrigels, showing reduced (to absent) capillary tube 
formation upon 3PO treatment. K,L, Morphometric quantification of EC spheroid sprouting, 
revealing that pyruvate supplementation did not rescue the 3PO-induced reduction of the 
number of sprouts per spheroid (K) and total sprout length (L) (mean±SEM; n=30; 
*P<0.05). M, Representative immunoblotting, showing that PFKFB3-blockade did not 
affect VEGFR2 protein levels. The ratio of VEGFR2 over Lamin A/C was densitometrically 
determined (mean±SEM, n=3; P=NS). Note that the VEGFR2 bands have the normal 
molecular weight of fully glycosylated VEGFR2 (~230 kDa). The lower VEGFR2 band 
represents an incompletely glycosylated form (~200 kDa). N, Representative FACS 
analysis of ECs, stained for VEGFR2, showing no difference in the surface levels of 
VEGFR2 in control conditions or after 3PO treatment (mean±SEM, n=3; P=NS).   
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FIGURE S3, RELATED TO FIGURE 3: PHARMACOLOGICAL BLOCKADE OF PFKFB3 IMPAIRS 
VASCULAR DEVELOPMENT IN ZEBRAFISH EMBRYOS 
A-D, Whole mount in situ hybridization for Dlx2 (A,B) and Pax2 (C,D), showing normal 
brain development in 48 hpf fli1:EGFPy1 zebrafish embryos treated with 3PO (45 µM) (B,D) 
or control vehicle (A,C). E-G, Confocal images of 60 hpf fli1:EGFPy1 embryos, showing 
recovery of vessel growth after removal of 3PO (40 µM) (G). Panel F shows a 
representative embryo with continuous 3PO treatment (40 µM) compared to control 
(DMSO) (E). Scale bars: 50 µm. H,I, Confocal images of 48 hpf fli1:EGFPy1 embryos, 
showing ISV defects upon treatment with YN1 (800 µM). Scale bars: 50 µm.  J, 
Quantification of the average incidence of ISV defects for 10 ISVs scored per embryo, 
showing recovery of vessel growth after removal of YN1. Defects: embryos with at least 1 
out of 10 ISVs that formed only partially (not reaching the horizontal midline or grown 
above the horizontal midline but without reaching the dorsal roof level) or with absent ISVs 
(n=39 embryos for ctrl, n=38 for continuous YN1 treatment, and n=41 for the YN1 washout 
condition; P<0.05 by Chi-square). 
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FIGURE S4, RELATED TO FIGURE 4: PHARMACOLOGICAL BLOCKADE OF PFKFB3 IMPAIRS 
VASCULAR DEVELOPMENT IN MICE 
A,B, Confocal images of isolectin-B4-stained (grey) retinal vessels of postnatal day 5 (P5) 
pups at high magnification, showing reduced vascular branching in YN1-treated mice (100 
mg/kg) (B) as compared to untreated (ctrl) mice (A). Scale bars: 50 µm. C,D, 
Quantification of radial expansion (C) and the number of branch points (D) in the retinal 
vasculature of YN1-treated mice (mean±SEM; n=3 for ctrl and n=5 for YN1, * P<0.001). 
E,F, Images of in situ hybridization of retinae for the tip cell marker pdgfb in control (E) and 
3PO-treated  (50 mg/kg) (F) pups showing no difference in pdgfb expression (green). The 
retinal vasculature is visualized by isolectin B4 staining (red).   
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FIGURE S5, RELATED TO FIGURE 5: PFKFB3 BLOCKADE INHIBITS VASCULAR 
HYPERBRANCHING IN VIVO  
A-G, Confocal images of 72 hpf fli1:EGFPy1 embryos after intracardiac injection with 
rhodamine-labeled dextran, showing enlarged ISV lumen in flt1KD embryos (A-C), which 
was largely normalized by 3PO treatment (30 µM) (D-F). Panels A,D: GFP signal; panels 
B,E: rhodamine-dextran signal; panels C,F: merge. Scale bars: 50 µm. Panel G shows the 
quantification of the number of perfused ISVs in control or 3PO treated 
Tg(kdrl:EGFP;gata1:DsRed) zebrafish (mean±SEM; n=3 for control and n=5 for 3PO; 
P=NS). H-K, Representative bright field micrographs of EC spheroids, showing increased 
vessel branching by DAPT (I) as compared to control (H), and blockade of this increased 
branching by 3PO (J). Morphometric quantitation of number of sprouts per spheroid (K), 
showed that DAPT increased sprouting, while co-incubation of DAPT with 3PO inhibited 
the DAPT-induced vascular hypersprouting phenotype (mean±SEM; n=30; *,&P<0.0001). 
L-N, Confocal images of 72-hpf fli1:EGFPy1 embryos, showing ISV hyperbranching in 
dll4KD embryos (M; arrowheads), as compared to normally patterned ISVs in a control 
embryo (L). Treatment of dll4KD embryos with 3PO (30 µM) largely normalized the vascular 
hyperbranching phenotype (N). Scale bars: 50 µm. O, Incidence of dll4KD fli1:EGFPy1 
zebrafish embryos with no, mild or severe vascular hyperbranching, revealing that 3PO 
reduced vascular hyperbranching (n=19 for control and n=22 for 3PO; *P<0.001). 
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Figure S6
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FIGURE S6, RELATED TO FIGURE 7: PFKFB3 BLOCKADE REDUCES PATHOLOGICAL 
ANGIOGENESIS: INFLAMMATION MODELS  
The current panels confirm previously published data (Telang et al., 2012) showing the 
ability of 3PO to reduce skin inflammation induced by Imiquimod (IMQ) treatment. For 
reasons of readability, we have enclosed these data in the supplement. A, Reduced 
epidermal thickness upon 3PO treatment (50 mg/kg) (mean±SEM; n=4 for untreated 
healthy, n=9 for IMQ-control treated, n=8 for IMQ-3PO treated; *P<0.0001). B, Reduced 
spleen weight upon 3PO treatment (mean±SEM; n=7 for untreated, n=9 for control and 
3PO; *P<0.001). C, Reduced CD3+ area in the dermis upon 3PO treatment (mean±SEM; 
n=7 for untreated, n=9 for control and 3PO; *P<0.005). 
MOVIE S1, RELATED TO FIGURE 3: PFKFB3 BLOCKADE INHIBITS ISV BRANCHING AND TIP 
CELL FILOPODIA FORMATION IN ZEBRAFISH EMBRYOS  
Confocal time lapse video-imaging of a control (A; DMSO) and a 3PO-treated (B; 40 µM) 
fli1:GFPy1 embryo from the +24 somite stage (24 hpf) until 34 hpf during sprouting of the 
ISVs. Imaging revealed normal formation of the ISVs and dorsal longitudinal anastomosing 
vessel (DLAV) in control embryos and incomplete ISV formation after PFKFB3 blockade. 
Note also that in 3PO-treated embryos tip cells of ISVs projected fewer, shorter and more 
slowly moving filopodia as compared to control embryos. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
CHEMICALS AND REAGENTS: Collagen type 1 (rat tail) was from Millipore or Novagen 
(Merck, Germany). The PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one) 
(3PO) was from ChemBridge Corporation (San Diego, USA) and 7,8-dihydroxy-3-(4-
hyroxyphenyl) chromen-4-one (YN1) was from Chess Fine Chemicals (Mannheim, 
Germany). Endothelial Cell Growth Supplements (ECGS), heparin, Sugen 5416, 
mitomycin C (MitoC), BrdU, 2-deoxy-D-glucose, 6-aminonicotinamide (6AN) and dimethyl 
sulfoxide (DMSO) were from Sigma-Aldrich (Bornem, Belgium). Hoechst 33342 was from 
Molecular Probes and L-glutamine, sodium pyruvate and penicillin/streptomycin were from 
Gibco® (Invitrogen, Life Technologies, Ghent, Belgium). The γ-secretase inhibitor N-[N-
(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) was from Merck 
Millipore (Overijse, Belgium).  Click-iT® EdU Cell Proliferation kit was from Invitrogen (Life 
Technologies, Ghent, Belgium). Dextran sodium sulfate (DSS) (molecular weight 36,000-
50,000) was from MP Biomedicals (Santa Ana, CA). Imiquimod cream was obtained from 
the hospital pharmacy of UZ Leuven (Aldara®).  
CELL CULTURE: Human umbilical vein endothelial cells (HUVECs, abbreviated as ECs) 
were freshly isolated from different donors as described (Jaffe et al., 1973), regularly 
tested for mycoplasma and used between passage 1 and 5. HUVECs were cultured in 
M199 medium (1 mg/ml D-glucose) supplemented with 20% fetal bovine serum (FBS), 2 
mM L-glutamine, 30 µg/l endothelial cell growth factor supplements (EGCS), 10 units/ml 
heparin, 100 IU/ml penicillin and 100 µg/ml streptomycin or in endothelial basal medium 
(EBM-2) supplemented with endothelial growth medium SingleQuots (Clonetics, Lonza, 
Braine-l’Alleud, Belgium). Human aortic ECs (HAECs) were purchased from Clonetics, 
Lonza (Braine-l’Alleud, Belgium) and cultured in the recommended medium supplemented 
with SingleQuots (EGM-2; Clonetics, Lonza, Braine-l’Alleud, Belgium). To reach contact 
inhibition, early passage HUVECs were cultured in M199 medium with 20% FBS and 
growth factor supplements for 7-9 days, until 70% of the cell population had reached G0 
cell cycle arrest as verified by flow cytometry (see below). Medium was replaced every 
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second day. Cells were routinely maintained in 5% CO2 and 95% air at 37°C. Mitotic 
inactivation was achieved by culturing the cells for 24 hours in the presence of 500-1000 
ng/ml MitoC, and was confirmed using a [3H]-Thymidine proliferation assay (see below). 
Except for Fig. 1A (where we tested 40 µM 3PO for the dose response), we used the 
maximal concentration of 3PO that reversibly impaired in vitro EC responses, ranging 
between 15 to 20 µM (the specific activity of 3PO slightly varied between the different 
synthesized lots). 
KNOCK-DOWN STRATEGIES: RNA INTERFERENCE:  To silence PFKFB3 expression, cells 
were transfected with a validated pool of siRNA duplexes directed against human PFKFB3 
(Trifekta Kit, IDT). A scrambled siRNA was used as control. ECs were transfected with the 
indicated siRNA (50 nM) using Lipofectamine RNAi Max (Invitrogen).  
IN VITRO ASSAYS: PROLIFERATION was quantified by incubating cells for 2 hours with 1 
µCi/ml [3H]-thymidine. Thereafter, cells were fixed with 100% ethanol for 15 min at 4°C, 
precipitated with 10% trichloroacetic acid and lysed with 0.1 N NaOH. The amount of [3H]-
thymidine incorporated into DNA was measured by scintillation counting. SCRATCH WOUND 
MIGRATION ASSAY: a scratch wound was applied on confluent MitoC treated EC monolayers 
using a 200 µl tip, 24 hours after seeding (75,000 cells per well in 24-well plates). After 
scratch wounding and photography (T0), the cultures were further incubated for the 
indicated time periods in defined M199 medium supplemented with growth factors and 
serum, and photographed again (Tx). Migration distance (gap area at T0 minus gap area 
at Tx) was measured with NIH Image J software package and is expressed in arbitrary 
units. BOYDEN CHAMBER MIGRATION ASSAYS were performed using MitoC-treated ECs. 
Therefore, 25,000 cells were seeded in fully supplemented EBM2 medium on 0.1% gelatin 
coated transwells. Upon adherence, the transwells were washed and refed with medium 
containing only 0.1% FBS and transferred to bottom wells containing medium with 0.1% 
FBS (baseline) or 5% FBS (migration stimulus). The cells were incubated overnight in the 
presence of 3PO or DMSO (top and bottom well). Transwells were processed and 
analyzed for migrated cells as described (Geudens et al., 2010). SPHEROID CAPILLARY 
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SPROUTING ASSAY: ECs were incubated overnight in hanging drops in EGM-2 medium 
containing 20% methylcellulose (Sigma-Aldrich, Bornem, Belgium) to form spheroids. For 
mitotic inactivation, MitoC (500 ng/ml) was added to this medium. Spheroids were then 
embedded in collagen gel as described (Korff et al., 2004) and cultured for 24 hours to 
induce sprouting. Compounds were added at the indicated concentrations during the 
collagen gel culture step, using corresponding vehicle concentrations as control. To 
assess cell death, unfixed spheroids were stained with 500 µ l TO-PRO3 (Invitrogen, Life 
Technologies, Ghent, Belgium) solution at room temperature for 10 min and washed with 
PBS. To assess proliferation, spheroids were pre-incubated overnight with 20 µM BrdU in 
the hanging drop before embedding. Cultures were fixed with 4% PFA at room 
temperature and stained for BrdU and/or incubated with Hoechst 33342 or live spheroids 
were stained with TO-PRO 3 and images were captured with a Zeiss LSM 510 Meta NLO 
confocal microscope (oil objectives: x 40 with NA 1.3, x 63 with NA1.4, x 100 with NA 1.3) 
(Carl Zeiss, Munich, Germany) or a Leica laser-scanning SP5 confocal microscope (Leica, 
Manheim, Germany). Analysis of the number of primary sprouts, branches, and nuclei per 
sprout, the total sprout length (cumulative length of primary sprouts and branches per 
spheroid) and of proliferating cells (BrdU staining, OBT 0030, Serotec) was done using the 
NIH Image J software package. MATRIGEL ASSAY: was performed as previously described 
(Arnaoutova et al., 2009; Grant et al., 1989; Lee et al., 1999; Martinez-Poveda et al., 2007; 
Passaniti et al., 1992). Briefly, Matrigel™ Basement Membrane Matrix  (BD Bioscience) 
rich in basement membrane components (laminin, collagen I, entactin, heparan sulfate 
proteoglycan, growth factors, matrix metalloproteinases and other proteinases) was plated 
on a 24 well plate and incubated for 30 min at 37°C. After polymerization, ECs were plated 
on top in M119 full medium containing 3PO or vehicle. Six hours later, the network was 
fixed using 4% PFA and images were captured using an inverted Leica DMI6000B 
epifluorescence microscope (Leica, Manheim, Germany). 
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RNA ANALYSIS: RNA expression analysis was performed by Taqman quantitative RT-
PCR as described (Carmeliet et al., 2001) using in house-designed primers and probes or 
premade primer sets (Applied Biosystems, Carlsbad, CA). Sequences or premade primer 
set ID numbers are available upon request. 
IMMUNOBLOT ANALYSIS: Protein extraction and immunoblot analysis were performed 
using a modified Laemmli sample buffer (125 mM Tris-HCl, pH 6.8 buffer containing 2% 
SDS and 10% glycerol) (Carmeliet et al., 2001) in the presence of protease and 
phosphatase inhibitors (Roche, Vilvoorde, Belgium). Lysates were separated by SDS-
PAGE under reducing conditions, transferred to a nitrocellulose or PVDF membrane, and 
analyzed by immunoblotting. Primary antibodies used were rabbit anti-VEGFR2 (SC-504, 
Santa Cruz Biotechnologies, California, U.S.A/C (No. 2032)) and rabbit anti-Lamin A/C 
(No.  2032). Equal loading was verified by Ponceau Red staining. Appropriate secondary 
antibodies were from Dako (Enschede, the Netherlands). Signal was detected using the 
ECL system (Amersham Biosciences, GE Healthcare, Diegem, Belgium) according to the 
manufacturer’s instructions. Densitometric quantifications of bands were done with NIH 
Image J software.   
PDGF IN SITU HYBRIDIZATION: Methanol fixed retinas were rehydrated through washing 
steps with 75%, 50% and 25% methanol at room temperature. Subsequently, they were 
treated with proteinase K (20 mg/ml; Life Technologies) for 20 min, fixed with 4% PFA-
0.1% glutaraldehyde and pre-hybridized at 65°C for 2 hours with Hb4 hybridization buffer.  
Probe-hybridization was performed overnight at 65°C using Hb4D5 buffer containing a 
DIG-labeled probe at a concentration of 1 µg/ml. The day after, retinas were washed with 
50% deionized formamide in 2 x SSCT (5 ml 20 x SSC, 250 µl 20% Tween-20 in 50 ml 
H2O), 2 x SSCT and 0.2 x SSCT at 65°C, allowed to cool down in PBS containing 0.1% 
Tween and blocked with PBS containing 0.1% Tween and 8% sheep serum (Sigma) for 2 
hours at room temperature. Thereafter, retinas were incubated overnight at 4°C with the 
sheep anti-DIG POD antibody (1:500; Anti-DIG-POD Fab fragments; Roche, Cat. No. 
11207733910). After 2 hours of washing with TBS containing 0.1% Tween followed by a 
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20-30 min incubation with fluorescein tyramide solution (TSA) diluted (1:500) in PBS 
containing 0.1% Tween, 0.001% H2O2 was added to the TSA solution to activate the TSA 
reaction. After 30-45 min, the TSA reaction was stopped by washing the retinas quickly 
with PBS.  Before proceeding with Isolectin B4 staining (see above), retinas were washed 
in PBS containing 0.1% Tween during 1 day at 4°C under slow agitation to reduce ISH 
unspecific signal, and were post-fixed with 4% PFA. 
MASS SPECTROMETRY: DETECTION OF 13C LACTATE FORMATION: Assessment of glycolytic 
flux in vivo was performed as described (Fan et al., 2012). Briefly, 1, 6 or 24 hours after 
injection of 3PO, a 20% solution of U-13C-glucose (Sigma) was sterile filtered and 100 µl of 
this solution (20 mg of U-13C-glucose) was injected into the tail vein of restrained mice. 
After 10 min, approximately 250 µ l blood was collected via eye bleeding, and blood was 
separated into plasma and blood cells by centrifugation for 15 min at 3,500 g. Plasma was 
immediately flash frozen in liquid nitrogen. To 50 µl of plasma 450 µl of methanol 
(Ultrapure, Sigma-Aldrich) at -80°C was added. The solution was put for 2 hours at -80°C 
and supernatant was collected following a centrifugation step at 4°C for 15 min at 20,000 x 
g. Next, the supernatant was dried using a vacuum centrifuge. To the dried fractions 100 
µl of N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide with 1% N-tert-Butyldimethyl-
chlorosilane (Sigma-Aldrich, Steinheim, Germany) was added, the reaction was carried out 
for 40 min at 60°C. Reaction mixtures were centrifuged for 15 min at 20,000 x g at 4 °C in 
order to remove insolubilities, the supernatant was transferred to a glass vial with conical 
insert (Agilent). GC/MS/MS analyses were performed using an Agilent 7890A GC 
equipped with a HP-5 ms 5% Phenyl Methyl Silox (30 m - 0.25 mm i.d. - 0.25 µm; Agilent 
Technologies, Santa Clara, California, USA) capillary column, interfaced with a triple 
quadruple tandem mass spectrometer (Agilent 7000B, Agilent Technologies) operating 
under ionization by electron impact at 70 eV. The injection port, interface and ion source 
temperatures were kept at 250 °C. Temperature of the quadrupoles was maintained at 
150°C. The injection volume was 1 µl, and samples were injected at 1:50 split ratio. 
Helium flow was kept constant at 1 ml/min. The temperature of the column started at 100 
°C for 3 min and increased to 190 °C at 12.5 °C/min, and held for 1 min. Next, a 50 °C/min 
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gradient was carried out until temp reached 300 °C and held at 300°C for 1 min. After the 
gradient, the column was heated for another 5 min at 325 °C. The GC/MS/MS analyses 
were performed in Single Ion Monitoring (SIM) scanning for the isotopic pattern of lactic 
acid (m/z range from 261.1 (m0) to 265.1 (m5)).  
FLOW CYTOMETRY: CELL CYCLE ANALYSIS: Cells in G0 were identified as a 2N DNA 
population lacking 5-ethynyl-2´-deoxyuridine (EdU, Invitrogen) incorporation. Briefly, cells 
were labeled with 10 µM EdU over 24 hours, collected by trypsinization and fixed (4% 
PFA). The incorporated EdU was detected by a ‘click-It reaction’ with Alexa fluor 647 
according to the manufacturer’s instructions. Alexa fluor 647 was excited with a 604 nm 
red laser and emission was recorded at 660 nm, while Hoechst 33342 was excited with a 
405 nm Violet Diode laser and emission was recorded at 450 nm. MEMBRANE PROTEIN 
EXPRESSION:  Surface expression of VEGFR2 was determined using monoclonal anti-
human VEGF receptor phycoerythrin sampler pack (R&D systems) according to the 
manufacturer’s instructions.  
METABOLISM ASSAYS: GLYCOLYSIS: Cells were incubated for 2 hours in growth medium 
containing 80 mCi/mmol [5-3H]-D-glucose (Perkin Elmer). Thereafter, supernatant was 
transferred into glass vials sealed with rubber stoppers. 3H2O was captured in hanging 
wells containing a Whatman paper soaked with H2O over a period of 48 hours at 37°C to 
reach saturation (Aragones et al., 2008). Radioactivity was determined by liquid 
scintillation counting. FRUCTOSE-2,6-BISPHOSPHATE LEVELS: Cells were lysed in 100 mM 
NaOH and centrifuged (20,000 g for 20 min). An aliquot of the homogenate was used for 
protein determination and the remaining sample was heated at 80°C for 5 min, centrifuged 
(20,000 x g for 20 min) and the resulting supernatant was used for the determination of 
F2,6P2 concentration as described (Van Schaftingen et al., 1982). ENZYMATIC ACTIVITIES: 
The effect of 3PO and YN-1 on the enzymatic activity of HK, G6PDH, PFK-1, TKT, 
GAPDH, PK, and LDH was determined as described (de Atauri et al., 2011; Mazurek et 
al., 2005). GLUCOSE MEDIATED RNA SYNTHESIS: was estimated by the incorporation of 14C 
into RNA using 100 µCi/mmol [6-14C]-D-glucose and was corrected for the total amount of 
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RNA per sample. OXIDATIVE PENTOSE PHOSPHATE PATHWAY (OXPPP): The contribution of the 
oxPPP to total glucose utilization was measured as 14CO2 formation using 0.9 µCi/ml [6-
14C]-D-glucose (14CO2 formation only in the TCA cycle) or 0.45 µCi/ml [1-14C]-D-glucose 
(14CO2 formation both in the TCA cycle and the oxPPP), by subtracting the [6-14C]-glucose 
flux from the [1-14C]-glucose flux. This value was corrected for total glucose utilization, as 
previously described (Ashcroft et al., 1972). OXYGEN CONSUMPTION AND LACTATE 
PRODUCTION: Cells were seeded at 40,000 cells per well on Seahorse XF24 tissue culture 
plates (Seahorse Bioscience Europe, Copenhagen, Denmark). The assay medium was 
unbuffered DMEM supplemented with 5 mM D-glucose and 2 mM L-glutamine, pH 7.4. 
The measurement of oxygen consumption was performed at 10 min intervals (2 min 
mixing, 2 min recovery, 6 min measuring) for 3 hours using the Seahorse XF24 analyzer. 
ENERGY BALANCE ASSESSMENT: 2 x 106 cells were harvested in ice cold 0.4 M perchoric acid 
supplemented with 0.5 mM EDTA. pH was adjusted by adding 100 µl of 2 M K2CO3. 100 
µl of the mixture was injected onto an Agilent 1260 HPLC equipped with a C18-Symmetry 
column (150 x 4.6 mm; 5 µm) (Waters), thermostated at 22.5 °C. Flow rate was kept 
constant at 1 ml/min. A linear gradient using solvent A (50 mM NaH2PO4, 4 mM 
tetrabutylammonium, adjusted to pH 5.0 using H2SO4) and solvent B (50 mM NaH2PO4, 4 
mM tetrabutylammonium, 30% CH3CN, adjusted to pH 5.0 using H2SO4) was 
accomplished as follows: 95% A for 2 min, from 2 to 25 min linear increase to 100% B, 
from 25 to 27 min isocratic at 100% B, from 27 to 29 min linear gradient to 95% A and 
finally from 29 to 35 min at 95% A. Detection of ATP, ADP and AMP occurred at 259 nm. 
GLUCOSE UPTAKE IN VIVO: At the indicated times after 3PO treatment, mice were injected 
intravenously with a bolus of 2-deoxy-D-glucose, 2-[1-14C] (Perkin Elmer). One hour later, 
animals were euthanized by cervical dislocation and heart and diaphragm were harvested. 
Tissues were digested overnight in 1 N NaOH at 60°C and then neutralized with 1 N HCl. 
Glucose uptake was determined using liquid scintillation counting.  
ZEBRAFISH MODELS OF ANGIOGENESIS: Tg(fli1:EGFP)y1, Tg(fli1:nEGFP)y7 zebrafish, or 
Tg(kdrl:EGFP;gata1:DsRed) zebrafish (Zebrafish International Resource Center, ZIRC, 
Oregon, USA) (Jin et al., 2005; Traver et al., 2003) were grown and subjected to flt1 or dll4 
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morpholino oligonucleotide injections as previously described (Geudens et al., 2010). For 
treatment with 3PO or YN1, embryos were placed in 12-well dishes (10-15 embryos per 
well, with random allocation for embryos that were subjected to flt1 or dll4 knockdown prior 
to control or inhibitor treatment). Inhibitor (20-45 µM 3PO; 800 µM YN1) was added to the 
water at 20 hours post-fertilization (hpf) (for ISV outgrowth phenotyping), except in the 
case of dll4 knockdown (dll4KD) (inducing ISV hyperbranching beyond 52 hpf (Geudens et 
al., 2010)), when treatment was started at 48 hpf. For combined inhibitor treatment, 
embryos were bathed in 3PO (20-30 µM) with or without SU5416 (0.5-1.0 mM) from 18-20 
hpf onwards. Control embryos were treated with the corresponding percentage of vehicle 
(DMSO). Live screening and quantification of ISV abnormalities in the trunk was performed 
on Tricaine-anaesthetized embryos (Tricaine, Sigma-Aldrich, Bornem, Belgium) at 24-28 
hpf (ISV formation), 35 hpf (3PO/SU5416 combined treatments), at 48 hpf (angiograms), 
at 60 hpf (3PO withdrawal experiment and perfusion in the Tg(kdrl:EGFP;gata1:DsRed) 
zebrafish) and 72 hpf (flt1 or dll4 knockdown). For high throughput assessment of flt1 
knockdown experiments, the number of ISVs (out of 10 ISVs per embryo) with vascular 
hyperbranches was counted first by live screening, and embryos were scored according to 
severe (4-10 ISVs with hyperbranches), mild (1-3 ISVs with hyperbranches), and normal 
phenotype (no hyperbranches). Then, hyperbranching was quantified by counting the total 
number of ISV branches per ISV. To assess EC proliferation, the number of cells in the 
DLAV was determined at 35 hpf by counting the nuclei (Tg(fli1:nEGFP)y7 embryos). For 
assessment of synergistic effects of 3PO and SU5416 on ISV formation, ISVs were scored 
within the segment of 10 somites posterior to the bifurcation of the dorsal aorta and 
posterior cardinal vein, according to their absence, partial formation without reaching the 
horizontal midline, partial formation reaching beyond the horizontal midline, and complete 
formation. Whole-mount in situ hybridization for neuronal markers was performed as 
described (Geudens et al., 2010) using probes for zebrafish Pax2.1 and Dlx2. Multiphoton 
angiogram images were captured immediately after intracardiac injection of 3 nl 25 mg/ml 
tetramethylrhodamine-dextran (Mr 2,000,000 Da) at 48 hpf. Multiphoton imaging of 
fli1:EGFPy1 or fli1:nEGFPy7 embryos was performed using a Zeiss LSM 510 Meta NLO 
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confocal microscope (oil objectives: x 40 with NA 1.3, x 63 with NA 1.4, x 100 with NA 1.3) 
(Carl Zeiss, Munich, Germany); embryos were anaesthetized and positioned on a 
coverslip in a drop of 0.5% low melting point agarose. Time-lapse movies for filopodia 
assessment were recorded after embedding (0.5% low melting point agarose) of 3PO pre-
treated (45 µM, 1 hour) Tricaine-anaesthetized embryos from 20 hpf until 30 hpf. During 
imaging 3PO (45 µM) was present in the water on top of the agarose to ensure continuous 
treatment and humidity. High resolution time lapse movies were recorded with a LD Plan-
Neofluar 20x NA 0.4 objective, 2 x zoom, 1024 x 1024 frame size, 8 x averaging and with 
16 min intervals. Filopodia number and length were assessed with NIH Image J software. 
Multiphoton images were acquired using ZEN 2011 software (Carl Zeiss, Munich, 
Germany). All experimental animal procedures were approved by the Institutional Animal 
Care and Research Advisory Committee of the University of Leuven.  
MOUSE MODELS OF ANGIOGENESIS: C57BL/6 mice were from Charles River, Belgium. 
Balb/C mice were from the animal facility of the KU Leuven. Housing and experimental 
procedures were approved by the Institutional Animal Care and Research Advisory 
Committee of the University of Leuven. CHOROIDAL NEOVASCULARIZATION: CNV was 
induced in male C57BL/6 mice by laser burn as previously described (Van de Veire et al., 
2010). Using a Purepoint® Laser (Alcon, Fort Worth, United States), three spots were 
made on the retina in a star shaped way (0.4 Watt, 0.1 sec, 50 µM spot size). Mice were 
randomly allocated to the treatment groups and injected i.p. with 38 or 50 mg/kg 3PO 
daily, and/or with 12.5 mg/kg anti-VEGFR2 (DC101) 3x/week as indicated. Two weeks 
later, the CNV lesions were then analyzed as previously described (Van de Veire et al., 
2010). Briefly, the eyes were enucleated 1 minute after retrobulbar injection with 
Fluorescein isothiocyanate (FITC)-conjugated dextran (Mr 2,000,000) (Sigma), fixed in 4% 
PFA and choroids were dissected and flat-mounted for analysis of the neovascular lesion 
area and volume as previously described (Jost et al., 2007; Van de Veire et al., 2010), or 
processed for immunohistochemistry (anti-CD45 (Becton Dickinson)) as described (Rolny 
et al., 2011). The choroids were flat-mounted on a coverslide and mounted with 
Vectashield mounting medium (Vector Laboratories, Inc. Burlingame, CA 94010) to 
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prevent bleaching of the fluorescent dye. Lesions were imaged using a Zeiss LSM780 
confocal microscope (Carl Zeiss, Munich, Germany). For 3D reconstruction of the 
neovascular volume, we used the ZEN 2011 software (Carl Zeiss, Munich, Germany) to 
capture Z stacks of the neovascular lesion at 20 x magnification (zoom 0.7) (LD Plan-
Neofluar 20x/0.4 Korr M27), using a frame-size of 1024 x 1024 x 7, 12-bit, a pixel dwell 
time of 0.79 µs, and line averaging of 4.  Excitation was done with an 488 nm Argon laser 
line at 2% and emission was detected with the following PMT settings:  master gain 692, 
digital gain 1, and digital offset 0. To measure the volume of the entire choroidal 
neovascular lesion, we used Leica MM AF MetaMorph ® image analysis software (Leica 
Microsystems, Mannheim, Germany) and first calculated the volume of each single stack 
by multiplying the FITC positive area of the single stacks with the thickness of the optical 
sections, and thereafter summed the volumes of each separate stack of the Z-stack. To 
determine the neovascular area, as percentage of the total lesion area, we imaged the 
lesions using a Zeiss Axioplan Imaging microscope (Carl Zeiss, Munich, Germany) at 20x 
magnification (Plan-Neofluar 20x/0.5). The neovascular lesion area was then measured by 
using a fixed threshold of the FITC fluorescence intensity using Leica MM AF, powered by 
MetaMorph ® image analysis software (Leica Microsystems, Mannheim, Germany). 
POSTNATAL RETINAL ANGIOGENESIS: Neonatal mice were treated with 50 mg/kg 3PO or 100 
mg/kg YN1 daily from postnatal day (P) 2 to P4 and euthanized at P5, at which time eyes 
were enucleated and organs were dissected and fixed with 2% paraformaldehyde (PFA). 
As all animal treatments were done in baseline conditions, no randomization was required. 
Retinal whole mounts were prepared for vascular analysis as described (De Bock et al., 
2013b) and all pups from all litters were included in the analysis. For detection of cell 
proliferation, BrdU (Sigma-Aldrich) was injected 2 hours before dissection. Radial vascular 
area, branch points, and number of filopodia were analyzed using the NIH Image J 
software package and the AxioVision morphometric analysis software (Carl Zeiss, Munich, 
Germany) with in-house developed macros (De Bock et al., 2013b). Primary antibodies 
used: isolectin GS-IB4-Alexa 488, isolectin GS-IB4-Alexa 568, isolectin GS-IB4- Alexa 647 
(Molecular Probes), anti-Erg (Santa Cruz Biotechnology), anti-GFP (Molecular Probes), 
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and anti-BrdU (Serotec). Alexa-488, -568 or -633 conjugated secondary antibodies were 
used (Molecular Probes). OXYGEN-INDUCED RETINOPATHY: Oxygen induced retinopathy 
(ROP) was induced by exposing C57BL/6 pups to 70% oxygen from P7-P12 (Scott and 
Fruttiger, 2010). Pups were then returned to normoxia and injected daily with 70 mg/kg 
3PO. At P17, pups were euthanized and eyes were enucleated, fixed in 4% PFA and 
retinal flatmounts were stained for isolectin B4, using previously published methods (De 
Bock et al., 2013b). Mosaic images were captured using the inverted Leica DMI6000B 
epifluorescence microscope (Leica, Manheim, Germany) and analysis of the vascular tuft 
area was performed using NIH Image J software. IMIQUIMOD-INDUCED SKIN INFLAMMATION: 
Ten week old female Balb/C mice received a daily topical dose of 5% imiquimod cream 
(62.5 mg) on the shaved back to induce skin inflammation, as described (Telang et al., 
2012). Thirty minutes after application of the cream, mice were injected with 3PO (i.p. 50 
mg/kg). After 4 days of treatment, skins and spleens were collected and fixed in 4% PFA. 
Paraffin sections of skins were stained for CD105 (R&D Systems), CD3 (Dako) and H&E. 
Images were captured with an upright Zeiss Axioplan 2 imaging microscope (Carl Zeiss, 
Munich, Germany). ACUTE DSS COLITIS MODEL: Acute colitis was induced in 11 week old, 
female C57BL/6 mice by treatment of mice with 2.5% DSS in the drinking water for 6 days 
(Cummins et al., 2008; Hindryckx et al., 2010). Mice were treated daily with 3PO (i.p. 50 
mg/kg). Bodyweight, occult blood in faeces and stool consistency were monitored daily. 
Colons were dissected on day 6 and fixed in 4% PFA. Paraffin sections were stained for 
CD105 (R&D Systems), CD45 (BD Biosciences) and H&E. Images were captured using an 
upright Zeiss Axioplan 2 imaging microscope (Carl Zeiss, Munich, Germany). Histological 
scoring was done as described previously (Cooper et al., 1993; Cummins et al., 2008). 
Briefly, a maximum score of 10 was determined using the following parameters: 1) severity 
of inflammatory cell infiltration (score of 0, none; score of 1, slightly dispersed cell infiltrate; 
score of 2, moderately increased cell infiltrates forming occasional cell foci; and score of 3, 
severely large areas of cell infiltrates causing loss of tissue architecture), 2) extent of injury 
(score of 0, none; score of 1, mucosal; score of 2, mucosal and submucosal; and score of 
3, transmural) and 3) crypt damage (score of 0, none; score of 1, basal and one third 
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damaged; score of 2, basal two third damaged; score of 3, only surface epithelium intact 
and score of 4, loss of entire crypt and epithelium). Scoring of the disease activity index 
(DAI) was performed as described previously (Cummins et al., 2008). Briefly, a maximum 
score of 12 was determined based on the following scoring system: score of 0, no weight 
loss, normal stool, no blood; score of 1, 1%–3% weight loss; score of 2, 3%–6% weight 
loss, loose stool, blood visible in stool; score of 3, 6%–9% weight loss; and score of 4, less 
than 9% weight loss, diarrhea, and gross bleeding. 
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During vessel sprouting, a migra-tory endothelial tip cell guides the 
sprout, while proliferating stalk cells elon-
gate the branch. Tip and stalk cell pheno-
types are not genetically predetermined 
fates, but are dynamically interchange-
able to ensure that the fittest endothe-
lial cell (EC) leads the vessel sprout. 
ECs increase glycolysis when forming 
new blood vessels. Genetic deficiency of 
the glycolytic activator PFKFB3 in ECs 
reduces vascular sprouting by impairing 
migration of tip cells and proliferation 
of stalk cells. PFKFB3-driven glycolysis 
promotes the tip cell phenotype during 
vessel sprouting, since PFKFB3 overex-
pression overrules the pro-stalk activ-
ity of Notch signaling. Furthermore, 
PFKFB3-deficient ECs cannot compete 
with wild-type neighbors to form new 
blood vessels in chimeric mosaic mice. 
In addition, pharmacological PFKFB3 
blockade reduces pathological angiogen-
esis with modest systemic effects, likely 
because it decreases glycolysis only par-
tially and transiently.
Results and Discussion
The vasculature is of crucial impor-
tance for delivering oxygen and nutrients 
to tissues. When this supply is limiting, 
new blood vessels are formed. This process 
(termed angiogenesis) is not only critical 
during embryonic development, but also 
promotes pathological conditions such as 
cancer and inflammatory disorders.1 Dur-
ing vessel sprouting, pro-angiogenic factors 
such as VEGF promote the induction of a 
migratory endothelial tip cell, while pro-
liferating endothelial stalk cells elongate 
the sprout.1 Most anti-angiogenic thera-
pies currently approved for clinical use or 
in (pre)-clinical development block mol-
ecules like VEGF. However, anti-cancer 
therapies targeting VEGF signaling suffer 
from resistance and toxicity, necessitating 
the development of novel anti-angiogenic 
strategies.2,3 Research over the past decades 
has identified several genetic signals that 
regulate angiogenesis, but the role of endo-
thelial cell (EC) metabolism in angiogen-
esis has not been intensely studied.
ECs remain quiescent for years, but 
can rapidly start to proliferate and migrate 
when stimulated by angiogenic signals. 
These processes require energy and molec-
ular building blocks for biomass duplica-
tion. Since angiogenic ECs have different 
metabolic needs than quiescent ECs, it has 
been postulated that a metabolic switch 
accompanies the angiogenic switch.4,5 
However, little is known about EC metab-
olism in relation to vessel branching and 
on which metabolic pathways ECs rely to 
form new vessels.
ECs line blood vessels and, thus, have 
immediate access to oxygen in the blood. 
Yet, they do not take advantage of this 
availability of oxygen to rely on oxida-
tive metabolism, but instead are highly 
glycolytic and generate up to 85% of 
their ATP from glycolysis.4,6 To evalu-
ate the importance of glycolysis in ves-
sel sprouting, we used pharmacological 
blockade or genetic silencing of phospho-
fructokinase-fructose-2,6-bisphospha-
tase-3 (PFKFB3), an enzyme producing 
Keywords: endothelial cell, angiogenesis, 
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fructose-2,6-biphosphate, which is a potent 
allosteric activator of the rate-limiting gly-
colytic enzyme phosphofructokinase-1. 
PFKFB3 inhibition in ECs reduced glycol-
ysis, but by no more than 40%, and did not 
cause general energy hypo-metabolism.4 
Nonetheless, even this partial inhibition 
of glycolysis sufficed to reduce EC prolif-
eration and migration, and vessel sprouting 
from EC spheroids in vitro.4,5 Furthermore, 
zebrafish treated with the pharmacological 
PFKFB3 blocker 3-(3-pyridinyl)-1-(4-
pyridinyl)-2-propen-1-one (3PO) and mice 
lacking PFKFB3 in ECs displayed vascular 
sprouting and branching defects.4,5 3PO 
was not cytotoxic for ECs, and its anti-
angiogenic effects were reversible.4,5
Consistent with reports that PFKFB3-
driven glycolysis promotes cellular pro-
liferation,7,8 endothelial loss of PFKFB3 
reduced EC proliferation and rendered 
stalk cells hypo-proliferative.4 However, 
blockade or loss of PFKFB3 in ECs also 
impaired various tip cell functions, such 
as directional migration and filopodia and 
lamellipodia formation, processes that 
require actin cytoskeletal remodeling.4 
Blockade of PFKFB3-driven glycolysis 
also affected additional processes of EC 
dynamics, involving cytoskeleton remod-
eling. Indeed, for a cell to establish contact 
with another cell, it must alter its shape. 
Since a sphere has a low surface tension, 
a cell preferably adopts a spheroid shape, 
and any deviation from this shape, such 
as when a cell is spreading or establishes 
cell–cell contacts, requires “adhesion 
energy”.9 Time-lapse imaging of sparsely 
plated GFP+ ECs showed that control cells 
established long-lasting cell–cell contacts 
with each other (Fig. 1A). In contrast, 
PFKFB3-silenced cells (using published 
methods4) only made transient “kiss and 
run” contacts, and after brief touching, 
they disconnected without maintaining 
stable contact (Fig. 1B). This was due 
to the fact that PFKFB3-silenced ECs 
formed only small, irregular, and transient 
lamellipodial projections (Fig. 1B), as 
quantified earlier.4
Tip and stalk cell phenotypes are not 
fixed predetermined cell fates, but instead 
are interchangeable phenotypes. Hence, a 
stalk cell can plastically differentiate to a 
tip cell over a period of 6 h.10 ECs must 
thus be competitive to reach the tip posi-
tion. We recently reported that PFKFB3 
deficiency impairs tip cell competitiveness 
during embryonic vascular development in 
the hindbrain.4 The process of tip and stalk 
cell differentiation is under tight control of 
genetic signaling by VEGF (a pro-tip sig-
nal) and Notch (a pro-stalk signal), among 
other angio-modulatory signals.1 Use of 
mosaic EC spheroids and transgenic zebraf-
ish showed that overexpression of PFKFB3 
provided ECs a competitive advantage for 
the tip position, not only in baseline condi-
tions, but even when Notch signaling was 
increased in transgenic ECs.4 The finding 
that PFKFB3 overexpression was capable 
of overruling the pro-stalk activity of 
Notch and promoted stalk cells to become 
tip cells is remarkable, as no other signal 
has been documented to overcome the 
strong pro-stalk activity of Notch. These 
data thus show that glycolysis provides a 
competitive advantage for ECs to reach the 
tip and establish that metabolism (glycoly-
sis) co-determines vascular branching, in 
parallel to genetic signals like VEGF and 
Notch.4 Importantly, the role of PFKFB3 
in vascular branching did not rely on a 
change in the genetic angiogenic signature, 
as the expression levels of pro-tip signals 
(such as VEGF) and pro-stalk signals (such 
as Notch) were unaffected when PFKFB3 
levels were altered.4 Conversely, VEGF or 
Notch signaling regulated PFKFB3 and 
glycolysis levels, indicating that glycolysis 
is downstream and required for angiogenic 
signaling.4
The tip cell responses that were affected 
by PFKFB3 blockade relied on remodeling 
of the actin cytoskeleton,4 a process that 
requires rapid production of large amounts 
Figure 1. PFKFB3 blokade impairs cell–cell contact and vessel formation. (A and B) Representative snapshot images of time-lapse imaging, showing 
that control cells make long lasting cell–cell contact (A), while PFKFB3-silenced cells make only transient contact (B). (C–J) Representative images of the 
postnatal aorta (open book preparation) of chimeric PFKFB3WT/Cherry (C–F) and PFKFB3KO/Cherry pups (G–J), stained for the endothelial nuclear marker Erg 
(green, C, E–G, I, and J) or expressing mCherry (red, labeling transgenic cells in D–F and H–J). (F and J) show a high magni!cation of the insets in (E and 
I). (C–F) A fraction of the ECs are PFKFB3WT/Cherry (arrowheads, red cells oriented in the vertical axis); likewise, a fraction of the smooth muscle cells is also 
PFKFB3WT/Cherry (red cells oriented in the horizontal axis). (G–J) All ECs are wild-type (host-derived), while PFKFB3KO/Cherry ECs are not detected (evidenced by 
the absence of vertically oriented red cells), even though other PFKFB3KO/Cherry cell types are present (smooth muscle cells in red, oriented in the horizontal 
axis). These !ndings indicate that PFKFB3KO/Cherry ECs are out-competed by wild-type ECs originating from the wild-type host blastocyst. The white arrow 
indicates the direction of blood "ow. Open book preparation: the ECs are facing upwards (the adventitia is facing downwards).
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of ATP by glycolysis in ECs. Indeed, bulky 
mitochondria were excluded from the thin 
lamellipodia and narrow filopodia, and 
altering mitochondrial respiration did 
not affect vessel sprouting.4 In contrast, 
PFKFB3 and other glycolytic enzymes 
were present in the perinuclear cytosol 
in quiescent ECs, but were relocated to 
lamellipodia in migrating ECs.4 ATP bio-
sensor imaging revealed ATP hotspots in 
motile lamellipodia, which were reduced 
by silencing of PFKFB3 but not by mito-
chondrial poisons.4 At the molecular 
level, PFKFB3 interacted with F-actin 
at increased levels in the leading mem-
brane ruffles of lamellipodia of motile 
ECs.4 Since binding of various glycolytic 
enzymes to F-actin promotes the forma-
tion of their active tetramerized state and 
favors the formation of an efficient assem-
bly line, whereby the product of one glyco-
lytic enzyme becomes the substrate of the 
next glycolytic enzyme,11 compartimental-
ization of glycolytic enzymes with F-actin 
provides a mechanistic explanation of how 
glycolysis fuels EC tip functions.4
The impaired tip and stalk cell activi-
ties of ECs lacking PFKFB34 prompted 
us to investigate whether PFKFB3-defi-
cient (PFKFB3KO) ECs would be able to 
compete with wild-type (WT) ECs for 
the formation and maintenance of blood 
vessels after birth. We therefore used 
PFKFB3-deficient (PFKFB3KO) ES cells, 
stably expressing a CherryRed marker, 
to visualize transgenic cells (PFKFB3KO/
Cherry).4 Wild-type (PFKFB3WT) ES cells 
transfected with CherryRed were used as 
a control (PFKFB3WT/Cherry).4 PFKFB3KO/
Cherry or PFKFB3WT/Cherry ES cells were then 
injected into WT blastocysts to gener-
ate highly (>90–95%) mosaic chimeras. 
We then assessed the contribution of 
PFKFB3KO/Cherry or PFKFB3WT/Cherry ECs 
to the formation and maintenance of the 
dorsal aorta at postnatal day 5 by stain-
ing for the EC-specific transcription factor 
Erg. Surprisingly, no PFKFB3KO/Cherry ECs 
were detectable in the aorta; even though 
PFKFB3WT/Cherry ECs were abundantly 
present (Fig. 1C–J). This was remarkable, 
since PFKFB3KO/Cherry ES cells differenti-
ated to smooth muscle cells, which were 
readily identified by their orientation, 
perpendicular to the alignment of ECs in 
the direction of blood flow (Fig. 1C–J). 
These findings indicate that ECs, lack-
ing PFKFB3, were outcompeted during 
embryonic development by their WT 
neighbors originating from the host blasto-
cyst cells, likely because of their impaired 
tip and stalk cell functions, overall illus-
trating the importance of PFKFB3-driven 
glycolysis for ECs for vessel formation.
Overall, these findings show that not 
only genetic signals, but also metabolism 
regulates vessel branching. This insight 
raised the question whether PFKFB3-
driven glycolysis might be a target for 
inhibiting angiogenesis in pathologi-
cal conditions. Indeed, pharmacological 
PFKFB3 blockade, using the compound 
3PO, reduces vessel sprouting in vitro 
and pathological angiogenesis in models 
of choroidal neovascularization, retinopa-
thy of prematurity and inflammatory skin 
and bowel diseases.5 Remarkably, how-
ever, treatment of adult mice (in which 
most vessels are quiescent) with 3PO for 
15 d did not affect the healthy established 
vasculature in the retina (Fig. 2A and D); 
neither did it change the vascular area in 
other organs such as the kidney (Fig. 2B 
and E) and the heart (Fig. 2C and F). 
3PO also did not affect the perfusion of 
retinal vessels (Fig. 2G–L) or cause ves-
sel wall leakage of various organs in adult 
healthy mice (Fig. 2M and N). These 
findings thus illustrate that proliferating 
and migrating ECs during pathologi-
cal angiogenesis are more susceptible to 
PFKFB3 blockade than quiescent ECs 
in established vessels, in accordance with 
reports that sprouting ECs have higher 
levels of glycolysis than quiescent ECs, 
and that 3PO inhibits the hypermetabo-
lism associated with sprouting ECs.5
We also explored whether 3PO treat-
ment induced systemic effects, given that 
glycolysis is part of the central metabolism 
in multiple other cell types. We therefore 
treated adult healthy mice for 15 d with 
the same dose of 3PO that decreased 
angiogenesis. The following effects were 
noticed. First, 3PO caused a <10% body 
weight loss and reduced red blood cell 
parameters by <10% (Table 1). Intestinal 
crypt stem cell proliferation was reduced 
by 18%, but crypts and villi were normal 
in morphology and size (Table 1), suggest-
ing that 3PO reduced but did not deplete 
the intestinal stem cell pool. Other param-
eters were not affected. For instance, 3PO 
did not induce striking differences in 
Table 1. Systemic e!ects of PFKFB3 blockade
DMSO control 3PO
Vascular parameters
̆Heart (endoglin+ area, % of total)
̆Kidney medulla (CD31+ area, % of total)
̆Kidney cortex (CD31+ area, % of total)
17.4 ± 0.7
15.8 ± 0.3
55.4 ± 2.8
15.8 ± 0.9
14.4 ± 0.6
54.2 ± 1.3
Liver parameters
̆ALT plasma level (U/L)
̆AlcP plasma levels (U/L)
̆γ-GT plasma levels (U/L)
̆Bilirubine plasma levels (mg/dL)
12 ± 0.5
33 ± 3
<3
<0.18
16 ± 1.4
33 ± 11
<3
<0.18
Renal parameters
̆Ureum (mg/dL)
̆Creatinine (mg/dL)
53 ± 6.5
<0.06
55 ± 6.2
<0.06
Small intestine parameters
̆Crypt cell proliferation (BrdU+ cells, % of total)
̆Villus height (μm)
̆Crypt depth (μm)
28 ± 0.8
379 ± 8
70 ± 2
23 ± 0.8*
378 ± 17
69 ± 2.3
Hematological parameters
̆WBCs (×103/μL)
̆Platelets (×103/μL)
̆Hematocrit (%)
̆RBCs (×106/μL)
̆Hemoglobin (g/dL)
6.1 ± 1.1
564 ± 63
42 ± 0.3
8.9 ± 0.1
15.8 ± 0.2
5.4 ± 0.9
690 ± 64
39 ± 0.9
8.3 ± 0.2*
14.4 ± 0.3*
Values are mean ± SEM, n = 5. ALT, alanine aminotransferase; AlcP, alkaline phosphatase; γ-GT, 
γ-glutamyl transpeptidase; WBCs, white blood cell counts; RBCs, red blood cells; *P < 0.05 vs DMSO.
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biochemical blood parameters (Table 1), 
nor did it induce histological abnormali-
ties in liver, muscle, colon, and kidney 
(Fig. 3A–H) or of the intestines, brain and 
heart (not shown). No overt signs of liver 
inflammation were detected (Fig. 3I), and 
no signs of eye toxicity were observed as 
shown by staining for the glial cell marker 
GFAP (Fig. 3J) and quantification of 
the thickness of the retinal nuclear lay-
ers (Fig. 3K–M). Plasma creatine kinase 
(CK) levels were also not elevated, sug-
gesting normal cardiomyocyte viability 
(Fig. 3N). We also tested if 3PO affected 
the recovery from myelosuppression by 
doxorubicin, cisplatin, capecitabine, and 
sorafenib, administered at doses inhibit-
ing tumor growth. Treatment with 3PO 
slightly aggravated myelosuppression by 
cisplatin and sorafenib (at a single time 
point after 14 or 7 d, respectively), but 
white blood cell counts fully recovered in 
all 3PO-treated mice (Fig. 3O).
We explored the underlying reasons 
of why 3PO did not induce more severe 
adverse effects than perhaps initially 
anticipated. First, 3PO had a short half-
life (30 min)12 and reduced glycolysis only 
partially (by 35–40%) and transiently 
(during <6 h) in vivo, though 3PO was 
again effective in reducing glycolysis upon 
re-administration.5 Nonetheless, this tran-
sient partial decrease in glycolysis was suf-
ficient to block pathological angiogenesis,5 
thus providing a new paradigm that anti-
glycolytic therapy does not need to block 
glycolysis completely and permanently in 
ECs to impair angiogenesis. Second, given 
that cells need glycolysis to proliferate, 
we also hypothesized that quiescent cells 
or cells not relying critically on glycolysis 
would be less sensitive to PFKFB3-block-
ade. Indeed, 3PO did not affect glycolysis 
or survival of neurons and resident macro-
phages, known to have negligible PFKFB3 
levels (Table 2).13,14 In other cells, such 
as hepatocytes and adipocytes, 3PO 
reduced glycolysis, but their survival was 
not compromised, indicating that these 
cells did not critically rely on PFKFB3-
driven glycolysis as their predominant 
metabolic pathway and likely were able 
to compensatorily switch to another type 
of metabolism (Table 2). By contrast, 
rapidly proliferating cells, such as ECs or 
tumor cells, have high levels of glycolysis, 
and their glycolytic flux and proliferation 
were reduced by 3PO (Table 2). Taken 
together, PFKFB3-blockade primarily tar-
gets rapidly proliferating/migrating cell 
types that critically rely on glycolysis.
Overall, the partial, transient blockade 
of glycolysis sufficed to reduce sprouting, 
yet was less toxic than perhaps intuitively 
Figure 2. PFKFB3 blockade does not target the quiescent vasculature. (A–F) Vascular densities in 
the retina (A and D, isolectin B4), kidney (B and E, CD31) and heart (C and F, endoglin) were not 
a!ected by 15 d treatment of adult healthy mice with 3PO. (A–C) control, (D–F) 3PO. Scale bars: 
200 µm (A and D), 50 µm (B and E), and 100 µm (C and F). (G–L) Confocal images of dextran-FITC 
injected (G and J) and isolectin-B4 (H and K) stained retina of healthy mice that were treated with 
3PO (J–L) or vehicle (G–I) for 15 d showing that 3PO does not induce vessel leakiness in the quies-
cent vessels of the retina. (I and L) show the merged images. (M) Quanti"cation of the Evans blue 
dye leakage in heart, lung, liver, and kidney, showing no e!ect of 3PO treatment (50 mg/kg/day for 
4 d) on vessel leakiness (mean ± SEM, n = 5, P = NS). (N) Quanti"cation of FITC-dextran+ area in the 
kidney after injection of FITC-dextran (MW 40 000 Da) followed by saline perfusion 10 min later, 
showing no e!ect of 3PO treatment on vessel leakiness (mean ± SEM, n = 5, P = NS).
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expected based on the widely held belief 
that many cell types require glycolysis. 
However, PFKFB3 inhibition does not 
indiscriminately affect any type of healthy 
cells, but primarily targets those cells that 
rely on glycolysis as a critical metabolic 
pathway, such as proliferating and migrat-
ing cells. Noteworthy in this respect, the 
vast majority (>90%) of cells in a healthy 
adult are quiescent. The finding that ECs 
rely on glycolysis more than other cell types 
explains why ECs are more vulnerable to 
PFKFB3 blockade. In addition, it is impor-
tant to stress that 3PO treatment decreased 
glycolysis only partially and transiently. A 
more sustained and more complete inhi-
bition of glucose metabolism by 80%, 
as obtained when treating ECs with the 
Figure 3. PFKFB3 blockade does not a!ect organ morphology and heart function. (A–H) No histological abnormalities were detected by H&E stain-
ing of the colon (A and E), liver (B and F), muscle (C and G), and kidney (D and H) of adult healthy mice treated for 15 d with 3PO. (A–D) control, 
(E–H) 3PO. (I) Quanti"cation of the CD45+ area in the liver, showing comparable numbers of in#ammatory cells upon 3PO treatment (50 mg/kg/day for 
15 d) (mean ± SEM, n = 5, P = NS). (J) Quanti"cation of the glial "brillary acidic protein (GFAP) positive area in the retina, showing similar number of glial 
cells and thus absence of gliosis upon 3PO treatment (50 mg/kg/day for 15 d) (mean ± SEM, n = 5, P = NS). (K–M) Quanti"cation of the thickness of the 
outer nuclear layer (ONL), outer plexiform layer (OPL), and inner nuclear layer (INL), showing no thinning of these retinal layers (a sign of neuroxocity) 
by 3PO (mean ± SEM, n = 5, P = NS). (N) Plasma creatine kinase levels showing similar levels after 3PO treatment (50 mg/kg/day for 15 d), suggesting 
normal cardiomyocyte viability (mean ± SEM, n = 10, P = NS). (O) White blood cell counts (WBCs) after treatment with the chemotherapeutics, cisplatin, 
capecitabine, doxorubicin, and the anti-angiogenic agent sorafenib at doses inhibiting tumor growth and angiogenesis, showing that 3PO aggravated 
the myelosuppressive toxicity only for cisplatin and sorafenib at a single time point, but WBCs in all 3PO-treated mice fully recovered (mean ± SEM; n = 5; 
*P < 0.05 vs. ctrl; &P < 0.05 vs. day 0).
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non-metabolizable glucose analog 2-deoxy-
D-glucose, is indeed more toxic, inducing 
cellular distress and killing ECs, ultimately, 
in particular in sprouting conditions.5
In this respect, it is also noteworthy 
that only <2.5% of the total ATP in the 
body is produced by glycolysis,15 thus 
implying that most other cells rely on 
non-glycolytic mechanisms for energy 
homeostasis and that blocking glycolysis 
(certainly when only transiently and par-
tially) should not necessarily be expected 
to cause widespread cellular demise. In 
contrast, proliferating ECs, tumor cells16,17 
and activated T cells18 critically rely on 
high glycolysis levels. Hence, 3PO inhib-
ited their proliferation, thereby reducing 
pathological neovascularization, as well 
as tumor growth and inflammatory dis-
eases.18,19 Our findings are also consistent 
with reports that human hereditary muta-
tions in glycolytic genes are well tolerated 
as long as they do not deplete cellular ATP 
levels.20 Careful assessment of potential 
toxicity and identification of possible con-
tra-indications will nevertheless be critical 
to design anti-angiogenic therapy based 
on partial, transient glycolysis inhibition.
Experimental Methods
Cell culture
Primary cells
Human umbilical vein endothelial cells 
(HUVECs) were freshly isolated from 
different donors and cultured as described.4 
Murine hepatocytes were isolated using 
a 2-step collagenase perfusion technique 
and fixed after short-term culture for 6 h, 
as described.21 Murine macrophages were 
collected from the peritoneal cavity and 
cultured in RPMI (Invitrogen, Life Tech-
nologies) containing 10% FBS. Murine 
adipocytes were isolated from epididymal/
gonadal fat pads using 0.1% collagenase 
II, separated from the stromal vascular 
fraction via centrifugation, and were cul-
tured in DMEM/F12 supplemented with 
10% FBS.22 Neuronal cultures were pre-
pared from the cortices of embryonic day 
14 (E14) mice and maintained in serum-
free NeuroBasal medium (Gibco) contain-
ing 25 mM glucose.23 After 4 d in culture, 
8 µM cytosine arabinoside was added to 
prevent non-neuronal proliferation.
Tumor cell lines
CT2A murine glioblastoma cells were 
cultured in DMEM containing 10% FBS 
and 2 mM glutamine (Invitrogen, Life 
Technologies) supplemented with condi-
tioned medium obtained from CT2A cells. 
Murine endothelial cells, infected with an 
ecotropic retrovirus encoding SV40 large 
T 58–3 allele (MS1 hemangioma) and sub-
sequently infected with a second retrovirus 
encoding activated H-ras (SVR angiosar-
coma) were obtained from Dr Arbiser and 
cultured in DMEM with glutamine and 
10% FBS.24 All cells were routinely main-
tained in 5% CO2 and 95% air at 37 °C. 
Knockdown strategies
Transduction of lentiviral vectors 
encoding a PFKFB3 or a scrambled con-
trol shRNA were performed as described.4
In vitro assays
Live cell imaging
GFP+ control and PFKFB3-silenced 
ECs were plated on a glass bottom 24-well 
plate and images were acquired continu-
ously overnight at 37 °C using a Zeiss 
LSM 510 Meta NLO confocal microscope 
(LD Plan-Neofluor 20´/0.4 Korr M27 
objective). 
Proliferation and survival
Proliferation was quantified using 
[3H]-thymidine incorporation4 and sur-
vival was measured by determining the 
LDH release in the medium using the 
Cytotoxicity Detection Kit (Roche applied 
sciences). 
Glycolysis
Flux through glycolysis was deter-
mined as described.4
In vivo assays
Housing of mice and experimental 
procedures were approved by the Animal 
Care and Use Committee of the Univer-
sity of Leuven. 
Mouse mosaics
Chimeric pups were generated by 
injecting 15–20 wild-type or PFKFB3KO 
ES cells, stably transfected with mCherry, 
into CD-1 or FVB host blastocysts. 
Injected blastocysts were transplanted into 
2.5 d pseudopregnant CD-1 foster moth-
ers and allowed to develop to term. Aortas 
were dissected at postnatal day 5, fixed in 
4% PFA, mounted as an open book prepa-
ration (by making a longitudinal section to 
spread open the inner surface of the aorta), 
and stained for anti-Erg (Santa Cruz Bio-
technology) and isolectin GS-IB4-Alexa 
488 (Molecular Probes).4 Images were cap-
tured with a Zeiss laser scanning LSM 780 
microscope (Carl Zeiss). 
Analysis of systemic effects
General
C57BL/6 mice (Charles River) were 
used in all experiments. Adult (8-wk-old) 
mice were treated intraperitoneally with 
3PO for 15 d (50 mg/kg/day; dissolved 
in DMSO). Organs (heart, liver, intes-
tines, brains, lungs, kidneys, muscle, eyes) 
were dissected, embedded in paraffin, 
and stained with H&E and for CD105 
(endoglin), CD31, CD45, or GFAP as 
Table 2. E!ects of 3PO on glycolysis, survival and proliferation of cells
Cell type Glycolysis E!ects of 3PO on
Glycolysis Survival (%)
Q
ui
es
ce
nt
neurons 651 ± 50 658 ± 65 109 ± 11
macrophages 367 ± 34 428 ± 16 121 ± 7
adipocytes 199 ± 13 120 ± 7* 107 ± 2
hepatocytes 219 ± 24 146 ± 11* 110 ± 15
Glycolysis Proliferation (%)
Pr
ol
ife
ra
tin
g HUVECs 1800 ± 37 1280 ± 57* 79 ± 2*
hemangioma (MS1) 3300 ± 60 2100 ± 43* 40 ± 3*
angiosarcoma (SVR) 6350 ± 288 3780 ± 23* 64 ± 1*
glioblastoma (CT2A) 4780 ± 110 3530 ± 67* 66 ± 3*
Data show the effect of 3PO treatment (20–40 µM) on glycolysis (nmol glucose/hr/mg protein) and 
survival (LDH release in medium; % of control) or proliferation (3H-thymidine incorporation; % of con-
trol) in different quiescent and proliferating cells. Values are mean ± SEM, n = 5 for adipocytes and 
hepatocytes, n = 4 for neurons and n = 3 for all other cell types. *P < 0.05 vs. glycolysis in control 
conditions.
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described.25,26 Crypt stem cell prolifera-
tion was assessed after BrdU injection and 
expressed as BrdU+ crypt cells relative 
to the total number of crypt cells. Gen-
eral morphology was examined on H&E 
stained sections and quantification of the 
vascular area, retinal layer thickness,26 
GFAP+, CD31+, CD105+, and CD45+ area 
was done using NIH Image J and AxioVi-
sion (Carl Zeiss) software packages. Daily 
i.p. injections of 3PO resulted in the for-
mation of precipitates, which caused local 
peritoneal inflammation beyond 2 wk. 
Hematological profiling
Hematological profiling was performed 
using Cell Dyn 3700 equipment (Abbott 
Diagnostics). Plasma measurements of 
renal, liver and heart parameters were per-
formed in the clinical laboratory of the 
university hospital of Leuven. 
Cytotoxicity agent
Mice were treated with single doses of 
cisplatin or doxorubicin via i.p. injection 
(7 mg/kg). Capecitabine (250 mg/kg) and 
sorafenib (30 mg/kg) were provided daily 
via gavage. 3PO treatment was started 
the first day after initiation of cytotoxic 
therapy. Blood samples were obtained for 
hematological profiling at day 0, 3, 7, 10, 
14, and 17 d. 
Vessel leakiness
Mice were injected daily with 3PO (50 
mg/kg/day) for 4 d. For analysis of vessel 
leakiness, Evans blue (16 h) or FITC dex-
tran (10 min; MW 40 000) was injected 
into the tail vein after which mice were 
euthanized and organs dissected. Evans 
blue leakiness in organs was quantified 
spectrophotometrically after formamide 
based extraction of the dye. FITC dextran 
leakiness outside the vessels was quanti-
fied on cryosections counterstained for the 
blood vessel marker CD105. 
Vessel perfusion
Vessel perfusion in the retinal vascu-
lature was determined after retrobulbar 
FITC dextran injection (3PO treatment: 
50 mg/kg/day for 15 d). All analyses were 
done with NIH ImageJ and AxioVision 
(Carl Zeiss) software packages.
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Fatty acid carbon is essential for dNTP
synthesis in endothelial cells
Sandra Schoors1,2*, Ulrike Bruning1,2*, Rindert Missiaen1,2, Karla C. S. Queiroz1,2, Gitte Borgers1,2, Ilaria Elia3,4,
Annalisa Zecchin1,2, Anna Rita Cantelmo1,2, Stefan Christen3,4, Jermaine Goveia1,2, Ward Heggermont5, Lucica Godde¨1,2,
Stefan Vinckier1,2, Paul P. Van Veldhoven6, Guy Eelen1,2, Luc Schoonjans1,2, Holger Gerhardt7,8,9, Mieke Dewerchin1,2,
Myriam Baes10, Katrien De Bock1,2,11, Bart Ghesquière1,2, Sophia Y. Lunt12, Sarah-Maria Fendt3,4 & Peter Carmeliet1,2
Themetabolism of endothelial cells during vessel sprouting remains poorly studied. Herewe report that endothelial loss
of CPT1A, a rate-limiting enzyme of fatty acid oxidation (FAO), causes vascular sprouting defects due to impaired pro-
liferation, not migration, of human andmurine endothelial cells. Reduction of FAO in endothelial cells did not cause energy
depletion or disturb redox homeostasis, but impaired de novo nucleotide synthesis for DNA replication. Isotope labelling
studies in control endothelial cells showed that fatty acid carbons substantially replenished the Krebs cycle, and were
incorporated into aspartate (a nucleotide precursor), uridine monophosphate (a precursor of pyrimidine nucleoside
triphosphates) and DNA. CPT1A silencing reduced these processes and depleted endothelial cell stores of aspartate and
deoxyribonucleoside triphosphates. Acetate (metabolized to acetyl-CoA, thereby substituting for the depleted FAO-
derived acetyl-CoA) or a nucleoside mix rescued the phenotype of CPT1A-silenced endothelial cells. Finally, CPT1
blockade inhibited pathological ocular angiogenesis in mice, suggesting a novel strategy for blocking angiogenesis.
Angiogenesis relies on the proliferation and migration of endothelial
cells1. The importance of endothelial cell proliferation for expansive
growth of the vascular network has long been recognized2.While numer-
ousmolecules regulating vessel sprouting have been identified3, little is
knownabout the roleofmetabolism.We recently reported that endothe-
lial cells generate 85% of their ATP for vessel sprouting via glycolysis4.
Fatty acid oxidation (FAO) has been linked in various cell types to ATP
productionand toROS scavengingduring cellular stress, but apart from
a few earlier in vitro reports5, the role and importance of FAO in endo-
thelial cells during angiogenesis in vivo is undefined.
By shuttling long-chain fatty acids intomitochondria, carnitine pal-
mitoyltransferase 1 (CPT1) constitutes a rate-limiting step of FAO.
Oxidation of palmitate generates acetyl-CoA,which fuels theTCAcycle.
Apart from generating ATP, the TCA cycle also provides precursors for
macromolecule synthesis, necessary for proliferation. However, fatty
acids have not yet been shown to function as carbon sources for biosyn-
thetic processes. Here we elucidated the role of FAO in endothelial cells
during angiogenesis, and studied how FAO determines endothelial cell
behaviour.
FAO stimulates vessel sprouting via EC proliferation
To study the role ofmitochondrial FAO in vessel sprouting, we silenced
CPT1A, the most abundant CPT1 isoform in human umbilical venous
endothelial cells (HUVECs), which lowered levels of CPT1A mRNA
and protein and reduced FAO flux (Extended Data Fig. 1a–f). In
contrast, silencing of CPT1C, expressed at lower levels (Extended
Data Fig. 1a), did not affect FAO (Extended Data Fig. 1g). As similar
data were obtained in other endothelial cell subtypes (Extended Data
Fig. 1d, h), we used HUVECs (hereafter referred to as endothelial cells
(ECs)) for our study.
In EC spheroids, CPT1A silencing (CPT1A knockdown
(CPT1AKD)) decreased vessel sprout length and numbers (Fig. 1a–c
and Extended Data Fig. 1i). This defect was due to decreased EC
proliferation, as CPT1AKD reduced proliferation and had only min-
imally additive effects on mitomycin-C-treated mitotically inacti-
vated ECs (Fig. 1c–f and Extended Data Fig. 1i, j). By contrast,
CPT1AKD did not affect EC migration or motility (Fig. 1g–i and
Extended Data Fig. 1k). Similar results were obtained when silencing
long-chain acyl-CoA dehydrogenase (ACADVL), another FAO gene
(Extended Data Fig. 1l–o). Additional evidence for a role of FAO in
vessel sprouting was provided by overexpression of CPT1A
(CPT1AOE), which yielded opposite results to those obtained by
CPT1AKD (Extended Data Fig. 1p–t). Thus, CPT1A-driven FAO reg-
ulates EC proliferation during vessel sprouting.
To study the effects of endothelial CPT1A deficiency on vessel
formation in vivo, we used Cpt1alox/lox mice intercrossed with VE-
cadherin(PAC)-CreERT2 mice (CPT1ADEC mice) (Extended Data Fig.
1u). Isolectin-B4 staining of retinal vessels of transgenic pups at post-
natal day (P) 5 revealed that EC loss of CPT1A diminished the num-
ber of vascular branch points, and reduced radial expansion of the
vascular plexus (Fig. 2a–e). This was not caused by increased vessel
regression (Fig. 2f–h) but by reduced EC proliferation (Fig. 2i–k).
Furthermore, CPT1ADEC mice had normal numbers of filopodia
(Fig. 2l–n) and vessel maturation (Fig. 2o, p and Extended Data Fig.
1v). Thus, impaired angiogenesis in CPT1ADEC mice was due to EC
proliferation defects.
*These authors contributed equally to this work.
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Figure 1 | FAO stimulates vessel sprouting via EC proliferation.
a, b, Representative images (original magnification, 103) of control (Ctrl) and
CPT1AKD EC spheroids. c, Total sprout length in control and CPT1AKD EC
spheroids treated with mitomycin C (MitoC) where indicated (n5 3). d, [3H]
thymidine incorporation inDNA in control andCPT1AKDECs (n5 5). d.p.m.,
disintegrations per minute. e, f, Representative images (original magnification,
103) of MitoC-treated control and CPT1AKD EC spheroids. g, Number of
MitoC-treated control and CPT1AKD ECs that traversed a Boyden chamber
(n5 4; P5NS). h, Scratch wound assay using MitoC-treated control and
CPT1AKD ECs (n5 4; P5NS). i, Lamellipodia area in control and CPT1AKD
ECs (n5 4; P5NS). Data are mean6 s.e.m. of n independent experiments.
Statistical test: mixed models (c, d, g–i). NS, not significant. *P, 0.05,
***P, 0.001, ****P, 0.0001.
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Figure 2 | CPT1A gene deletion in ECs causes vascular defects in vivo.
a, b, Representative images (original magnification,320) of retinal vessels of
wild-type (WT; a) andCPT1ADEC (b) mice. c, d, Branch point quantification in
WT and CPT1ADEC mice in the front (c) and rear (d) of the retinal vasculature
(5 litters, n5 11 pups forWTandCPT1ADEC). e, Retinal vascular outgrowth in
wild-type and CPT1ADEC mice (6 litters, n5 13 pups for WT and 18 for
CPT1ADEC). f, g, Representative images (original magnification, 203) of the
retina stained for isolectin-B4 (green) and collagen IV (red) in WT (f) and
CPT1ADEC mice (g). h, Quantification of isolectin-B42 collagen IV1 empty
sleeves in WT and CPT1ADEC pups (4 litters, n5 8 pups for WT and 14 for
CPT1ADEC; P5NS). i, j, Representative images (original magnification, 103)
of retina stained for EdU (red) and isolectin-B4 (green) in WT (i) and
CPT1ADEC (j) mice. k, Quantification of EdU1 ECs in WT and CPT1ADEC
mice (3 litters, n5 9 pups for WT and 6 for CPT1ADEC). l, Quantification of
filopodia inWT and CPT1ADEC mice (6 litters, n5 20 pups forWT and 16 for
CPT1ADEC; P5NS). m, n, Representative images of filopodia (original
magnification, 633) in WT (m) and CPT1ADEC (n) mice. o, p, Representative
images (original magnification, 203) of the retinal vasculature of WT (o) and
CPT1ADEC mice (p) stained for isolectin-B4 (blue) and the pericyte marker
NG2 (pink). Data aremean6 s.e.m. of n individual mice. Statistical test: mixed
models (c–e, h, k, l). NS, not significant. *P, 0.05, **P, 0.01, ***P, 0.001.
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CPT1AKD does not cause ATP or redox imbalance
To explore by which mechanism FAO regulates EC proliferation, we
studied whether CPT1AKD impaired EC proliferation by causing ener-
gy stress due toATPdepletion.However, CPT1AKDdid not lowerATP
levels, nor did it affect the energy charge or ADP/ATP ratio (Fig. 3a, b
and ExtendedData Fig. 2a). This was not surprising, as FAOgenerated
only 5% of the total amount of ATP in ECs4. Oxygen consumption
(OCR) coupled to ATP synthesis was modestly reduced (Fig. 3c), but
could not explain the sprouting defect, as blockingmitochondrial ATP
production with oligomycin failed to affect sprouting of control and
CPT1AKD ECs, suggesting that CPT1AKD impaired sprouting inde-
pendently of mitochondrial ATP production (Fig. 3d and Extended
Data Fig. 2b). Additional experiments confirmed that CPT1AKD ECs
were not in energy stress (Extended Data Fig. 2c, d).
We also explored whether CPT1AKD impaired vessel sprouting by
altering redox balance. CPT1AKD increasedROS levels by only 20%, an
increase reported to enhance EC proliferation6, without affecting the
percentage of oxidized glutathione or disturbing redox homeostasis
(Fig. 3e, f). Furthermore, lowering ROS levels by usingN-acetyl-cysteine
(NAC) did not restore vessel sprouting upon CPT1A silencing (Fig. 3g
andExtendedData Fig. 2e). Finally, CPT1AKDdid not compromise EC
survival and did not increase levels of oxidative DNA damagemarkers
(Extended Data Fig. 2f–j). Thus, CPT1AKD did not impair vessel sprout-
ing by inducing toxic ROS levels.
FAO is used for de novo synthesis of nucleotides
We thus considered a novel role for FAO in EC proliferation and
explored whether FAO regulated the production of biomass building
blocks. Supplementing EC monolayers with [U-13C]palmitate or an
algal [U-13C]fatty acid mix revealed that carbons from fatty acids
provided a substantial fraction of the total carbon fuelling the TCA
cycle intermediates and TCA-cycle-derived amino acids; this fraction
was similar to the contribution of carbons from glutamine and glyco-
lytic carbon (Fig. 4a–c)7. Thiswas unexpected asmany cancer cell types
rely almost exclusively on glucose and glutamine to fuel the TCA
cycle8. CPT1AKD also lowered the cellular pool size of citrate, aspartate
and glutamate (Fig. 4d).
Since TCA intermediates are used for the synthesis of biomass pre-
cursors, and inhibition of FAO limited the supply of these TCA inter-
mediates, we explored whether CPT1AKD impaired protein and/or
nucleotide synthesis. CPT1AKD did not, however, impair de novo pro-
tein synthesis (Fig. 4e) and did not consistently alter intracellular
amino acid levels (Fig. 4d). Also, CPT1AKD still lowered EC prolifera-
tion when protein synthesis was reduced by cycloheximide (Fig. 4f),
suggesting that a decrease of de novo protein synthesis did not prevent
CPT1A silencing to establish its proliferation defect.
Given that aspartate is a precursor of nucleotides and its levels were
reduced upon CPT1AKD, we explored whether fatty-acid-derived
carbons were used for de novo ribonucleotide synthesis. Label from
[U-14C]palmitate was incorporated into RNA in control ECs, and this
process was decreased uponCPT1AKD (Fig. 4g). However, despite this,
CPT1AKD ECs did not have reduced RNA levels and pools of ribonu-
cleotides (rNTPs) (Fig. 4h, i), presumably because of compensatory
production by salvage pathways. Thus, insufficient RNA synthesis did
not cause the proliferation defect of CPT1AKD ECs.
We therefore assessed whether impaired de novo deoxyribonucleo-
tide synthesis caused the proliferation defect of CPT1AKD ECs. Label
from [U-14C]palmitatewas incorporated intoDNA, and thiswas reduced
upon CPT1A silencing (Fig. 4j). As CPT1AKD also decreased de novo
DNA synthesis (Fig. 1d), we hypothesized that FAO blockade reduced
aspartate levels and thereby compromised de novo deoxyribonucleo-
tide biosynthesis. Indeed, labelled carbons from[U-13C]palmitatewere
incorporated in the pyrimidine precursors uridine monophosphate
(UMP) and uridine-59-triphosphate (UTP), and this incorporation was
reduced upon CPT1A silencing (Fig. 4k, l and Extended Data Fig. 3a).
Moreover, quantification of deoxyribonucleotide (dNTP) levels con-
firmed that CPT1AKD lowered the intracellular levels of all pyrimidine
(dCTP,dTTP)andpurinedeoxyribonucleotides (dATP,dGTP)needed
for DNA replication (Fig. 4m). Thus, in contrast to the retained rNTP
levels, CPT1AKD depleted the pool of dNTPs.
To functionally confirm that the effect of CPT1AKD depends on
reduced de novo nucleotide synthesis, we inhibited de novo synthesis
of nucleotides bymethotrexate (MTX) and 5-fluorouracil (5FU), which
reduced vessel sprouting in control but did not further reduce vessel
sprouting in CPT1AKD cells (Fig. 4n, o and Extended Data Fig. 3b, c).
Thus, CPT1AKD reduced sprouting mainly via inhibition of de novo
deoxyribonucleotide synthesis.
To confirm the role of fatty-acid-derived carbons for nucleotide syn-
thesis,we supplementedCPT1AKDcellswith acetate (which is converted
to acetyl-CoA that can fuel the TCA cycle). Treatment ofCPT1AKDECs
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with acetate completely restored the levels of aspartate and dNTPs
(Fig. 5a, b). Furthermore, CPT1AKD and control cells incorporated com-
parable amounts of [U-13C]acetate into UMP and UTP (Fig. 5c, d).
Functionally, acetate rescued the sprouting defect of CPT1AKD ECs
(Fig. 5e andExtendedDataFig. 3d–g).Also, blockadeof theATP synthase
did not prevent this rescue, indicating that acetate was not used for the
production of ATP but instead for the synthesis of biomass (Extended
Data Fig. 3h, i).
Supplementation of amix of nucleosides or dNTPs also fully rescued
the sprouting defect of CPT1AKD vessels, indicating that FAO block-
ade impaired nucleotide synthesis (Fig. 5f and ExtendedData Fig. 3j, k).
Notably, acetate or the nucleoside mix were unable to rescue the
CPT1AKD sprouting defect upon mitotic inactivation of CPT1AKD
ECs, indicating that their effect relied on stimulating EC proliferation
(Extended Data Fig. 3l; not shown). Thus, CPT1A-driven FAO is crit-
ical for de novo deoxyribonucleotide synthesis to ensure EC prolifera-
tion during sprouting.
Glucose partly compensates for FAO loss
Nucleotides can also be synthesized from glucose and glutamine9, so
we asked whether ECs would compensate for the loss of FAO using
these nutrients. CPT1AKD increased the oxidation of glucose but not
of glutamine (Extended Data Fig. 3m, n), and increased glycolytic
carbon incorporation into citrate and aspartate, whereas glutamine
incorporation into citrate and aspartate was not (citrate), or only
negligibly (aspartate), altered (Fig. 5g and Extended Data Fig. 3o).
The relative activity of pyruvate dehydrogenase and pyruvate carbox-
ylase was increased in CPT1AKD ECs (Fig. 5h–j), which can contribute
to the increase in glucose oxidation. Nonetheless, this compensation
was insufficient to rescue the proliferation defect of CPT1AKD ECs,
indicating that fatty acids are irreplaceable forDNA replication in ECs.
Most cells do not use fatty acids for DNA synthesis
To assess the broader relevance of the role of FAO in deoxyribonucleo-
tide synthesis, we studied [U-13C]palmitate contribution to citrate in a
panel of normal and malignant proliferating cells. Fibroblasts (and to a
certain extent pericytes) but no other primary cells incorporated sub-
stantial amounts of fatty-acid-derived carbon into citrate (Fig. 6a). Except
for breast cancer (T47D, MCF7) and lung cancer (A549) cell line
(known to rely on FAO for ATP and NADPH production10), fatty
acids contributed minimally to citrate production (Fig. 6a). Notably,
even when these cancer cells incorporated fatty-acid-derived carbons
into citrate, they incorporated them to a much lesser extent into DNA
(Fig. 6b), implying that fatty-acid-derived carbons entering the TCA
b
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cyclewere used for other purposes thandeoxyribonucleotide synthesis.
In fact, only fibroblasts incorporated similar amounts of fatty-acid-
derived carbons into DNA to ECs (Fig. 6b).
Inhibition of CPT1A impairs angiogenesis
Pharmacological agents with FAO-blocking activity are being used
clinically11. To explore whether pharmacological blockade of CPT1
reduced pathological angiogenesis, we used etomoxir, an irreversible
inhibitor of mitochondrial long-chain FAO. Etomoxir reduced FAO
andECproliferation, butnotmigration in vitro (ExtendedDataFig. 4a–c).
In vivo, etomoxir induced similar retinal vascular defects as CPT1A
deficiency in ECs (Extended Data Fig. 4d–g) and reduced pathological
angiogenesis in a model of retinopathy of prematurity (Fig. 6c–e). The
mechanistic model of our findings is represented in Fig. 6f.
Discussion
The novelty of this study relates to several observations. First, FAO is
critical for vessel sprouting in vivo, and the extent of its function is
greater than expected based on earlier reports5. Second, FAO affects
proliferation, not migration, of ECs, which caused vessel sprouting
defects.Unlike PFKFB3-driven glycolysis, which affects ECproliferation
and migration4, FAO selectively regulates EC proliferation, indicating
that distinct metabolic pathways control distinct EC functions during
vessel sprouting. Third, we discovered an unknown role of fatty-acid-
derived carbons in de novo nucleotide synthesis for DNA replication in
ECs. Our results indicate that FAO promotes de novo deoxyribonucleo-
tide synthesis by providing carbons for the production of aspartate and
glutamate. The fact that aspartate is a direct carbon donor for the syn-
thesis of the pyrimidine nucleobase (Extended Data Fig. 3a) and that
the pool of aspartate was reduced in CPT1AKD ECs explains why
pyrimidine dNTP levels were reduced. But aspartate and glutamate
also serve as a nitrogen source for the production of the nucleobase of
pyrimidines and purines. This explains why the synthesis of purine
dNTPs was also impaired upon FAO blockade. Interestingly, of other
primary andmalignant cell types tested, only ECs and fibroblasts used
substantial amounts of fatty acid carbons for DNA synthesis, even
though certain cancer cell lines incorporated fatty-acid-derived car-
bons in the TCA cycle.
Fatty acids were irreplaceable for DNA synthesis, but not for protein
andRNAsynthesis.Apossibility is thatCPT1AKDECsmaintainedRNA
levels by producing rNTPs via nucleotide salvage. Indeed, quiescent/
hypo-proliferative cell types (CPT1AKDECs are hypo-proliferative) rely
primarily on nucleotide salvage rather than on de novo nucleotide syn-
thesis to synthesize RNA12. By contrast, proliferating cells switch on de
novo synthesis of dNTPs to duplicate their DNA genome13. Support for
the notion that ECs use nucleotide salvage primarily for RNAsynthesis
is provided by evidence that incorporation of carbons from hypox-
anthine (a nucleotide salvage intermediate) was higher in RNA than
DNA (Extended Data Fig. 3p). This may explain why FAO blockade
affected dNTPs levels but not rNTP levels. A recent study on the role of
pyruvate kinase isoenzymes documented that PKM1 expression reduced
incorporation of 13C label from [U-13C]glucose and [U-13C]glutamine in
UMPanddecreaseddNTP levels and cell proliferation, yet didnot alter
rNTP levels14, illustrating that the production of rNTPs and dNTPs is
regulated differently.
Fourth, we identified that fatty-acid-derived carbons entering the
TCAcycle are used for biomass production. Thiswas unexpected since
evidence in rapidly proliferating cancer cells indicated that glucose and
glutamine are used as the primary carbon source for de novo deoxyr-
ibonucleotide synthesis8,14. The utilization of fatty acids for biomass
production is, however, not unprofitable. Indeed, given that fatty acids
are amuch richer carbon source than glucose or glutamine, use of fatty
acids is an efficient mechanism to generate nucleotides. Finally, phar-
macological CPT1 blockade reduced pathological angiogenesis, which
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may hint at an underappreciated therapeutic potential of lowering
FAO for the inhibition of pathological angiogenesis.
Online ContentMethods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
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Figure 6 | Most other cell types do not use fatty acid carbons for dNTP
synthesis, and inhibition of CPT1A impairs angiogenesis. a, Total
contribution of [U-13C]palmitate to citrate in various primary cells and cancer cell
lines, expressed relative to the value in ECs (n59 for ECs, n5 8 for pericytes
(Per), n56 for T cells, B16, A549 and 143B, n55 for Panco2, n5 4 for DU145,
T47D and MDA, n5 3 for fibroblasts (Fib), ES cells, HCT, CT2A, U87 and
MCF7). b, Contribution of [U-14C]palmitate to DNA, expressed relative to the
value in ECs (n5 14 for ECs, n56 for pericytes (Per), n5 5 for B16, Panco2 and
A549, n54 for fibroblasts (Fib), T47D, 143B and T cells, n5 3 for HCT, MDA,
DU145, U87, CT2A, MCF7 and ES cells). c, d, Representative images (original
magnification, 103) of retinal flat-mounts of retinopathy of prematurity (ROP)
mice treated with vehicle (c) or etomoxir (Eto) (d). e, Vascular tuft area in control
and etomoxir-treated pups (n5 13 for WT and 9 for etomoxir). f, Mechanistic
model. Top, control ECs: uptake of palmitate and FAO in ECs are not essential for
the production ofATP andNADPH (indicated in the shaded box), but fatty-acid-
derived carbons are incorporated in amino acids, and in precursors of rNTPs and
dNTPs; how critically these pathways regulate ECproliferation cannot be assessed
in control cells (denoted by question mark). Bottom, CPT1AKD ECs: silencing of
CPT1A reveals, however, that decreasing FAO depletes dNTP pools, without
affecting rNTPandprotein synthesis, implying that fatty acids are irreplaceable for
DNA synthesis; since de novo synthesis of dNTPs is critical for DNA replication,
CPT1A silencing impairs EC proliferation. Data are mean6 s.e.m. of
n independent experiments (a, b) or the total number of mice (of 4 litters)
(e). Statistical test: two-sided t-test (a, b); mixed models (e). NS, not significant.
*P,0.05, **P, 0.01, ***P,0.001, ****P, 0.0001.
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 METHODSChemicals and reagents. Collagen type 1 (rat tail) was from Millipore or from
PureCol (bovine) (AdvancedBiomatrix,USA).TheCPT1A inhibitor (1)-etomoxir
sodium salt hydrate was purchased fromCNIOCarlos III Therapies. Mitomycin C
(MitoC), sodiumpalmitate, dimethyl sulfoxide (DMSO),N-acetyl-cysteine (NAC),
sodium acetate, oligomycin, cycloheximide, cytidine, adenine, guanosine, metho-
trexate, carnitine, dNTP mix and tamoxifen were from Sigma-Aldrich (Bornem,
Belgium). 5-fluorouracil (TEVAPharmaBelgium)was obtained from the pharmacy
of the university hospital Leuven. Nucleoside mix was from Millipore (Belgium)15.
Hoechst 33342 and L-homopropargylglycine (HPG) were fromMolecular Probes
and L-glutamine and penicillin/streptomycin were from Gibco (Invitrogen, Life
Technologies, Ghent, Belgium). Uniformly labelled [U-13C]potassium palmitate,
[U-13C]acetate, [U-13C]glucose, [U-13C]glutamine and [U-13C]algal fatty acid
mix were obtained from Cambridge isotope laboratories, Inc. [U-14C]palmitate,
[9,10-3H]palmitate, [6-14C]-D-glucose, [8-14C]-hypoxanthine and [3H]-thymidine
were from Perkin Elmer.
Cell culture. Primary cells: humanumbilical vein endothelial cells (HUVECs)were
freshly isolated from different donors as described16 (with approval of medical
ethical committee KU Leuven/UZ Leuven and informed consent obtained from
all subjects), regularly tested for mycoplasma and used between passage 1 and 5.
HUVECs were cultured in M199 medium (1mg ml21 D-glucose) from Gibco
(Invitrogen, Life Technologies, Ghent, Belgium) supplemented with 20% fetal
bovine serum (FBS) Biochrom GmbH (Germany), 2mM L-glutamine, 30mg l21
endothelial cell growth factor supplements (EGCS), 10unitsml21 heparin (Sigma),
100 IUml21 penicillin and 100mg ml21 streptomycin or in endothelial basal
medium (EBM-2) supplemented with endothelial growth medium SingleQuots
(Promocell, Germany). In all experiments, HUVECs were always used as single-
donor cultures. Human aortic ECs (HAECs) and adult human dermal blood micro-
vascular ECs (HMVEC-dBlAd) were either from Clonetics, Lonza (Braine-l’Alleud,
Belgium) or isolated from umbilical cords for arterial ECs or from placenta for
microvascular ECs, and were cultured in the recommended medium supplemented
with SingleQuots (EGM-2 or EGM-2 MV; Clonetics, Lonza, Braine-l’Alleud,
Belgium). Human pericytes were isolated from human placenta using
gentleMACS tissue dissociator (Miltenyi Biotec) and incubation with collagenase
0.2% (GIBCO) and DNase 80Uml21 (Life technologies) for 30min at 37 uC
followed by Percoll gradient 5 (GE Healthcare) centrifugation, or from human
adipose tissue using collagenase 0.2% in 0.9% NaCl and 2mM CaCl2 for 1 h at
37 uC. Thereafter, the cell suspension was immunomagnetically sorted by using
CD31 and CD146 antibodies conjugated with microbeads (Miltenyi Biotec).
CD1461CD312 sorted cellswere seeded inaMEMplus 10%FBSand5 nMplatelet
derived growth factor-BB (PDGF-BB). Human T cells: peripheral blood mono-
nuclear cells (PBMCs) were isolated from whole blood by Ficoll-Paque Plus
(Amersham Biosciences) density gradient centrifugation. PBMCs were collected,
washed with cold PBS and subsequently used for naive T-cell isolation. Naive
T-cells were isolated with a pan T-cell isolation kit (MACS Myltenyi Biotec).
After isolation, naive T cells were seeded in plates coated with anti-CD3 antibody
(5mgml21), and anti-CD28 (0.5mgml21) and IL-2 (10 ngml21) were added to the
medium. All cell preparations were used in experiments as single donor cultures.
Murine fibroblasts were freshly isolated from lungs of FVBmice and cultured and
used between passage 1 and 5. Briefly, dissected lungs were chopped and digested
in a solution of 2mgml21 collagenase (Sigma blend L, Sigma-Aldrich) in RPMI
media from Gibco (Invitrogen, Life Technologies, Ghent, Belgium) containing
2.5% fetal bovine serum (FBS), 10mM HEPES, 2mM glutamine, 100 IUml21
penicillin and 100mgml21 streptomycin (5ml per lung) for 1 h at 37 uC.
Organoids were pelleted at 1,100 r.p.m., washed four times with digestion solution
and then plated into standard tissue culture flasks in DMEM/F12 medium from
Gibco (Invitrogen, Life Technologies, Ghent, Belgium) containing 5% fetal bovine
serum(FBS), 2mMglutamine, 100 IUml21 penicillin and 100mgml21 streptomy-
cin. The day after isolation, the medium was refreshed. Cells were then routinely
maintained in 5% CO2 and 95% air at 37 uC and the medium was replaced every
second day. ES cells: G4 ES cells were routinely passaged every 2–3 days onto
freshly prepared Mitomycin-C-arrested feeder layers, and were re-fed daily with
fresh ES cell culture medium consisting of 500ml Knockout DMEM medium
(Life Technologies) supplemented with 2mM L-glutamine (Life Technologies),
90ml fetal bovine serum (Biochrom BmgH), MEM nonessential amino acids
1003 (GIBCO/Invitrogen), 0.01mM b-mercaptoethanol (Sigma-Aldrich),
1mM sodium pyruvate (GIBCO/Invitrogen), penicillin/streptomycin 1003
(Life Technologies), and 2,000Uml21 leukaemia inhibitory factor (Merck
Millipore). Prior to testing whether ES cells use fatty acids for DNA synthesis they
were replated at least 3 times on gelatinized dishes without any feeders. Doing so,
all feeder cells were selectively removed from the cultures, resulting in 100% pure
undifferentiated ES cell cultures. Tumour cell lines: murine melanoma B16 clone
F10.9 (obtained fromAmerican Type Culture Collection, ATCC; LGC Standards,
Molsheim Cedex, France) and Panco2 murine pancreatic carcinoma cells
(provided by B. Wiedenmann, Charite¨, Berlin, Germany) were cultured in
RPMI containing 10%FBS.MCF7 (human breast cancer),HCT116 (human colon
carcinoma),MDA-MB-468 (human breast carcinoma cells), T47D (human ductal
breast epithelial tumour cells), DU145 (human prostate cancer cells), 143B
(human osteosarcoma cells) and A549 (human lung carcinoma cells) were cul-
tured inDMEMcontaining 10%FBS, 2mMglutamine, 100 IUml21 penicillin and
100mgml21 streptomycin. CT2A murine glioblastoma cells and U87 human
glioblastoma cells were cultured in DMEM containing 10% FBS and 2mM
glutamine (Invitrogen, Life Technologies, Ghent, Belgium) supplemented with
conditioned medium obtained from CT2A or U87 cells.
Knock-down and overexpression strategies. RNA interference: CPT1A silen-
cing was achieved using a validated pool of siRNA duplexes directed against
human CPT1A (Trifekta Kit, IDT) and lipofectamine RNAi Max transfection
reagent (Invitrogen, Belgium) according to the manufacturer’s instructions. A
scrambled siRNA was used as negative control. Lentiviral transductions: for
overexpression of murine CPT1A, the cDNA was cloned in the pRRLsinPPT.
CMV.MCS MMW prevector17. Of note, this increased FAO in some but not all
EC isolations, suggesting that in such cases CPT1A abundance was not limiting
the maximal capacity of FAO. However, whenever FAO was enhanced, sprout
numbers and length of EC spheroids were increased. To generate shRNA vectors
against CPT1A, CPT1C, or ACADVL, oligonucleotides were cloned into the
pLKO-shRNA2 vector (No. PT4052-5; Clontech, Westburg BV, Leusden, The
Netherlands) (for RNA sequences, see below). A nonsense scrambled shRNA
sequence was used as a negative control. Production of lentiviruses by transfec-
tion into 293T cells was performed as described18. For transductions, a multipli-
city of infection (MOI) of 20 was used in all shCPT1A experiments. For
transductions with shACADVL and shCPT1C and for fluorescent ubiquitina-
tion-based cell cycle indicator (FUCCI; see below) and CPT1A overexpression, a
MOI of 10 was used. Cells were transduced overnight and re-fed with fresh
medium the next day. Transduced cells were used in functional assays at least 3
to 4 days after transduction. Of note, similar data were obtained using siRNA and
two non-overlapping shRNAs directed against CPT1A.
In vitro assays. Proliferation was quantified by incubating cells for 2–24h with
1mCiml21 [3H]thymidine. Thereafter, cells were fixed with 100% ethanol for
15min at 4 uC, precipitated with 10% trichloroacetic acid and lysed with 0.1N
NaOH. The amount of [3H]thymidine incorporated into DNA was measured by
scintillation counting. Scratchwoundmigration assay: a scratchwoundwas applied
on confluent EC monolayers (pretreated with MitoC where indicated) using a
200ml tip, 24h after seeding (100,000 cells per well in 24-well plates). After scratch
wounding and photography (T0), the cultures were further incubated in fully sup-
plemented EBM2medium for 6–8 h (until near closure was reached in the control
condition), and photographed again (Tx).Migration distance (gap area atT0minus
gap area at Tx) was measured with NIH Image J software package and is expressed
in arbitrary units. Modified Boyden chamber migration assays were performed
using MitoC-treated (24 h treatment with 2mg ml21 MitoC) ECs. Therefore,
50,000 cells were seeded in fully supplemented EBM2 medium on 0.1% gelatine-
coated transwells. Upon adherence, the transwells were washed and re-fed with
medium containing only 0.1% FBS and transferred to bottom wells containing
mediumwith 0.1%FBS (baseline) or 5%FBS (migration stimulus). Transwellswere
incubated for 16h and processed and analysed for migrated cells as described19.
Lamellipodia formation assay: the number and area of lamellipodia were measured
on still photos of time-lapse recordings of sparsely seededECs, using theAxiovision
morphometric analysis software (Carl Zeiss, Munich, Germany) with in-house
developed macros. Lamellipodia area is expressed in per cent of total cell area.
Directionality of migration was assessed by analysis of the total length of the
migration track of a cell. The directionality value was then calculated by dividing
the distance between the start and end location of the cell by the total track length; a
higher directionality value denotes higher migration directionality. Experiments
were performed with or without genetic shRNA CPT1A silencing. Spheroid capil-
lary sprouting assay: ECs were incubated overnight in hanging drops in EGM-2
medium containing methylcellulose (20 volume% of a 1.2% solution of methylcel-
lulose 4000 cP) (Sigma-Aldrich, Bornem, Belgium) to form spheroids. For mitotic
inactivation, MitoC (2mgml21) was added to this medium. Spheroids were then
embedded in collagen gel as described20 and cultured for 20 h to induce sprouting.
Compounds were added at the following concentrations during the collagen gel
culture step, using corresponding vehicle concentrations as control: 20mM sodium
acetate, 53 nucleosidemix, 10mMNAC, 1.2mMoligomycin, 20mgml21 cyclohex-
imide, 50mgml21 5FU or 20mMMTX. Cultures were fixed with 4% PFA at room
temperature and imaged under bright field using aMotic AE 31microscope (Motic
Electric Group Co Ltd, Xiamen, China) or Leica DMI6000 microscope (Leica
Microsystems, Mannheim, Germany). Analysis of the number of sprouts per spher-
oid and the total sprout length (cumulative length of primary sprouts and branches
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per spheroid) was done on phase contrast images using the NIH Image J software
package. To assess the number of viable versus dead cells, unfixed spheroids were
stained with 500ml of 1/500 dilution of TO-PRO3 (Invitrogen, Life Technologies,
Ghent, Belgium) solution at 37 uC for 10min, washed with PBS and imaged by
confocal microscopy Zeiss LSM 510Meta NLO or Zeiss LSM 780 confocal micro-
scope (objectives: 310 with NA 0.3, 320 with NA 0.4) (Carl Zeiss, Munich,
Germany)21. ATP measurement: analysis of total ATP levels was performed using
a commercially available kit (ATPlite, PerkinElmer). Apoptosis: analysis of apop-
tosis was done by fluorescent staining for cleaved caspase 3 (Cell Signaling
Technology, Bioke¨, Leiden, The Netherlands) in PFA-fixed monolayers.
RNA analysis. RNA expression analysis was performed by Taqman quantitative
RT–PCR as described22 using in-house-designed primers and probes or pre-made
primer sets (Applied Biosystems, Carlsbad, CA and IDT, Belgium). Sequences or
pre-made primer set ID numbers are available upon request. For comparison of
gene expression between conditions, expression (normalized to HPRT endogen-
ous control) is expressed relative to control condition. For comparison between
different genes, absolute expression levels were determined based on respective
cDNA standard curves, and levels are expressed as copies mRNA per 103 copies
HPRT mRNA.
Immunoblot analysis.Protein extractionand immunoblot analysiswereperformed
using a modified Laemmli sample buffer (125mM Tris-HCl, pH6.8 buffer contain-
ing 2% SDS and 10% glycerol)22 or cell lysis buffer (Cell Signaling Technology) in the
presence of protease and phosphatase inhibitors (Roche, Vilvoorde, Belgium).
Lysates were separated by SDS–PAGE under reducing conditions, transferred to
a nitrocellulose or PVDF membrane, and analysed by immunoblotting. Primary
antibodies used were rabbit anti-CPT1A (No. 12252), rabbit anti-lamin A/C (No.
2032), rabbit anti-b-actin (No. 4970), anti-total AMPKa (No. 2532), rabbit anti-
phospho-AMPKa Thr 172 (No. 2531), anti-p21 (No. 2947), anti-phospho-ATM
(No. 5883), anti-total ATM(No. 2873) (Cell SignalingTechnology, Bioke¨, Leiden,
The Netherlands), and anti-total p53 (FL 393, Santa Cruz Biotechnology, The
Netherlands). Autophagy was analysed via western blot determination of LC3
II/I ratio (No. 3868, Cell Signaling Technology) to reveal the on-state of autophagy
(autophagic flux). Equal loading was verified by Ponceau Red staining and lamin
A/C or b-actin as loading controls. Appropriate secondary antibodies were from
Dako (Enschede, The Netherlands). Signal was detected using the ECL system
(AmershamBiosciences, GEHealthcare, Diegem, Belgium) according to theman-
ufacturer’s instructions. Densitometric quantifications of bands were done with
NIH Image J software.
Flow cytometry. Protein/RNA synthesis: protein synthesis was determined by
incubation of cells with a methionine analogue (HPG, Invitrogen) for 24h in full
medium. RNA synthesis was determined by incubation of cells with a uridine ana-
logue (59-ethynyl uridine, EU, molecular probes). Cells were trypsinized, PFA fixed
and incorporated HPG or 59-ethynyl uridine was detected by a Click-IT reaction
with Alexa fluor 647 according to the manufacturer’s instructions. Alexa fluor 647
was excited with a 604-nm red laser and emission was recorded at 660nm using a
BD FACS Canto flow cytometer (Becton Dickinson Benelux NV, Erembodegem,
Belgium). Intracellular ROS analysis: intracellular ROS levels were measured using
theCM-DCFdyeaccording to themanufacturer’s instructions (Invitrogen,Belgium).
For flow cytometry analysis the BD FACS Verse flow cytometer was used. For
assessment of cell number, cells were seeded in a 24-well plate and trypsinized after
48h growth. Cells were re-suspended in 150ml of PBS and 100ml of cell suspension
was countedat a flowrateof 1ml per second.Datawere analysedusingFlowJoanalysis
software.
Metabolism assays. Fatty acid oxidation: ECswere incubated in fully supplemented
EBM2 medium with 100mM unlabelled palmitate and 50mM carnitine. Cells were
incubated for 2 h in growth medium containing 2mCiml21 [9,10-3H]palmitate23,24.
Thereafter, supernatant was transferred into glass vials sealed with rubber stop-
pers. 3H2O was captured in hanging wells containing a Whatman paper soaked
with H2O over a period of 48 h at 37 uC to reach saturation25. Radioactivity was
determined by liquid scintillation counting. Glycolysis was measured analogously
to fatty acid oxidation (cf supra) using 80mCimmol21 [5-3H]-D-glucose (Perkin
Elmer)23. 14C-glucose oxidation: cells were incubated for 6 h in growth medium
containing 100mCimmol21 [6-14C]-D-glucose. Thereafter, 250ml of 2Mperchloric
acidwas added to eachwell to stop cellularmetabolism andwells were immediately
coveredwitha13hyaminehydroxide-saturatedWhatmanpaper.Overnight absorp-
tion of 14CO2 released during oxidation of glucose into the paper was performed
at room temperature, and radioactivity in the paper was determined by liquid
scintillation counting. 14C-glutamine oxidation was performed similarly as glucose
oxidation, except that we used 0.5mCiml21 [U-14C]glutamine as tracer. Palmitate or
hypoxanthine mediated RNA and DNA synthesis was measured by the incorpora-
tion of 14C into RNA or DNA using 100mCimmol21 [U-14C]palmitate or [8-14C]
hypoxanthine and was corrected for the total amount of RNA or DNA per sample.
Total RNA and DNA were isolated using commercially available column-based
DNAandRNAextraction kits (Qiagen) or usingTrizol as an alternative extraction
method for RNA orDNA. ATP coupled oxygen consumption: cells were seeded at
40,000 cells per well on Seahorse XF24 tissue culture plates (Seahorse Bioscience
Europe, Copenhagen, Denmark). The measurement of oxygen consumption was
performedat 10min intervals (2minmixing, 2min recovery, 6minmeasuring) for
3 h using the Seahorse XF24 analyser. For ATP-coupled oxygen consumption,
measurements were performed before and after oligomycin (1.2mM) treatment.
Energy balance assessment: 1.53 106 cells were harvested in ice cold 0.4M per-
chloric acid supplemented with 0.5mMEDTA. pHwas adjusted by adding 100ml
of 2M K2CO3. 100ml of the mixture was injected onto an Agilent 1260 HPLC
equipped with a C18-Symmetry column (1503 4.6mm; 5mm) (Waters), thermo-
stated at 22.5 uC.Flowratewaskept constant at 1mlmin21.A linear gradient using
solvent A (50mM NaH2PO4, 4mM tetrabutylammonium, adjusted to pH5.0
using H2SO4) and solvent B (50mM NaH2PO4, 4mM tetrabutylammonium, 30%
CH3CN, adjusted to pH5.0 using H2SO4) was accomplished as follows: 95%A for
2min, from 2 to 25min linear increase to 100% B, from 25 to 27min isocratic at
100%B, from27 to 29min linear gradient to 95%Aand finally from29 to 35minat
95% A. Detection of ATP, ADP and AMP occurred at 259nm. GSSG/GSH ratio
measurement: samples were collected in 300 ml 5% TCA (trichloro-acetic acid,
Sigma). 50ml was loadedonto anUltimate 3000UPLC (Thermo Scientific, Bremen,
Germany) equippedwithaAcquityUPLCHSST3column(catalogueno. 186003976;
2.135mm; 1.8mmparticles;Waters) in line connected to aQExactivemass spectro-
meter (Thermo Fisher Scientific). A linear gradient was carried out using solventA
(0.05% formic acid) and solvent B (60%methanol, 0.05% formic acid). Practically,
samples were loaded at 99% solvent A and from 10 to 12min a ramp to 100%
solvent Bwas carried out. From15 to 16min the columnreturned to 99% solventA
and the run was stopped at 21min. Elution of GSH and GSSG occurred at 3 and
5.5min, respectively (isocratic separation). Flow rate was constant at 250mlmin21
and the column temperature was kept constant at 37 uC. The mass spectrometer
operated in targeted SIM mode following the ions m/z 311.11456 and 308.59499
(GSH and GSSG, respectively) using the ion 445.12003 as lock mass. The mass
spectrometer ran in positive polarity, the source voltage was 3.0 kV, and the capil-
lary temperature was set at 350 uC. Additional sheath gas flow was put at 35 and
auxiliary gas flow rate at 10. Auxiliary gas heater temperature was put at 60 uC.
AGC target was put at 100,000 ions with amaximum ion injection time of 200ms,
acquired at a resolution of 70,000. For the data analyses we manually integrated the
peaks representing GSH and GSSG using the Thermo XCalibur Qual Browser soft-
ware (Thermo Scientific) and data are represented as area of the respective GSH and
GSSG peaks. Determination of 13C-palmitate, glucose and glutamine incorpora-
tion in metabolites and total metabolite levels: for 13C-carbon incorporation from
palmitate in metabolites, cells were incubated for 48 h with labelled substrates
(confirmation of steady state at that time was confirmed, see Extended Data Fig. 5).
For ECs, [U-13C]palmitate labelling was done in two ways: (1) ‘100% labelling’,
whereby all cold palmitate in M199 culture medium (120 mM) was replaced by
120mM [U-13C]palmitate using M199 medium, containing charcoal stripped
serum(whichdoes not contain any fatty acids); and (2) ‘50/50% labelling’, whereby
100 mM [U-13C] palmitate was added to the EGM2 culture medium containing
100mM cold palmitate. Both types of labelling yielded similar data and were thus
pooled. For comparison with cancer cells, only the 100% labelling strategy was
used. Similar labelling methods were used for glucose (5.5mM) and glutamine
(2mM). Labelling with the algal [U-13C]fatty acid mix was performed by using
100% labelling; this fatty acid mix contained 50mMpalmitate. Metabolites for the
subsequent mass spectrometry analysis were prepared by quenching the cells in
liquid nitrogen followed by a cold two-phase methanol-water-chloroform extrac-
tion7,26. Phase separationwas achieved by centrifugation at 4 uCand themethanol-
water phase containing polar metabolites was separated and dried using a vacuum
concentrator24. The dried metabolite samples were stored at 280 uC (refs 7, 26).
Polar metabolites were derivatized for 90min at 37 uC with 7.5ml of 20mgml21
methoxyamine in pyridine and subsequently for 60min at 60 uC with 15ml of
N-(tert-butyldimethylsilyl)-N-methyl-trifluoroacetamide, with 1% tert-butyldi-
methylchlorosilane7,26. Isotopomer distributions and metabolite levels were mea-
sured with a 7890A GC system (Agilent Technologies) combined with a 5975C
Inert MS system (Agilent Technologies). One microlitre of sample was injected
onto aDB35MScolumn in splitlessmodeusing an inlet temperature of 270 uC(refs 7,
26).The carrier gaswasheliumwith a flowrateof 1mlmin21.Upon injection, theGC
oven was held at 100 uC for 3min and then ramped to 300 uC with a gradient of
2.5 uCmin21. TheMS systemwas operated under electron impact ionization at 70 eV
and a mass range of 100–650 amu (atomic mass units) was scanned. Isotopomer
distributions were extracted from the raw ion chromatograms using a custom
Matlab M-file, which applies consistent integration bounds and baseline correc-
tion to each ion27. In addition, we corrected for naturally occurring isotopes using
the method of Fernandez et al.28. For relative metabolite levels, the total ion count
wasnormalized to the internal standardsnorvaline andglutarate and to the protein
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content7,26. To correct for enrichment dilution, we used previously reportedmeth-
ods7,29; that is, we divided the fractional contribution of a labelled metabolite of
interest by the fractional contribution of its precursor (calculated by the formula
below).
The total contribution of carbon was calculated using the following equation7,29:
total contribution of carbon~
Xn
i~0
i|mi= n
Xn
i~0
mi
 !
where n is the number of C atoms in the metabolite, i represents the different mass
isotopomers and m refers to the abundance of a certain mass. Glycolytic carbon
contribution was calculated based on [U-13C]glucose labelling and label dilution in
pyruvate7. For totalmetabolite levels, arbitrary units of themetabolite of interest were
normalized to the protein content. A time-course experiment of the incorporation of
[U-13C]glucose, [U-13C]glutamineand[U-13C]palmitate inTCAintermediatesdem-
onstrated that the incorporation values reached apseudo-isotopic steady statewithin
experimentalmeasurement precision (ExtendedData Fig. 5).Determination of dNTP
levels by RT–PCR: dNTP levels were determinedby using a fluorescence-based PCR
assay30 using G1 sorted ECs, identified as CherryRed1Venus– cells upon transduc-
tionwith a fluorescent, ubiquitination-based cell cycle indicator (FUCCI) construct31.
Determination of 13C-palmitate or 13C-acetate incorporation inUMP andUTP: cells
were labelled with [U-13C]palmitate (100% labelling with 100 mM [U-13C]palmitate;
see above) or [U-13C]acetate (20mM supplementation with [U-13C]acetate) for
48 h and were then collected in 500ml ice-cold acetonitrile buffer (50% methanol,
30% acetonitrile and 20% water). Samples were spun for 5min and supernatants
were dried down and were then reconstituted in 50ml of HPLC-grade water,
vortexed, centrifuged, and transferred into HPLC vials. LC-MS/MS analysis was
done on aWaters XevoTQ-Smass spectrometrywas coupled to anH-ClassUPLC
system.Metaboliteswere separated bypolarity using a SupelcoAscentis ExpressC18
column (2.7mm particle size, 5 cm3 2.1mm). LC parameters are as follows: auto-
sampler temperature, 5 uC; injection volume, 5ml; column temperature, 50 uC; flow
rate over 11min: t5 0, 0.4mlmin21; t5 2, 0.3mlmin21; t5 3, 0.25mlmin21;
t5 5, 0.15mlmin21; t5 9, 0.4 mlmin21; t5 11, 0.4mlmin21. The LC solvents
were solvent A: 10mM tributylamine and 15mMacetic acid in 97:3water:methanol
(pH 4.95); and solvent B: methanol. Elution from the column was performed over
11minwith the following gradient: t5 0, 0%B; t5 1, 0%B; t5 2, 20%B; t5 3, 20%
B; t5 5, 55%B; t5 8, 95%B; t5 8.5, 95%B, t5 9, 0%B; t5 11, 0% B.Mass spectra
were acquired using negative-mode electrospray ionization operating in multiple
reaction monitoring (MRM) mode. The capillary voltage was 3,000V, and cone
voltage was 50V. Nitrogen was used as cone gas and desolvation gas, with flow rates
of 150 l h21 and 600 l h21, respectively. The source temperature was 150 uC, and
desolvation temperature was 500 uC. Argon was used as collision gas at a manifold
pressure of 4.33 1023mbar. Collision energies and source cone potentials were
optimized for each transition using Waters QuanOptimize software. Data were
acquired and analysed usingMassLynx 4.1 andQuanLynx software. Isotope labelling
data was corrected for the natural abundance of different isotopes using IsoCor32.
Determination of rNTP levels by LC-MS: rNTP was extracted with the same
method as described for UTP and UMP. Additionally, 13C-internal standards
(generated based on fully labelled yeast extracts33) were spiked into the extraction
solution. rNTP concentrations were determined with the same LC-MSmethod as
described for UTP and UMP. All samples were normalized to the 13C-internal
standard and protein content.
Mouse models of ocular angiogenesis. Generation of EC-specific CPT1A con-
ditional knockout mice: for generation of the Cpt1alox/lox mice, loxP sites were
introduced flanking a segment comprising exons 11 and 12 via homologous
recombination in embryonic stem (ES) cells. The targeting vector contained from
59 to 39: a 3.5-kb 59 homology flank, a 2-kb floxedmid-flank consisting of the loxP
flanked exon 11–12 segment, a FRT flanked neomycine resistance (NEO) cas-
sette, a 2.5-kb 39 homology flank. Correctly targeted ES clones were identified by
appropriate Southern blot and PCR analysis, and subjected to transient transfec-
tion with a Flp recombinase expression plasmid to remove the FRT-flanked NEO
cassette. Correctly excised clones were used formorula aggregation, and resulting
chimaeric animals were bred for germline transmission, yieldingCpt1aWT/lox and
eventually Cpt1alox/lox mice. For postnatal EC-specific loss of function studies,
VE-Cadherin(PAC)-CreERT2 mice34 (provided by R. Adams) were intercrossed with
Cpt1alox/loxmice andnamedCPT1ADEC. Correct Cre-mediated excision of the floxed
Cpt1a segment in tamoxifen-treated CPT1ADEC mice was confirmed via PCR ana-
lysis of genomicDNAusing primers spanning the floxed region, by the appearance of
a 300-bp band (Extended Data Fig. 1u). CPT1ADECmice were always compared with
tamoxifen-treatedCre2Cpt1alox/lox littermates (denoted asWT).Analysis of postnatal
retinal angiogenesis: genetic endothelial-cell-specific inactivation of CPT1A in neo-
natal mice was achieved by intraperitoneal injection of 100 mg kg21 tamoxifen
solution (Sigma T5648; dissolved in 1:10 EtOH:corn oil) once daily from postnatal
day (P) 1 to P4 in CPT1ADEC mice. Pharmacological blockade of FAO in neonatal
C57BL/6 WTmice (animal facility KU Leuven) was achieved by treatment with 30–
35mgkg21 etomoxir from P2 to P4. For detection of cell proliferation, EdU
(Invitrogen) was injected 2 h before dissection. At P5, pups were killed and eyes
were enucleated, fixed with 4% PFA for 2 h at 4 uC and prepared for vascular
analysis. As all animal treatments were done in baseline conditions, no randomi-
zation was required. Retinal whole mounts were prepared for vascular analysis as
described4. Only litters for which the WT littermates (for CPT1ADEC mice) or
vehicle-treated littermates (for etomoxir treated mice) reached normal outgrowth
and body weight at P5 were included for analysis. Radial vascular area, branching
points, and number of filopodia were analysed on isolectin GS-IB4 stained retinas
(see below) using the NIH Image J software package and Leica LASAF-MMAF
morphometric analysis software (MetaMorph) (Leica Microsystems, Mannheim,
Germany) with in-house developed macros. No statistical method was used to
predetermine the sample size. Oxygen-induced retinopathy: oxygen-induced
retinopathy (ROP) was induced by exposing C57BL/6 pups with their mother to
70% oxygen from P7 to P12 (ref. 35). Pups were then returned to normoxia and
injected daily with 30mgkg21 etomoxir or vehicle. At P17, pups were killed and
eyes were enucleated, fixed in 4% PFA and retinal flat-mounts were stained for
isolectin B4, using previously published methods4. Mosaic images were captured
using the inverted LeicaDMI6000B epifluorescencemicroscope (Leica,Manheim,
Germany) and analysis of the vascular tuft area was performed using NIH Image J
software. For all mouse experiments, data analysis was done by experimenters
blinded to the group allocation. All experimental animal procedures were
approved by the Institutional Animal Care and Research Advisory Committee
of the University of Leuven.
Immunohistochemistry. PFA-fixed cell cultures (4% PFA except for CPT1A
staining where 2% PFA was used), spheroids (4% PFA) or whole-mount retinas
(4% PFA) were subjected to immunofluorescence staining using the following
isolectin conjugates or primary antibodies: isolectin GS-IB4-Alexa 488, isolectin
GS-IB4-Alexa 568, isolectin GS-IB4-Alexa 647 (Molecular Probes), anti-CPT1A
(Cell Signaling), anti-NG2 chondroitin sulfate proteoglycan (Chemicon), anti-
Tomm20 (Abcam) and anti-collagen IV (Southern Biotech). Alexa-488, -568 or
-633 conjugated secondary antibodies were used (Molecular Probes). EdU, EU
and HPG staining was performed using a Click-IT assay with Alexa fluor 555
according to manufacturer’s instructions.
Statistics. Data represent mean6 s.e.m. of pooled experiments unless otherwise
stated. n values represent the number of independent experiments performed or
the number of individual mice phenotyped. For each independent in vitro experi-
ment, at least three technical replicates were used, except for the [U-13C]palmitate
incorporation analysis in cell lines (at least two technical replicates) (Fig. 6a).
Statistical significance between groups was calculated usingmixedmodel statistics
(this test does not assume normality or equal variance)with experiment as random
factor to correct for variation between umbilical donors (ECs were isolated from
human umbilical cords) or mouse litters. SAS statistical software version 9.3 was
used for statistical analysis. For comparison of ECs with other cell types, a one-
sample t-testwas used. Sample size for each experimentwas not pre-determined.A
P value,0.05 was considered statistically significant.
RNA sequences. shCPT1 RNA sequence 1, GCCATGAAGCTCTTAGACAAA;
shCPT1 RNA sequence 2, CGATGTTACGACAGGTGGTTT; shACADVLRNA
sequence, GCAGACATCTTCACGGTCTTT; siCPT1ARNA sequence (from IDT
trifecta), AGCUCUUAGACAAAUC/AGAGAGAUAGAUUUGU.
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Extended Data Figure 1 | FAO regulates vessel sprouting. a, mRNA
expression of CPT1 isoforms (n5 3). b, CPT1A mRNA levels upon CPT1A
silencing (CPT1AKD) (n5 11). c, Representative immunoblot of CPT1A for
control and CPT1AKD ECs. d, FAO flux upon CPT1A silencing in venous
(HUV) and arterial (HA) ECs, or upon small interference RNA transfection in
venous ECs (siRNA) (n5 6 for HUV shRNA, n5 3 for HA shRNA and HUV
siRNA). e, Schematic representation of FAO measurement using [9,10-3H]
palmitate (reprinted from Immunity 35,Wang, R. et al. The transcription factor
Myc controls metabolic reprogramming upon T lymphocyte activation,
871–882 (2011), with permission from Elsevier; ref. 24). f, Representative
immunoblot for CPT1A upon genetic silencing of CPT1A using siRNA
(siCPT1A). g, FAO flux upon silencing of CPT1C (CPT1CKD) (n5 3; P5NS).
h, FAO flux levels in venous (HUV), arterial (HA) and microvascular (HMV)
ECs (n5 4 for HUV versus HA and n5 3 for HUV versus HMV). i, Sprout
number in control and CPT1AKD EC spheroids with mitomycin C (MitoC)
treatment as indicated (n5 3). j, Flow cytometry counting of viable control and
CPT1AKD ECs (n5 3). k, Analysis of random cell-motility tracks in control
and CPT1AKD ECs (n5 4; P5NS). l, FAO flux and proliferation upon
silencing of ACADVL (ACADVLKD) (n5 3 for each).m, Wound closure in
control and ACADVLKD ECs (n5 3; P5NS). n, o, Quantification of vessel
sprouting in control and ACADVLKD EC spheroids with MitoC treatment as
indicated, total sprout length (n) and sprout numbers per spheroid (o) (n5 5).
p, Sprout number in control andCPT1AOEEC spheroidswithMitoC treatment
as indicated (n5 3). q, Total sprout length in control and CPT1AOE EC
spheroids treated with MitoC as indicated (n5 5). r, s, Representative phase
(original magnification, 103magnification) contrast images of control (r) and
CPT1AOE (s) EC spheroids. t, Scratch wound assay in control and CPT1AOE
ECs treated with MitoC as indicated (n5 3; P5NS). u, PCR analysis of
genomic DNA from WT and CPT1ADEC pups, confirming Cre-mediated
recombination of the floxed Cpt1a allele as shown by the appearance of a
300-bp band. v, NG21 area in neonatal vascular plexus of WT and CPT1ADEC
mice (3 litters, n5 8 pups forWT and 7 pups for CPT1ADEC; P5NS). Data are
mean6 s.e.m. of n independent experiments (a, b, d, g–q, t) or the total
number of mice (v). Statistical test: mixed models. NS, not significant.
*P, 0.05, **P, 0.01, ***P, 0.001, ****P, 0.0001.
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Extended Data Figure 2 | CPT1A silencing does not cause cellular distress.
a, ADP/ATP ratio in control and CPT1AKD ECs (n5 3; P5NS). b, Sprout
number upon oligomycin treatment (oligo) in control and CPT1AKD EC
spheroids (n5 3). c, Glycolysis measurement in control and CPT1AKD ECs
(n5 3; P5NS). d, Representative immunoblot for phosphorylated AMPK
(pAMPK) and total AMPK (AMPK) and for LC3b I and II in control and
CPT1AKD ECs. The ratio of the densitometrically quantified bands of pAMPK/
AMPK and LC3b II/I is shown below the blots (n5 3; P5NS). e, Sprout
number uponN-acetyl-cysteine (NAC) treatment in control and CPT1AKD EC
spheroids (n5 3). f, g, Representative images (original magnification, 103) of
EC spheroids upon staining for TO-PRO3 in control (f) and CPT1AKD
spheroids (g). h, i, Representative pictures (original magnification, 103) of
Hoechst/cleaved-caspase-3-stained control (h) and CPT1AKD (i) ECs.
j, Representative immunoblots showing the ratio of phosphorylated (pATM)/
total-ATM (ATM), p21/lamin and p53/lamin in control and CPT1AKD ECs.
The ratios of the densitometrically quantified bands are shown below the blots
(n5 3; P5NS). Data are mean6 s.e.m. of n independent experiments
(a–e, j). Statistical test: mixed models. NS, not significant. ****P, 0.0001.
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Extended Data Figure 3 | FAO is used for de novo nucleotide synthesis.
a, Schematic representation of the different carbon sources used for de novo
synthesis of UMP. Note that palmitate contributes three carbons to the nine
carbon skeleton of UMP. PRPP, 5-phosphoribosyl-1-pyrophosphate. b, Sprout
number upon 5-fluorouracil (5FU) treatment in control and CPT1AKD EC
spheroids (n5 4). c, Sprout number upon methotrexate (MTX) treatment in
control and CPT1AKD EC spheroids (n5 4). d, Sprout number upon acetate
treatment in control and CPT1AKD EC spheroids (n5 3). e–g, Representative
images (original magnification, 103) of EC spheroids upon acetate treatment.
h, i, Rescue of the sprouting defect of CPT1AKD spheroids by acetate was not
affected by oligomycin treatment; panel h, total sprout length; panel i, sprout
numbers/spheroid (n5 3; P5NS). j, k, Quantification of vessel sprouting
using the EC spheroidmodel, showing that the reduction of total sprout length
(j) and number of sprouts per spheroid (k) upon CPT1A silencing (CPT1AKD)
was rescued by supplementation with a dNTP mix (n5 3). l, Quantification of
MitoC-treated EC spheroid sprouting upon acetate or nucleoside mix
supplementation (n5 3; P5NS). m, Glucose oxidation in ECs, measured by
14CO2 formation from [6-
14C]glucose in control and CPT1AKD ECs (n5 4).
n, Glutamine oxidation in ECs, measured by 14CO2 formation from [U-
14C]
glutamine in control and CPT1AKD ECs (n5 4; P5NS). o, Total contribution
of [U-13C]glucose and [U-13C]glutamine to aspartate in control and CPT1AKD
ECs (n5 3). p, [8-14C]hypoxanthine incorporation in RNA and DNA in
control ECs (n5 3). Data are mean6 s.e.m. of n independent experiments
(b–d, h–p). Statistical test: mixed models. NS, not significant. *P, 0.05,
**P, 0.01, ****P, 0.0001.
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Extended Data Figure 4 | Etomoxir reduces vessel sprouting. a, FAO flux
upon etomoxir (Eto) treatment (n5 6). b, [3H]thymidine incorporation upon
etomoxir treatment (n5 5). c, Scratch wound assay using MitoC-treated ECs
upon etomoxir (Eto) treatment (n5 4; P5NS). d, Branch point quantification
in the retinal vasculature of control (Ctrl) and etomoxir-treated (Eto) pups
(8 litters, n5 24 pups for control and 16 for etomoxir treatment).
e, f, Representative confocal images (original magnification, 103) of retinal
vessels stained for isolectin-B4 in control (e) and etomoxir (f) treated pups.
g, Filopodia quantification in the retinal vascular front of control and etomoxir
(Eto) treated pups (4 litters, n5 11 for WT and 9 for etomoxir; P5NS). Data
aremean6 s.e.m. of n independent experiments (a–d, g) or the total number of
mice (d, g). Statistical test: mixed models. NS, not significant. ****P, 0.0001.
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Extended Data Figure 5 | Analysis of steady state. PercentageM12 or M14 citrate and aspartate over different time points (24, 36, 48 and 52 h) after labelling
with [U-13C]glucose (a), [U-13C]glutamine (b), or [U-13C]palmitate (c). Data are mean6 s.d. of n5 3 independent experiments.
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Chapter 7 
 
 Discussion 
 
In this PhD thesis we demonstrate for the first time that metabolism, besides 
genetic signals, can regulate vessel sprouting. Furthermore, we have identified 
two novel metabolic regulators of angiogenesis (PFKFB3 and CPT1a) and 
provided proof of principle for the potential of these enzymes as novel anti-
angiogenic targets. I will first briefly highlight the main findings of our research 
and thereafter discuss outstanding questions and future perspectives. 
 
PFKFB3-DRIVEN GLYCOLYSIS REGULATES VESSEL SPROUTING  
 
 Silencing of PFKFB3 reduced glycolytic flux by no more then 30%, which 
was sufficient to impair vessel sprouting in vitro and in vivo. These sprouting 
defects were due to effects on both migrating tip and proliferating stalk cells 
(Figure 8). In agreement with findings that cell proliferation requires glycolysis 
(Lunt and Vander Heiden, 2011), PFKFB3 inactivation reduced EC proliferation, 
implying that the impaired vessel formation was at least partially due to 
proliferation defects. However, we also showed that PFKFB3 is important for EC 
motility. Indeed PFKFB3 levels determined the competitiveness of an EC for the 
tip position. Even more, overexpression of PFKFB3 was able to overcome the 
strong pro-stalk activity of Notch signaling, thereby pushing the cell towards a tip 
position.  
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Figure 8: Schematic representation of the role of PFKFB3-driven glycolysis 
during vessel sprouting. PFKFB3-driven glycolysis supports stalk cell 
proliferation and stimulates tip cell migration. Blocking PFKFB3 reduced stalk cell 
proliferation and results in a non-competitive, slowly migratory tip cell with short 
immobile filopodia. (Adapted from De Bock et al, Cell, 2013) 
 
COMPARTMENTALIZATION OF PFKFB3-DRIVEN GLYCOLYSIS 
 
 Mechanistically, PFKFB3 co-localized with F-actin in lamellipodia and 
filopodia. Live ATP imaging demonstrated that PFKFB3-driven glycolysis 
supports ATP production in these structures, necessary for actin-cytoskeletal 
remodeling and directional migration. Furthermore, all other glycolytic enzymes 
also co-localized in the lamellipodia/filopodia (De Bock et al., 2013d), allowing us 
to postulate the following model. In the endothelial tip cell, a glycolytic hub is 
created in the lamellipodia/filopodia, where the product of one enzyme becomes 
the substrate of the next, allowing sufficient, local and rapid ATP production to 
fuel migration (Figure 9). Indeed, binding of glycolytic enzymes to actin 
stimulates their activity (al-Habori, 1995). Thus, compartmentalization of 
glycolysis contributed to the competitiveness of an EC to reach the tip. 
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Figure 9: Compartmentalization of glycolysis in lamellipodia and filopodia. 
Endothelial tip cell containing filopodia and lamellipodia, where PFK1 and other 
glycolytic enzymes (Aldolase A, ALDO1; Glyceraldehyde-3-phosphate 
dehydrogenase, GAPDH) co-localize with F-actin thereby creating an assembly 
line of glycolytic enzymes. This compartmentalization of glycolysis in the tip cell 
ensures sufficient, rapid and local ATP production to fuel cytoskeletal remodeling 
during migration. (Adapted from De Bock et al, Cell Metabolism, 2014) 
 
RATIONALE FOR SILENCING PFKFB3-DRIVEN GLYCOLYSIS 
 
 Previous reports already suggested that ECs are highly glycolytic. We 
provided experimental evidence that ECs are indeed more glycolytic than other 
healthy cell types. Furthermore, a direct comparison with several cancer cell lines 
to demonstrated their equivalent dependence on glycolysis. To investigate the 
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importance of glycolysis for vessel sprouting, we silenced PFKFB3, a regulator of 
a regulator of glycolysis. A complete block of glycolysis was previously attempted 
using 2-deoxyglucose (2DG, inhibits hexokinase, one of the rate limiting 
enzymes of glycolysis). Indeed 2DG reduced glycolysis by more then 90%, which 
inhibited EC proliferation but also compromised cell viability. We therefore 
attempted to block glycolysis only partially by targeting a regulator of glycolysis, 
instead of a rate limiting glycolytic enzyme. This approach was further supported 
by our observation that angiogenic ECs increase glycolysis by only 30% 
compared to their quiescent counterparts. It is this extra 30% glycolysis that we 
aimed to inhibit, thereby still allowing sufficient glycolytic flux for quiescent cell 
homeostasis. 
PARTIAL AND TRANSIENT REDUCTION OF GLYCOLYSIS REDUCES PATHOLOGICAL 
ANGIOGENESIS 
 
 The pharmacological PFKFB3 inhibitor 3PO phenocopied the effects of 
genetic PFKFB3 blockade in vivo and in vitro. Moreover, 3PO reduced 
pathological neovascularization in ocular and inflammatory models in the mouse, 
and amplified the anti-angiogenic activity of a VEGF receptor tyrosine kinase 
inhibitor and anti-VEGF receptor-2 antibody in the zebrafish and choroidal 
neovascularization (CNV) mouse model, respectively. Together, inhibition of 
PFKFB3 by 3PO reduces vessel formation in physiological and pathological 
conditions in the models tested. 
 
 As mentioned above, previous anti-glycolytic anti-cancer strategies 
attempted to block glycolysis completely and permanently, but these approaches 
also caused adverse effects (Granchi and Minutolo, 2012). In contrast, our 
approach only reduced glycolysis partially, inducing EC quiescence without 
causing EC death in vitro. Likewise, in vivo, 3PO reduced glycolysis only partially 
and transiently, without however inducing permanent refractoriness, since a 
second 3PO administration 24 hours later reduced glycolysis again to the same 
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level as the first treatment. Thus, a partial and daily transient decrease of 
glycolysis sufficed to suppress pathological neovascularization.  
 
SAFETY/SYSTEMIC EFFECTS OF PFKFB3 BLOCKADE 
 
Initial in vivo studies showed acceptable tolerability of 3PO treatment. In contrast 
to 2DG treatment, which induced EC apoptosis in vitro by blocking glycolysis 
nearly completely, EC viability was unaffected by 3PO treatment. These findings 
were confirmed in vivo, where only minimal systemic effects were observed. A 
possible explanation relates to the high dependence of ECs on glycolysis. 
Compared to other healthy cells, glycolytic flux in ECs was much higher, which 
renders ECs more sensitive to PFKFB3 blockade. Furthermore, glycolysis was 
reduced transiently and partially (by only 30%). Indeed PFKFB3 blockade did not 
cause an energy crisis or disturb redox homeostasis in ECs. These findings 
contribute to the limited systemic effects observed upon 3PO treatment.  
 
FUTURE PERSPECTIVES FOR PFKFB3 BLOCKADE? 
 
Current anti-angiogenic therapies are successful for the treatment of ocular 
diseases (Carmeliet and Jain, 2011b). However, it is their low efficacy for cancer 
treatment, which warrants investigation for novel anti-angiogenic strategies. In 
this respect, it is interesting to note that PFKFB3 blockade was already shown to 
target cancer cells as well. 3PO treatment in mice reduced tumor growth and 
compromised tumor cell survival. Therefore, 3PO was already proposed as a 
potential new anti-cancer drug (Clem et al., 2008; Clem et al., 2013). Our study 
now provides an additional dimension to this proposal in which 3PO blockade 
would not only target the tumor cells but also to the tumor vasculature. Ongoing 
studies in the lab are investigating this hypothesis. 
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ANGIOGENESIS: IS IT REALLY ALL ABOUT GLYCOLYSIS? 
 
The few reports available in the literature suggest that oxidative phosphorylation 
is of limited importance for angiogenic ECs. Indeed, to date only a signaling role 
for mitochondria has been described in ECs (Kluge et al., 2013). We also show 
that the magnitude of glycolytic flux is at least 200 fold higher than that of all 
mitochondrial oxidative fluxes in ECs. Furthermore, blocking mitochondrial 
respiration did not affect EC spheroid sprouting. ECs sprout in avascular hypoxic 
areas, therefore anaerobic glycolysis seems to be the most efficient way to 
generate ATP. While mitochondrial oxidative phosphorylation could be another 
source of ATP in ECs, this process however requires oxygen, which is limited in 
hypoxic areas. Mitochondrial metabolism not only provides ATP, but also 
biomass building blocks and redox molecules, which all fuel proliferation. 
However only ATP generation requires oxygen consumption in the electron 
transport chain. Therefore, the question arises whether oxidative phosphorylation 
plays any role at all during angiogenesis.  
 
 
FATTY ACID DERIVED CARBONS ARE ESSENTIAL FOR DNTP SYNTHESIS IN ENDOTHELIAL 
CELLS 
 Our study now shows that oxidative catabolism of fatty acids in 
mitochondria is critical for vessel sprouting in vivo, thus more important than 
expected based on the current literature (Dagher et al., 2001a; De Bock et al., 
2013b; Spahr et al., 1989b; Spolarics et al., 1991b). Unlike PFKFB3-driven 
glycolysis, which affects both EC proliferation and migration (De Bock et al., 
2013d), FAO selectively regulates EC proliferation, indicating that distinct 
metabolic pathways control distinct EC functions during vessel sprouting. We 
discovered an unknown role of fatty acid-derived carbons in de novo nucleotide 
synthesis for DNA replication in ECs (Figure 10). Fatty acid derived carbons were 
incorporated in DNA, RNA and protein. Surprisingly, only dNTP levels and DNA 
synthesis were impaired upon FAO blockade. Indeed, salvage synthesis 
pathways can maintain RNA and protein synthesis when FAO is blocked. In 
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contrast, DNA synthesis critically relies on de novo nucleotide synthesis (Schoors 
et al., 2015). Surprisingly, ECs are quite unique in this perspective. Only 
fibroblasts and to some extent pericytes, used fatty acid derived carbons for de 
novo nucleotide synthesis while malignant cell types with measurable FAO levels 
did not.  
 Like any other proliferating cell type, ECs need sufficient nucleotides for 
DNA replication. What is remarkable about ECs is that their reliance on fatty acid 
carbons to synthesize nucleotides is apparently not compensated by other 
carbon sources. Hence, when fatty acid carbons become limiting, ECs slow down 
proliferation and angiogenesis. The utilization of fatty acids for biomass 
production is however not unprofitable. Indeed, fatty acids are, per mole, a much 
richer carbon source then glucose or glutamine. Hence, while ECs use glycolysis 
for generation of ATP, they oxidize little glucose but utilize FAO instead as rich 
carbon source for biomass production. This may also explain why FAO can 
substantially contribute to biomass production in ECs, even despite the fact that 
its flux levels are much lower than those of glycolysis (De Bock et al., 2013d). 
Since ECs can use intracellular lipids (Dagher et al., 2001a), this raises the 
intriguing question whether FAO of intracellular lipid stores might allow ECs to 
continue proliferating and vascularizing avascular tissues, even when fatty acid 
supplies in the extracellular milieu become limiting.  
 
 Finally, etomoxir (a pharmacological CPT1 blocker) reduced pathological 
angiogenesis in a mouse model of retinopathy of prematurity. While not the focus 
of this study, these data may hint to an underappreciated therapeutic potential of 
lowering FAO for the inhibition of pathological angiogenesis, meriting further 
consideration.  
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Figure 10: Fatty acid carbons support nucleotide biosynthesis to fuel EC 
proliferation. Upper panel shows the metabolism of control ECs where fatty acid 
carbons support dNTP synthesis, necessary for EC proliferation. The lower panel 
depicts a CPT1a deficient EC which leas to decreased dNTP levels while rNTP 
and amino acid levels remain unaffected. Overall, EC proliferation is impaired 
due to depleted dNTP levels. (Adapted from Schoors et al, Nature, 2015) 
 
FATTY ACID OXIDATION DOES NOT SERVE ANAPLEROSIS 
 
Our data demonstrate that fatty acid carbons significantly contribute to the TCA 
cycle and that blockade of FAO depletes aspartate and dNTP levels, necessary 
for EC proliferation. However, by no means do our data suggest that the Krebs 
cycle is replenished by net contribution of fatty acid carbons in the traditional 
sense of anaplerosis (Figure 11). Indeed, even though labeled acetyl-CoA from 
fatty acids enters the Krebs cycle and labels oxaloacetate, this does not 
imply net formation of oxaloacetate from acetyl-CoA, derived from fatty acids. 
Rather, our data suggest that in conditions of adequate availability of anaplerotic 
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substrates (glucose, glutamine), fatty acid oxidation is important to produce 
sufficient amounts of dNTPs. Fatty acids provide acetyl-CoA, which helps to 
sustain the TCA cycle in conjunction with an anaplerotic substrate.1 
 
  	  
 
 
 
 
 
 
 
 
 
 
Figure 11: Fatty acid does not serve anaplerosis. Schematic representation of 
the TCA cycle, showing entry of two fatty acid-derived carbons in the TCA cycle 
which are incorporated in all TCA intermediates and aspartate during one run of 
the cycle. Also, two carbons exit the TCA cycle (as CO2) during one cycle 
however these are not fatty acid derived carbons. This scheme shows that even 
though fatty acids derived carbons contribute to the TCA cycle, they do not 
supply net cabons to the Krebs cycle.  
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  This clarification will be published as a corrigendum at Nature. 	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A METABOLIC MODEL FOR VESSEL SPROUTING? 
 
 To date, only genetic signals have been considered to control vessel 
sprouting. Our findings add an extra dimension to this traditional concept and 
imply that metabolism also controls vessel sprouting. Aside from a genetic 
signature, tip and stalk cells thus likely also have a metabolic signature. Our 
studies already documented a role for glycolysis and fatty acid oxidation during 
vessel sprouting. PFKFB3-driven glycolysis is necessary for stalk cell 
proliferation and for ATP production for tip cell function. CPT1a driven FAO on 
the other hand does not affect tip cell function but is essential for de novo 
nucleotide synthesis to fuel stalk cell proliferation. Other metabolic pathways 
might also influence vessel formation and certainly merit further investigation to 
complete the metabolic blue print of tip versus stalk cells. In addition, the 
crosstalk between genetic angiogenic signals and metabolism will be an 
interesting line of investigation. 
 
FUTURE PERSPECTIVES 
 
In addition to evaluating PFKFB3 blockade as an anti-cancer strategy, it would 
also be interesting to investigate CPT1 blockade for this purpose. Like PFKFB3, 
CPT1 has been implicated in survival of cancer cells in stressed conditions. 
Therefore blocking CPT1 might affect tumor cell viability as well as the 
vasculature. Furthermore, the question arises whether dual blockade of PFKFB3 
and CPT1a might have an additive effect on pathological angiogenesis. However 
further drug discovery for both targets might be necessary before reliable studies 
can be done. Indeed, 3PO is only a first generation PFKFB3 blocker while 
etomoxir was taken out of clinical trials due to hepatotoxicity (likely not related to 
FAO blockade as ranolazine – another FAO blocker – is an approved drug for the 
treatment of angina) (Carracedo et al., 2013).   
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 Nevertheless, the interaction between metabolism and angiogenesis is an 
exciting and promising field of research for discovery of novel anti-angiogenic 
targets. The research done so far only scratched the surface of an entire 
metabolic landscape, which will be further discovered in ongoing research in the 
host lab. 
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